MAIN PROGRAM - gth2017.org · Rurioctocog alfa pegol (Recombinant Coagulation Factor VIII) SHIRE · BAXALTA SCHWEIZ AG Müllerenstrasse 3, Postfach, CH-8604 Volketswil | Telefon +41

www.gth2017.org

Fanhdi® 250 I.E., 500 I.E., 1000 I.E. und 1500 I.E., Trockensubst. u. Lösungsm. zur Herstellung einer Injektionslösung. Wirkstoff: Blutgerinnungsfaktor VIII v. Menschen. Zusammensetzung: 250 I.E., 500 I.E., 1000 I.E. od. 1500 I.E. Blutgerinnungsfaktor VIII v. Menschen (FVIII) u. 300 I.E., 600 I.E., 1200 I.E. od. 1800 I.E. von-Willebrand-Faktor (VWF) pro Durchstechflasche. Fanhdi® 250 I.E./500 I.E./1000 I.E. enth. nach Rekonstitution in 10 ml Wasser f. Injektionszwecke ungefähr 25 I.E./50 I.E./100 I.E. Blutgerinnungsfaktor VIII v. Menschen pro ml. Fanhdi® 1500 I.E. enthält nach Rekonstitution in 15 ml Wasser f. Injektionszwecke ungefähr 100 I.E. Blutgerinnungsfaktor VIII v. Menschen pro ml. Sonstige Bestandteile: Arginin, Albumin (human), Histidin, Wasser f. Injektionszwecke (Lösungsmittel). Anwendungsgebiete: Behandlung u. Prophylaxe v. Blutungen bei Patienten mit Hämophilie A (angeborener Faktor-VIII-Mangel). Dieses Produkt kann zur Behandlung v. erworbenem Faktor-VIII-Mangel eingesetzt werden. Gegenanzeigen: Überempfindlichkeit gegen den Wirkstoff, Heparin (theoretisch in Spuren aus dem Herstellungsprozess enthalten) od. einen der sonst. Bestandteile. Nebenwirkungen: Überempfindlichkeit od. allergische Reaktionen (wie z.B. Quincke-Ödem, Brennen u. Stechen an der Einstichstelle, Schüttelfrost, Hitzegefühl, generalisierte Urtikaria, Kopfschmerz, Ausschlag, Hypotonie, Lethargie, Übelkeit, Ruhelosigkeit, Tachykardie, Engegefühl in der Brust, Stechen, Erbrechen, Giemen) wurden selten beobachtet u. können in manchen Fällen zu schwerer Anaphylaxie (mit Schock) führen. In seltenen Fällen wurde Fieber beobachtet. Heparin, welches theoretisch in Spuren aus dem Herstellungsprozess enthalten sein kann, kann allergische Reaktionen hervorrufen u. die Blutplättchenzahl vermindern mit der Folge einer Blutgerinnungsstörung. Patienten, bei denen durch Heparin bedingt allergische Reaktionen aufgetreten sind, sollten heparinhaltige Arzneimittel nicht injiziert werden. Patienten mit Hämophilie A können neutralisierende Antikörper (Hemmkörper) gegen Faktor VIII entwickeln. Treten solche Hemmkörper auf, so manifestiert sich dies in einer ungenügenden klinischen Wirksamkeit. Es wird empfohlen, in diesen Fällen ein spezialisiertes Hämophilie-Zentrum zu kontaktieren. Informationen zur Sicherheit hinsichtlich übertragbarer Krankheiten: s. Fachinformation. Verschreibungspflichtig. Pharm. Unternehmer: Grifols Deutschland GmbH, Lyoner Straße 15, 60528 Frankfurt, Tel.: 069/660 593 100, Fax: 069/660 593 110 Stand der Information: Oktober 2014

NATÜRLICHER SCHUTZmit dem FVIII/VWF-Komplex

Für weitere Information: Grifols Deutschland GmbHTel. +49 69 660593-100 [email protected]

www.grifols.com

PGR_FAK_16001_Anzeige_148x210_RZ.indd 1 22.11.16 12:47

61st A

nnua

l Mee

ting

of th

e So

ciet

y of

Thr

ombo

sis

and

Hem

osta

sis

Rese

arch

, 15-

18 F

ebru

ary

2017

, Bas

el, S

witz

erla

nd

MAIN PROGRAM

Rurioctocog alfa pegol(Recombinant Coagulation Factor VIII)

SHIRE · BAXALTA SCHWEIZ AG Müllerenstrasse 3, Postfach, CH-8604 Volketswil | Telefon +41 44 564 34 00 | Fax +41 44 564 34 10 | www.ShireSwitzerland.ch

ADYNOVI® · Zusammensetzung: Rurioctocog alfa pegolum (Factor VIII coagulationus humanis (ADNr)); Applikation 250, 500, 1000, 2000I.E. Indika-tion: Behandlung und Prophylaxe von Blutungen bei Patienten mit Hämophilie A (kongenitaler Faktor VIII-Mangel). Dosierung/Anwendung: Nach Schweregrad des FVIII Mangels, nach dem Ort und dem Ausmass der Blutung und dem klinischen Zustand des Patienten; intravenöse Verabreichung. Kontraindikation: Bekannte lebensbedrohliche Überempfindlichkeitsreaktionen gegenüber der Ausgangssubstanz ADVATE, Maus- oder Hamsterpro-teinen, sowie anderen Bestandteilen. Vorsichtsmassnahmen: Die Bildung von neutralisierenden Antikörpern ist möglich und muss mit geeigneten Labortests überwacht werden. Unerwünschte Wirkungen: Die häufigsten Ereignisse in klinischen Studien waren Kopfschmerzen, Diarrhoe, Übelkeit und Hitzewallung. Interaktionen: Wechselwirkungen von ADYNOVI mit anderen Arzneimitteln sind nicht bekannt. Packungen: Lyophilisat mit 250, 500, 1000, 2000I.E. ADYNOVI/5ml Wasser für Injektionszwecke. Abgabekategorie B. Zulassungsinhaberin: Baxalta Schweiz AG, CH-8604 Volketswil. Stand der Information: August 2016. Ausführliche Informationen finden Sie unter www.swissmedicinfo.ch HEM154 12-2016

* N=569/591. 85,4% mit 1 Infusion (n=505), und 10,8% mit 2 Infusionen (n=64). 1. Konkle BA. et al. Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A. Blood 2015;

126(9): 1078-1085.

= Blutungen effektiv vorbeugen.

Spontane Blutungen und Gelenkblutungen betrugen im Median Null.1

96% aller Blutungen wurden mit 1 oder 2 Infusionen gestoppt.1*

Einfache Dosierung: 2x wöchentlich 40–50 I.E./kg 1

98% der Patienten benötigten keine Dosisanpassung.1

+

+

+

+

ADYNOVI® vereint die Eigenschaften von ADVATE®

mit einer 40–50% längeren Halbwertszeit.1

AY_Inserat A5.indd 1 14.12.16 13:45

efmoroctocog alfa(rekombinanter humaner Gerinnungsfaktor VIII,Fc Fusionsprotein [rFVIIIFc])

Swedish Orphan Biovitrum AgDammstrasse 19, CH-6300 Zug

Alprolix® (Eftrenonacog alfa). I: Behandlung und Prophylaxe von Blutungen bei vorbehandelten Patienten mit Hämophilie B (kongenitaler Faktor-IX-Mangel). D: Intravenöse Anwendung nach Rekonstitution. Berechnung der Dosis in Abhängigkeit von Körpergewicht und den zu erreichenden Faktor-IX-Spiegeln. Empfohlene Faktor-VIII-Spiegel Hämarthrose im Frühstadium, Muskelblutung oder orale Blutung 20-40 I.E./dl; umfangreichere Hämarthrose, Muskelblutung oder Hämatom 30-60 I.E./dl; lebensbedrohende Blutungen 60-100 I.E./dl; kleinere chirurgische Eingriffe 30-60 I.E./dl; grössere chirurgische Eingriffe 80-100 I.E./dl. Individualisierte Langzeitprophylaxe 50 I.E./kg einmal wöchentlich oder 100 I.E./kg alle 10 Tage. Therapieüberwachung empfohlen. KI: Überempfindlichkeit gegenüber Wirkstoff oder Hilfsstoffen. W/VM: allergische Überempfindlichkeitsreaktionen, Bildung neutralisierender Antikörper, Risiko thrombotischer Komplikationen. IA: Keine bekannt. Unerwünschte Wirk.: Häufig: Kopfschmerzen, orale Parästhesie, obstruktive Uropathie; Gelegentlich: verminderter Appetit, Schwindel, Dysgeusie, Palpitationen, Hypotonie, Mundgeruch, Hämaturie, Nierenkolik, Müdigkeit, Schmerzen an der Infusionsstelle P: Pulver und Lösungsmittel zur Herstellung einer Injektionslösung. Packung enthält 1 Durchstechflasche mit Pulver, 5 ml Lösungsmittel in einer Fertigspritze, 1 Kolbenstange, 1 Adapter für die Durchstechflasche, 1 Infusionsset, 2 Alkoholtupfer, 2 Pflaster, 1 Mullkompresse. Verkaufskategorie B. Stand: Oktober 2016. Zul.-Inh.: Swedish Orphan Biovitrum AG, Luzern. Ausführliche Informationen: Arzneimittel-Fachinformation unter www.swissmedicinfo.ch.

Elocta® (Efmoroctocog alfa). I: Behandlung und Prophylaxe von Blutungen bei vorbehandelten Patienten mit Hämophilie A (kongenitaler Faktor-VIII-Mangel). D: Intravenöse Anwendung nach Rekonstitution. Berechnung der Dosis in Abhängigkeit von Körpergewicht und den zu erreichenden Faktor-VIII-Spiegeln. Empfohlene Faktor-VIII-Spiegel Hämarthrose im Frühstadium, Muskelblutung oder orale Blutung 20-40 I.E./dl; umfangreichere Hämarthrose, Muskelblutung oder Hämatom 30-60 I.E./dl; lebensbedrohende Blutungen 60-100 I.E./dl; kleinere chirurgische Eingriffe 30-60 I.E./dl; grössere chirurgische Eingriffe 80-100 I.E./dl. Individualisierte Langzeitprophylaxe 50 I.E./kg alle 3-5 Tage. Therapieüberwachung empfohlen. KI: Überempfindlichkeit gegenüber Wirkstoff oder Hilfsstoffen. W/VM: Überempfindlichkeitsreaktionen oder allergische Reaktionen, Bildung neutralisierender Antikörper. I: Keine bekannt. Unerwünschte Wirk.: Gelegentlich Kopfschmerzen, Schwindel, Dysgeusie, Bradykardie, Hypertonie, Hitzewallungen, Angiopathie, Husten, Unterbauchschmerzen, Ausschlag, Arthralgie, Myalgie, Rückenschmerzen, Gelenkschwellung, Unwohlsein, Schmerzen im Brustraum, Kältegefühl, Hitzegefühl, positiver Test auf Faktor-VIII-Antikörper, Hypotonie im Rahmen des Eingriffs. Selten allergische Überempfindlichkeitsreaktionen bis hin zum anaphylaktischen Schock. Bei unzureichendem klinischen Ansprechen aufgrund Bildung neutralisierender Antikörper gegen Faktor VIII, ein spezialisiertes Hämophiliezentrum kontaktieren. P: Pulver und Lösungsmittel zur Herstellung einer Injektionslösung. Packung enthält 1 Durchstechflasche mit Pulver, 3 ml Lösungsmittel in einer Fertigspritze, 1 Kolbenstange, 1 Adapter für die Durchstechflasche, 1 Infusionsset, 2 Alkoholtupfer, 2 Pflaster, 1 Mullkompresse. Verkaufskategorie B. Stand: Mai 2016. Zul.-Inh.: Swedish Orphan Biovitrum AG, Luzern. Ausführliche Informationen: Arzneimittel-Fachinformation unter www.swissmedicinfo.ch.

WIE DEFINIEREN SIE PROTEKTION BEI IHREN

HÄMOPHILIE A UND B PATIENTEN?

• Elocta (rFVIIIFc ) und Alprolix (rFIXFc): die ersten, rekombinanten, durch Fc-Fusionstechnologie halbwertszeitverlängerten Faktorpräparate für Hämophilie A und B Patienten

• Niedrige Blutungsraten und geringe Injektionsfrequenzen1-4

• Flexibilität und individualisierte Behandlung5,6

• > 2 Jahre Langzeiterfahrung mit Elocta und Alprolix7-10

1. Mahlangu, J. et al. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood. 2014;123:317-25. 2. Young, G. et al. Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A. J Throm Haemost. 2015;13:967-77. 3. Powell, J. S. Phase 3 Study of Recombinant Factor IX Fc Fusion Protein in Hemophilia B. N Engl J Med. 2013;269:2313-23. 4. Kulkarni R et al. Kids B-Long: Safety, efficacy, and pharmacokinetics of long-acting recombinant factor IX Fc fusion protein (rFIXFc) in previously treated children with hemophilia B. 67th Annual Meeting of the National Hemophilia Foundation (NHF), 13–15 August 2015; Dallas, USA. Poster CRCT07. 5. Fachinformation ELOCTA, Stand: Mai 2016. 6. Fachinformation ALPROLIX, Stand: Oktober 2016. 7. Sobi™ Press Release. 9 June 2014. 8. Sobi Press Release. 24 November 2015. 9. Sobi™ Press Release. 31 March 2014. 10. Biogen™ Press Release. 13 May 2016

Alprolix und Elocta sind Marken von Swedish Orphan Biovitrum AB (publ). © 2015 Swedish Orphan Biovitrum AB (publ) – Alle Rechte vorbehalten

AZ_Kombi_A_E_148x210mm_CH_04.indd 1 19.12.16 10:06



























TABLE OF CONTENTS

Welcome Address .................................................................................................................................................. 5

Acknowledgments ................................................................................................................................................. 7

Contacts & Committees ....................................................................................................................................... 8

GTH 2017 Abstract-Reviewers .......................................................................................................................... 9

General information ............................................................................................................................................. 10

Travel information ................................................................................................................................................. 12

Information for Speakers and Presenters ..................................................................................................... 13

Awards and Grants of the GTH ........................................................................................................................ 14

Scientific Program ............................................................................................................................................... 15

Scientific Program Wednesday ........................................................................................................................ 16

Scientific Program Thursday .............................................................................................................................26

Scientific Program Friday .................................................................................................................................. 42

Scientific Program Saturday ..............................................................................................................................55

Poster List .............................................................................................................................................................. 60

List of Chairs, Speakers and Authors ............................................................................................................. 70

Industrial Exhibition ............................................................................................................................................. 74

Industrial Exhibition – List of Exhibitors, numerical .................................................................................... 75

Industrial Exhibition – List of Exhibitors, alphabetical ............................................................................... 76

List of Sponsors ................................................................................................................................................... 77

FSA Disclosure Requirement ............................................................................................................................ 78

Floor Plan Ground Floor ..................................................................................................................................... 79

Floor Plan Second and Third Floor ................................................................................................................. 81

City Map of Basel ................................................................................................................................................ 82

Rurioctocog alfa pegol(Recombinant Coagulation Factor VIII)

SHIRE · BAXALTA SCHWEIZ AG Müllerenstrasse 3, Postfach, CH-8604 Volketswil | Telefon +41 44 564 34 00 | Fax +41 44 564 34 10 | www.ShireSwitzerland.ch

ADYNOVI® · Zusammensetzung: Rurioctocog alfa pegolum (Factor VIII coagulationus humanis (ADNr)); Applikation 250, 500, 1000, 2000I.E. Indika-tion: Behandlung und Prophylaxe von Blutungen bei Patienten mit Hämophilie A (kongenitaler Faktor VIII-Mangel). Dosierung/Anwendung: Nach Schweregrad des FVIII Mangels, nach dem Ort und dem Ausmass der Blutung und dem klinischen Zustand des Patienten; intravenöse Verabreichung. Kontraindikation: Bekannte lebensbedrohliche Überempfindlichkeitsreaktionen gegenüber der Ausgangssubstanz ADVATE, Maus- oder Hamsterpro-teinen, sowie anderen Bestandteilen. Vorsichtsmassnahmen: Die Bildung von neutralisierenden Antikörpern ist möglich und muss mit geeigneten Labortests überwacht werden. Unerwünschte Wirkungen: Die häufigsten Ereignisse in klinischen Studien waren Kopfschmerzen, Diarrhoe, Übelkeit und Hitzewallung. Interaktionen: Wechselwirkungen von ADYNOVI mit anderen Arzneimitteln sind nicht bekannt. Packungen: Lyophilisat mit 250, 500, 1000, 2000I.E. ADYNOVI/5ml Wasser für Injektionszwecke. Abgabekategorie B. Zulassungsinhaberin: Baxalta Schweiz AG, CH-8604 Volketswil. Stand der Information: August 2016. Ausführliche Informationen finden Sie unter www.swissmedicinfo.ch HEM154 12-2016

* N=569/591. 85,4% mit 1 Infusion (n=505), und 10,8% mit 2 Infusionen (n=64). 1. Konkle BA. et al. Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A. Blood 2015;

126(9): 1078-1085.

= Blutungen effektiv vorbeugen.

Spontane Blutungen und Gelenkblutungen betrugen im Median Null.1

96% aller Blutungen wurden mit 1 oder 2 Infusionen gestoppt.1*

Einfache Dosierung: 2x wöchentlich 40–50 I.E./kg 1

98% der Patienten benötigten keine Dosisanpassung.1

+

+

+

+

ADYNOVI® vereint die Eigenschaften von ADVATE®

mit einer 40–50% längeren Halbwertszeit.1

AY_Inserat A5.indd 1 14.12.16 13:45

3TA

BLE

OF

CO

NTE

NTS

From individual patients to pathophysiological insights

Dear Colleagues and Fellow researchers

after 11 years we have the great pleasure to welcome you back to Basel, Switzerland.

The 61st GTH Annual Meeting is being held in the Congress Center Basel at the ever changing Messeplatz, since 2014 dominated by the New Hall with its basket weave texture and huge circular skylight, built by world-renowned, Basel-born architects, Herzog and de Meuron.

“Nature is nowhere accustomed more openly to display her secret mysteries than in cases where she shows traces of her workings apart from the beaten paths; nor is there any better way to advance the proper practice of medicine than to give our minds to the discovery of the usual law of nature, by care-ful investigation of cases of rarer forms of disease.”

William Harvey (1578 – 1657) in a letter, dated April 24th 1657, to Dutch physician Johan van Vlakveld of Haarlem, the Netherlands

For a number of years now, rare diseases have received more attention from governmental insti-tutions and funding bodies, as well as the pharmaceutical industry, and already on February 28th 2017 the 10th Rare Disease Day will be held.

In our field of thrombosis and hemostasis, rare diseases and patients with instructive phenotypes have for decades been important in advancing the understanding of pathophysiological mecha-nisms, have helped to identify causative factors, and provided insights into the complexity of systems biology and indicated targets for drug development. Among the many, only two – with strong links to Switzerland and the 61st GTH congress – are mentioned: ADAMTS13 and Throm-botic Thrombocytopenic Purpura, a discovery that celebrates its 20th anniversary in February 2017; and the exploration of a peculiar bleeding phenotype in a large kindred from a remote valley in Canton Uri, leading to the discovery of coagulation factor XIII. Nature’s experiments continue to fascinate. A wealth of new and powerful molecular tools and animal models boosts our knowledge of pathophysiological mechanisms. They are often the key to understanding more common and complex diseases that affect large numbers of patients and are of vital interest to the community at large.

The comprehensive program has the well-known formats of former GTH congresses, such as plenary lectures and state-of-the-art sessions, new, hot or discussed sessions, oral communi-cations of submitted abstracts, poster walks and satellite symposia organized by our partners from the pharmaceutical industry. In addition, there are five highlight sessions, each with a clinical pearl, a personal view on the most remarkable advances of the last 12–18 months in our field of thrombosis and hemostasis and oral communications of the top scoring abstracts. Moreover, as attendee you have the possibility to select the best basic research and clinical science posters from the highest scoring poster abstracts, which are presented in two concise poster sessions, as well as to be in the audience and part of the jury of the first GTH Science slam contest at the Networking event on Friday evening.

WELCOME ADDRESS

Prof. Dr. med. Johanna A. Kremer Hovinga, Bern

Foto

: Tan

ja L

äser

, Ins

el G

rupp

e A

G, C

H-3

010

Ber

n

Entdecken Sie den besten rFVIII, den Bayer je entwickelt hat.

Neue Maßstäbe im Herstellungsprozess –komplexere Glykosylierung und besseres Capping1–3

Besser geschütztes Protein mit höherer Stabilität3

Im Zeichen des Vertrauens

Bayer SymposiumFreitag 17.02., 12:15 – 13:45 Uhr Raum: Shanghai 1+2

Dieses Arzneimittel unterliegt einer zusätzlichen Überwachung. Bitte melden Sie jeden Verdachtsfall einer Nebenwirkung über das Bundesinstitut für Impfstoffe und biomedizinische Arzneimittel Paul-Ehrlich- Institut, Website: http://www.pei.de. Bezeichnung des Arzneimittels: Kovaltry 250/500/1000/2000/3000 I. E. Pulver und Lösungsmittel zur Herstellung einer Injektionslösung. (Vor Verschreibung Fachinformation beachten.) Zusammensetzung: Wirkstoff: Jede Durchstechflasche enthält nominal 250/500/1000/2000/3000 I. E. humanen Blutgerinnungsfaktor VIII. Sonstige Bestandteile: Pulver: Sucrose, Histidin, Glycin, Natriumchlorid, Cal-ciumchlorid, Polysorbat 80; Lösungsmittel: Wasser für Injektionszwecke. Anwendungsgebiete: Behandlung u. Prophylaxe von Blutungen bei Patienten mit Hämophilie A (angeborener Faktor VIII-Mangel). Kovaltry kann bei allen Altersgruppen angewendet werden. Gegenanzeigen: Überempfindlichkeit gegen den Wirkstoff od. einen der sonstigen Bestandteile; bekannte Überempfindlichkeit gegen Maus- od. Hamsterproteine. Warnhinweise u. Vorsichtsmaßnahmen: Allergische Überempfindlichkeitsreaktionen sind möglich. Die Bildung von neutralisierenden Antikörpern (Inhibitoren) gegen Faktor VIII ist eine bekannte Komplikation bei der Behandlung von Patienten m. Hämophilie A. Bei Hämophilie-Patienten m. kardiovaskulären Risikofaktoren od. Erkrankungen kann das gleiche Risiko kardiovaskulärer Ereignisse bestehen wie bei Patienten ohne Hämophilie, nachdem die Gerinnung durch eine FVIII-Behandlung normalisiert wurde. Wenn ein zentralvenöser Katheter (ZVK) erforderlich ist, sollte an das Risiko von ZVK-assoziierten Komplikationen inkl. lokaler Infektionen, Bakteriämie und ZVK-assoziierter Throm-bosen gedacht werden. Nebenwirkungen: häufig: Lymphadenopathie, Palpitationen, Sinustachykardie, Bauchschmerzen, abdominale Beschwerden, Dyspepsie, Fieber, Brustbeschwerden, Reaktionen an d. Injektionsstelle (einschl. Extravasat an d. Injektionsstelle, Hämatom, Schmerzen an d. Infusionsstelle, Pruritus, Schwellung), Kopfschmerzen, Schwindel, Insomnie, Pruritus, Ausschlag (Ausschlag, erythematöser Hautausschlag, Ausschlag m. Juckreiz), allergische Dermatitis; gelegentlich: Überempfindlichkeitsreaktionen, Dysgeusie, Urtikaria, Hitzegefühl. Verschreibungspflichtig. Pharmazeutischer Unternehmer: Bayer Pharma AG, 13342 Berlin, Deutschland, Stand: FI/1; 02/2016

1 Chan S et al., 2003. US Patent No.: US 2005/0048608 AI 2 Ishaque A et al., Biotechnol Bioeng 2007; 97(1): 144–155 3 Vogel JH et al., Haemophilia 2010; 16(S 4): 1–158, 08P40

BVKO-0067-0003_161219_RZ_kovaltry-anzeige_148x210.indd 1 19.12.16 09:30

5W

ELC

OM

E A

DD

RES

S

I would like to thank the Bern and national organization teams, the GTH executive board, all invited speakers who have accepted to share their research and expertise with us, all authors of lecture manuscripts that compile together the two first issues of Hämostaseologie 2017, all researchers who have submitted their abstracts for oral or poster presentation, all colleagues who have accepted to act as chairs, or abstract and manuscript reviewers, as well as our sponsors and partners from the industry. Last but not least, I would like to express my gratitude to the project team of Meister ConCept in Aarau, Lilo Meister, Karin Schaer and Jessica Tobé. Working with you all was a great experience.

Let me end with a quote by Louis Pasteur (1822 – 1895, on the occasion of his inaugural lecture in Douai/Lille 1854) “… dans les champs de l’observation le hazard ne favorise que les esprits préparés.” Broad knowledge, an opportunity to look deeply into a subject, networking with fellow researchers, an open and associative mind are indispensable for future discoveries.

The congress’ educational and research program and venue provide a backbone for this, the rest you have to bring yourself.

Enjoy the 61st GTH Congress – Welcome to Basel!

Yours sincerely, Johanna A. Kremer Hovinga Congress President

The Organizers of GTH 2017 gratefully acknowledge the support of the Canton of Basel-Stadt and the following companies:

ACKNOWLEDGMENTS

Gold Sponsors

Silver Sponsor

Platinum Sponsors

Supporters

76W

ELC

OM

E A

DD

RES

S

AC

KN

OW

LED

GEM

ENTS

Organizer

Society of Thrombosis and Hemostasis Research Feodor-Lynen-Str. 5 30625 Hanover / Germany P +49 511 532 84 88 F +49 511 532 1684 88 [email protected]

Congress president

Johanna A. Kremer Hovinga Department of Hematology and Central Hematology Laboratory Inselspital Bern University Hospital and Department of Clinical Research University of Bern 3010 Bern / Switzerland [email protected]

Professional congress organizer

Meister ConCept GmbH Bahnhofstrasse 55 5001 Aarau / Switzerland P +41 62 836 20 90 F +41 62 836 20 97 [email protected]

The organizer of the industrial exhibition and the satellite symposia is Meister ConCept GmbH, Aarau / Switzerland.

National organization committee

Lorenzo Alberio (Lausanne)Manuela Albisetti Pedroni (Zurich)Anne Angelillo-Scherrer (Bern)Lars Asmis (Zurich)Henri Bounameaux (Geneva)Kenneth J. Clemetson (Bern)Silvio Kathriner (Lucerne)Rainer Kobelt (Wabern)Hans-Peter Kohler (Bern)Wolfgang Korte (St. Gallen)Thomas Kühne (Basel)Bernhard Lämmle (Bern/Mainz)Markus G. Mohaupt (Bern)Elsbeth Müller-Kägi (Zurich)Michael Nagler (Bern)Robert Rieben (Bern)Monica Schaller Tschan (Bern)Verena Schröder (Bern)Jan-Dirk Studt (Zurich)Eveline Stutz-Grunder (Bern)Dimitrios Tsakiris (Basel)Nicolas von der Weid (Basel)Walter A. Wuillemin (Lucerne)

GTH executive board

Bettina Kemkes-Matthes (Giessen)Michael Spannagl (Munich)Andreas Tiede (Hanover)Edelgard Lindhoff-Last (Frankfurt am Main)Lorenzo Alberio (Lausanne)Werner Streif (Innsbruck)Barbara Zieger (Freiburg)

Ingo AhrensLorenzo AlberioManuela Albisetti PedroniKonrad AndrassyAnne Angelillo-ScherrerLars AsmisGünter AuerswaldCihan AyTamam BakchoulJürg Hans BeerGregor BeinChristoph BidlingmaierChristoph J. BinderArijit BiswasChristoph BodeHenri BounameauxHans-Hermann BrackmannMaria Alexandra BrehmUlrich BuddeHeiko BuggerAlessandro CasiniHugo ten CateKenneth J. ClemetsonMihaela DelceaCarl-Erik DempfleDaniel DürschmiedWolfgang EberlSabine Eichinger-HasenauerJeroen EikenboomMargitta ElversBernd EngelmannPierre FontanaChristof GeisenSylvia HaasViola Hach-WunderleJob HarenbergWolf-Achim HassenpflugAlexander HaushoferSabine HerterichHans-Jürg Hertfelder

Katharina SchüttSusanne HolzhauerIngrid HrachovinovaKurt HuberVytautas IvaskeviciusKerstin JurkPeter KalhsBeate KehrelMalte KelmBettina Kemkes-MatthesKarim KentoucheCarl KirchmaierRobert KlamrothPaul KnöblHans-Peter KohlerStavros KonstantinidesWolfgang KorteJohanna A. Kremer HovingaThomas KühneKarin KurnikBernhard LämmleFlorian LangerHans-Jürgen LawsThomas LecompteMarcel LeviStefan LorkowskiChristoph MaleNikolaus MarxWolfgang MiesbachMarkus G. MohauptJens MüllerWolfgang MunteanMichael NaglerBernhard NieswandtUlrike Nowak-GöttlHelmut OstermannIngrid Pabinger-FaschingAnna PavlovaDirk PeetzKarlheinz Peter

Bernd PötzschZoltán ProhászkaPeter QuehenbergerEberhard RabeBirgit ReipertThomas RennéRobert RiebenJürgen RingwaldJohannes RischewskiMattia RizziWolfram RufUlrich SachsSentot SantosoMonica Schaller TschanRüdiger E. ScharfInge ScharrerUte ScholzWolfgang SchrammVerena SchröderRoger SchutgensErhard SeifriedRainer SeitzGabriele SiegertOliver SöhnleinMichael SpannaglHenri SpronkUdo SteigerwaldErwin StrasserWerner StreifJan-Dirk StudtEveline Stutz-GrunderAndreas TiedeDimitrios TsakirisNicolas von der WeidChristian von HeymannAnne Sophie von KroghUlrich WalterAlisa WolbergWalter A. WuilleminBarbara Zieger

GTH 2017 ABSTRACT-REVIEWERSCONTACTS & COMMITTEES

98C

ON

TAC

TS &

CO

MM

ITTE

ES

GTH

201

7 A

BS

TRA

CT-

REV

IEW

ERS

GENERAL INFORMATION

Congress venue

Congress Center BaselMesseplatz 214058 Basel / SwitzerlandP +41 58 206 28 [email protected]

Congress website

www.gth2017.org

Opening hours

Wednesday, 15 February 2017 07:30 – 18:00Thursday, 16 February 2017 07:30 – 18:00Friday, 17 February 2017 07:30 – 18:00Saturday, 18 February 2017 07:30 – 12:30

Congress language

The official congress language is English. The educational and scientific lectures will be held in English. All PowerPoint presentations have to be prepared in English only.

Satellite symposia and workshops will be held in German or English.

Simultaneous oral translation is exclusively available for the special symposium TTP & ADAMTS13 on Saturday, 18 February 2017, 08:30 –11:15.

Internet

During the meeting wireless internet access is available throughout the venue – you will receive a password at the registration desk.

Registration desk

The registration desk is located in the entrance hall (ground floor). Registration on-site is pos-sible at the registration desk. However, waiting time can be shortened by online registration in advance. Pre-registered participants can pick up their badge at the pre-registered desk in the entrance hall (ground floor).

P +41 58 206 28 20F +41 58 206 21 66

Registration fees

Methods of payment at the registration desk

On-site you can pay in cash or with credit card (Visa, MasterCard, Maestro).

The following is included in the registration fee:

• Name badge• Congress bag and congress documents• Opening Ceremony and Get Together on

Wednesday, 15 February 2017• Admission to all scientific sessions and sym-

posia, poster area and industrial exhibition• Free WLAN access

Name badges

All congress attendees must wear their official name badge at all times to gain admission to the meeting rooms and industrial exhibition area.

In case of lost or forgotten badges, replacement can be obtained at the registration desk, an ad-ministrative fee of CHF 20.00 will be charged.

Helpful telephone numbers

Police 117

Fire 118

Ambulance 144

Taxi +41 61 222 22 22 Basel City +41 79 655 77 67 Airport Taxi Service

Credit Allowance

Certificate of Attendance with EFN codes

The certificate of attendance can be submitted to the Ärztekammer in Germany where you are registered.In order to issue your certificate, we kindly ask you to scan your EFN codes as well as the bar-code on your badge each day in the afternoon. Please note that for technical reasons barcodes cannot be scanned after the congress or on another day. Certificates stating the total of your acquired credits will be available for download on the website www.gth2017.org within four weeks after the congress.

Certificate of Attendance without EFN codes

The congress is accredited by the following Swiss societies with the following credit amount:

SSGIM Swiss Society of General Internal Medicine:19 AIM/MIG credits

SPOG Swiss Paediatric Oncology Group:12 credits

SSH Swiss Society of Hematology:17.5 creditsWednesday, 15 February 2017: 4 creditsThursday, 16 February 2017: 5.5 creditsFriday, 17 February 2017: 6 creditsSaturday, 18 February 2017: 2 credits

The certificate of attendance can be submitted to the respective “Österreichische Landesärzte-kammer”.

Cloakroom

The cloakroom is located in the entrance hall and closes each day 30 minutes after the last session in the program.

Social program

Wednesday, 15 February 2017, 17:30:Opening Ceremony, room San Francisco followed by Welcome Reception and Get Together in the industrial exhibition.

Friday, 17 February 2017, 18:30:Networking Evening, at the Offene Kirche Elisabethen, Elisabethenstrasse 10–14, 4051 Basel

Tickets can be purchased at the Registration desk:CHF 75.00 for GTH members and non-membersCHF 45.00 for PhD students, MTAs, nursing staffphysicians in training, retired members and stu-dents.

Industrial exhibition

Opening hours

Wednesday, 15 February 2017 09:00 – 18:00Thursday, 16 February 2017 07:30 – 18:00Friday, 17 February 2017 07:30 – 18:00

Please visit the industrial exhibition on the first floor. For further information, please see the list of exhibitors (page 74) and the floor plan (page 81).

Disclaimer

The organizer and the congress organization dis claim responsibility for any kind of damage to property and persons which may occur in con-junction with the congress. Attendees take part in all events of this congress at their own risk.

The organizer reserves the right to make pro-gram changes if necessary. No full or partial re-funds are made to the attendees in the event of cancellations or other changes in the program or of non-appearance of speakers. Program changes will be posted at the registration desk, at the entrance of the session halls, as well as on the website.

Currency

The currency of Switzerland is CHF (Swiss Francs). You will find cash machines/ATMs next to the Congress Center Basel as well as at the airport and most banks, post offices, hotels and shopping areas in Basel. Currency exchange of-fices are also widely available at banks and post offices in Basel as well as at the airport and train stations.

On-site fees

Day tickets**

Member of GTH CHF 390.00 CHF 185.00

Non-member CHF 485.00 CHF 220.00

PhD student, MTA, nursing staff, phy-sician in training, retired member (*)

CHF 180.00 CHF 120.00

Student (*) CHF 75.00 CHF 40.00

Patients Saturday only

CHF 20.00

* Proof of current status needs to be provided along with the registration or on-site at the latest. Only then can a deduction be granted

** Only one day ticket may be purchased.

1110G

ENER

AL

INFO

RM

ATIO

N

GEN

ERA

L IN

FOR

MAT

ION

Speakers Center / media check

The Speakers Center / media check is located on the 2nd floor of the Congress Center.

Opening hours

Wednesday, 15 February 2017 07:00 – 18:00Thursday, 16 February 2017 07:00 – 18:00Friday, 17 February 2017 07:00 – 18:00Saturday, 18 February 2017 07:30 – 12:15

Technical requirements

The Speakers Center and all meeting rooms are equipped with Microsoft Windows-based notebooks. For smooth operation of ses-sions, speakers are requested not to bring their presentation directly to meeting rooms. All presentations and additional media files have to be uploaded in the speakers cen-ter at least 1 hour before the corresponding session starts. It is essential to verify proper function at the speakers center, particularly if video and/or animation are included in the presentation. Please note that internet access will not be available during your presentation.

When reviewing your presentation at the spea-kers center, make sure all fonts, images, and animations appear as expected and that all audio or video clips are working properly. The following presentation file types are accept-able: Microsoft Office PowerPoint (.ppt, .pptx), Adobe Acrobat (.pdf), Media Files (.wmv, .mpg, .avi, .swf, .wav, .mov, .mp3).

Please prepare your PowerPoint presentations with an aspect ratio of 16:9.

Oral communications of scientific abstracts

Presenters are advised to finish their presenta-tions well in advance.

Presentation time is 9 min, followed by 3 min for questions/discussion. Please make sure that your presentation does not take longer, chair-persons are advised to follow the schedule stric-tly and to interrupt if necessary.

Abstracts

All abstracts will remain online to enable you sharing with your colleagues and linking to your CV.

Poster exhibition

The poster exhibition is located in the foyer on the second floor.

Posters should be prepared in English and be of DINA0 size (841x1189mm), portrait format. Pos-ters have to be mounted on the poster boards provided before Thursday, 16 February 2017 10:00. Posters will remain accessible to all at-tendees throughout the congress until the end of the poster session on Friday, 17 February 2017.

Adhesives to mount your poster can be picked up at the registration desk.

Poster session

Friday, 17 February 2017 17:15 – 18:15

During this session, poster presenters should be available for questions and discussions.

Please remove posters at the end of the poster session. Remaining posters will be disposed of and cannot be stored.

Best poster

During the sessions “Best Poster Basic Sci-ence” on Thursday, 16 February 2017, 11:00 – 12:00 and “Best Poster Clinical Science” on Friday, 17 February 2017, 11:00 –12:00 the ten top scoring poster abstracts will be presented concisely in each session.

Presentation time is 3 min, followed by 2 min for questions/discussion. Please make sure that your presentation does not take longer, chair-persons are advised to strictly follow the sched-ule and to interrupt if necessary.

Congress attendees have the possibility to select the best poster in basic science as well as the best poster in clinical science from these 20 abstracts at the designated computer sta-tion in the industrial exhibition from Thursday, 16 Feb ruary 2017 10:00 to Friday, 17 February 2017 14:00.

The highest scoring posters will receive the best poster award during the poster viewing session on Friday, 17 February 2017 in the poster area.

TRAVEL INFORMATION INFORMATION FOR SPEAKERS AND PRESENTERS

City of Basel (see map on page 82)

Basel is located in the triangle where Switzer-land, France and Germany meet. A beautiful, well-tended old city, the river Rhine – all of this is Basel. Added to this is a wide selection of hotels, restaurants and bars, good shopping and a comprehensive range of possibilities for free-time activities, including some 40 museums – some of which enjoy an international reputati-on (i.e. the Beyeler Foundation, the Art Museum Basel, or the Tinguely Museum).

Basel is the oldest university city in Switzerland (550 years) and one of Europe’s leading tea-ching and research locations for the life scien-ces, medical research, as well as for energy technology and culture. As Switzerland’s most dynamic economic region and one of the most productive and innovative worldwide, Basel is a key location for the pharmaceutical industry.

Public transportation within the city

Reservation in a Basel hotel includes the “Mo-bility Ticket” which allows you to use the public transportation system in and around the city for the duration of your stay free of charge (zones 10, 11, 13 and 15, incl. the way to and from the EuroAirport). On the day of arrival, your printed hotel reservation confirmation guarantees a free transfer by public transport from the train station or the EuroAirport to the hotel, where you will be given the Mobility Ticket upon check-in. No waiting around or puzzling over ticket machines – because you’ve got the Mobility Ticket!

Arrival by plane

EuroAirport Basel-Mulhouse-Freiburg is fif-teen minutes from the city center. Bus connec-tions to the city center leave every 15 minutes. Take bus Nr. 50 to “Basel SBB” and then Tram No. 2 to “Messeplatz/Exhibition Square”.From Zurich Airport: there are direct train connections to Basel every hour, travel time one hour.

Arrival by railway

Basel is an international rail hub with direct ICE, IC and EC day and night connections to and from Germany, Austria, Italy, France and the Benelux countries.All three of Basel’s railway stations – SBB (Swit-zerland), SNCF (France) and DB (Basel Badi-scher Bahnhof, Germany) – are within 5–10 mi-nutes of the Congress Center Basel.With tram No. 1 or 2 from the Swiss or French (SBB/SNCF) railway stations; you can reach the Congress Center Basel in 10 minutes (Messe-platz/Exhibition Square).From the German Railway (DB) station (Basel Badischer Bahnhof) you can be at “Messeplatz / Exhibition Square” in 5 minutes by tram No. 2 or 6.

Arrival by car

Basel is the point where the Swiss, French and German motorway networks meet. Please take the exit “Messe” from the A2 motorway which leads directly to Exhibition Square and the Con-gress Center Basel. There is a multi-storey car park with space for 1300 vehicles (day rate: CHF 50.00).

GPS

Parkhaus Messe BaselRiehenstrasse 1014058 Basel / Switzerland

Tourist information Barfüsserplatz

Steinenberg 14, 5051 Basel-CenterP +41 61 268 68 68Open: Mo-Fr 09:00 –18:30; Sa 09:00 –17:00

Tourist information Bahnhof SBB

Centralbahnstrasse 104051 Basel – Basel HauptbahnhofP +41 61 268 68 68Open: Mo–Fr 08:00 –18:00; Sa 09:00 –17:00

1312TR

AVEL

INFO

RM

ATIO

N

INFO

RM

ATIO

N F

OR

SP

EAK

ERS

AN

D P

RES

ENTE

RS

AWARDS AND GRANTS OF THE GTH SCIENTIFIC PROGRAM

Annually, the GTH confers a number of awards and grants.

The award and grant recipients of 2017 will be announced in the opening ceremony of the 61st GTH Annual Meeting in Basel, Switzerland on Wednesday, 15 February 2017.

The society appreciates it when applicants are present at the opening ceremony of the con-gress to pick up the respective award or grant in person.

Session types

Plenary lectures

Ten plenary lectures given by distinguished invi-ted speakers in five sessions (thematically grou-ped and containing one basic research and one clinically orientated lecture) will provide updates on main topics of the meeting and showcase some of the latest clinical and basic science in the field of thrombosis and hemostasis.

Special symposia

Two special symposia, one dedicated to FXIII (on Thursday, 16 February 2017), the other to Thrombotic Thrombocytopenic Purpura and ADAMTS13 (on Saturday, 18 February 2017), each with 6 lectures, impart a deep insight into both clinical and basic science in these topics.

Additional special symposia on Friday, 17 Feb-ruary and Saturday, 18 February 2017 deal with different aspects of the care of patients with hemophilia and related disorders. The special symposia on Saturday are of special interest to patients and were organized together with pa-tients.

State of the Art

Fourteen state of the art and two new, hot or discussed sessions usually comprising lectures of three invited speakers introduce the attendee to recent developments in basic and clinical science.

Highlight session

There are five highlight sessions each with a cli-nical pearl, a personal view of the invited spea-ker on the most remarkable advances of the last 12 –18 months in the field of thrombosis and he-mostasis, and oral communications of top sco-ring abstracts (two per session), recognized with a GTH 2017 best abstract award.

Oral communications

Eight oral communication-sessions of scientific abstracts feature the most interesting develop-ments in various topics.

Satellite symposia

There are 20 interesting satellite symposia sponsored by our industrial partners, who chose the topics and speakers. Thematical-ly, they outline some of the most innovative treatment options in hemostasis, thrombosis and vascular medicine.

Workshops

On the first day of the congress workshops are offered for health care professionals.

P Plenary

SSy Special symposia

SOA State of the Art

HL Highlight

OC Oral communications

SAT Satellite symposia

WS WorkshopsAlexander Schmidt Award

• For excellent research in hemostasis.

Award for Young Researchers

• For excellent research by young scientists in the field of thrombosis and vascular medicine.• For excellent research by young scientists in the field of bleeding disorders.

Hans-Egli-Research Grant

• For young physicians for a 6 months research project on congenital bleeding disorders.

Rudolf Marx Grant

• For young scientists from German-speaking countries.

1514SESSION TYPES

AW

AR

DS

AN

D G

RA

NTS

OF

THE

GTH

SC

IEN

TIFI

C P

RO

GR

AM

SCIENTIFIC PROGRAM

Plenary Highlight Poster State of the Art Working Group Miscellaneous NEW, HOT or DISCUSSED Oral Communication Sat./Lunch Symposium Symposium Workshop

Boston 1+2 Ground Floor

Delhi Ground Floor

Kairo 1+2 Ground Floor

Lima Ground Floor

08:00

Ärztlicher Beirat der Deutschen

Hämophiliegesellschaft

08:3008:4509:00

MTA-Workshop I(Haemochrom

Diagnostica GmbH) Hämophilie und ihre

Diagnostik

09:1509:3009:4510:0010:1510:3010:4511:00

Ständige Kommission Hämophilie

11:1511:3011:4512:0012:1512:3012:4513:00 AG

Thrombotische Mikroangiopathie

Ständige Kommission Pädiatrie

MTA-Workshop IIBMA- / MTA-Arbeitskreis

Weiterbildung für Hämophilie-

Assistentinnen und -Assistenten (Novo Nordisk

Pharma GmbH) Hämophiliebehandlung im praktischen Alltag

13:1513:30 German Pediatric

Hemophilia Research13:4514:00

State of the ArtLaboratory Diagnostics

14:1514:3014:4515:0015:1515:30

Satellite SymposiumPfizer AG

SIPPET and the Future Management of

Hemophilia

Satellite SymposiumDaiichi Sankyo

Deutschland GmbH Safety first:

Antikoagulation auch bei Risikopatienten?

Satellite SymposiumCSL Behring GmbH

Beginn einer neuen Zeitrech-nung – neue Optionen zur

Individualisierung der Therapie der Hämophilie A und B

15:4516:0016:1516:3016:4517:0017:1517:3017:4518:0018:1518:3018:4519:0019:15

Shanghai 1+2 Ground Floor


Sydney 2nd Floor

San Francisco 3rd Floor

08:0008:3008:4509:00

Nurse-Workshop(Bayer)

Hämophilie und Schmerz: Was mit Therapie und Kommunikation alles

möglich ist

09:1509:3009:4510:0010:1510:3010:4511:0011:1511:3011:45

AG Perioperative Hämostase

12:0012:1512:3012:4513:00 AG

Women’s Health Aktuelles aus der AG

13:1513:30

State of the ArtPerioperative Hemostasis

13:4514:00

State of the ArtAtherothrombosis and

Platelets

State of the ArtHemostasis in the Elderly

14:1514:3014:4515:0015:1515:30

Satellite SymposiumGrifols Deutschland GmbH

Current Views on Immunology in Hemophilia and von Wille-

brand Disease

Satellite SymposiumBiotest AG

«Wer die Wahl hat …»

15:4516:0016:15 BDDH Symposium

Thrombophilie und Wirtschaftlichkeits prinzip

Pro und Contra

16:3016:4517:0017:1517:30

Opening ceremony

17:4518:0018:1518:3018:4519:0019:15

1716W

EDNE

SDAY

THUR

SDAY

FRID

AYSA

TURD

AY

WED

NESD

AYTH

URSD

AYFR

IDAY

SATU

RDAY

SC

IEN

TIFI

C P

RO

GR

AM

SC

IEN

TIFI

C P

RO

GR

AM

WEDNESDAY, 15 FEBRUARY 2017 WEDNESDAY, 15 FEBRUARY 2017

SCIENTIFIC PROGRAM

08:00 – 09:45

Delhi

Ärztlicher Beirat der Deutschen Hämophiliegesellschaft

09:00 – 12:30

Kairo 1+2

MTA Workshop I (Haemochrom Diagnostica GmbH)Hämophilie und ihre Diagnostik

09:00 Hämophilie, ein Überblick: Ursachen, Molekular Mechanismen & GenetikA. Karst (Essen, Germany)

09:30 Grundlagen der primären und sekundären Hämostase unter besonderer Berücksichtigung von FVIII und FIX: Thrombozyten funktion & Zu sammen spiel mit den GerinnungsfaktorenA. Karst (Essen, Germany)

10:30 Kaffeepause

11:00 Therapiekonzepte: Substitution & GentherapieB. Schuster (Essen, Germany)

11:15 Hämophilie im Gerinnungslabor: Diagnostik der Hämophilie, Monitoring der Therapie & Diagnostik der FaktoreninhibitorenB. Schuster (Essen, Germany)

12:30 Ende des MTA Workshops

09:00 – 12:00

Shanghai 1+2

Nurse-Workshop (Bayer)Hämophilie und Schmerz:Was mit Therapie und Kommunikation alles möglich ist

09:00 Begrüssung

09:10 Physiotherapeutische Ansätze der SchmerzbehandlungJ. Dayo (Frankfurt am Main, Germany)

09:50 Schmerz bei Patienten mit Hämophilie und die therapeutischen OptionenK. Holstein (Hamburg, Germany)

10:30 Kaffeepause

11:00 Mit Patienten darüber reden: der Berliner SchmerzfragebogenB. Rothe (Berlin, Germany) S. Gottstein (Berlin, Germany) K. Grosse (Berlin, Germany)

11:50 Feedback aus den Gruppen und Zusammenfassung

11:00 – 12:30

Delhi

Ständige Kommission HämophilieChairs: R. Klamroth (Berlin, Germany), K. Kurnik (Munich, Germany)

Aktuelle ProjekteKonstitution der ArbeitsgruppenTreffen der ArbeitsgruppenWahl der Sprecher

11:45 – 12:45

Shanghai 3+4

AG Perioperative HämostaseChairs: L. Graf (St. Gallen, Switzerland), W. Korte (St. Gallen, Switzerland)

Schwerpunkt präoperative Abklärungen: Vorgehensweisen, Vorschlag Feasibility-Studie

13:00 – 13:30

Delhi

Ständige Kommission Pädiatrie

13:00 – 14:30

Kairo 1+2

MTA Workshop IIBMA-/MTA-Arbeitskreis

13:00 Tätigkeitsbericht “MTA-Arbeitskreis” seit Gründung 2009G. Stöver (Aschaffenburg, Germany)

13:20 Wahlvorschläge Nachfolge | Wahl neue Sprecherinnen und SprecherG. Klose (Mannheim, Germany) G. Stöver (Aschaffenburg, Germany)

13:40 Geräte- bzw. Reagenzprobleme im Alltag | Kurzvorträge diverser Referent innen und Referenten

14:20 Diskussion

1918W

EDNE

SDAY

THUR

SDAY

FRID

AYSA

TURD

AY

WED

NESD

AYTH

URSD

AYFR

IDAY

SATU

RDAY

SC

IEN

TIFI

C P

RO

GR

AM

SC

IEN

TIFI

C P

RO

GR

AM


SCIENTIFIC PROGRAM SCIENTIFIC PROGRAM

13:00 – 17:00

Lima

Weiterbildung für Hämophilie-Assistentinnen und -Assistenten(Novo Nordisk Pharma GmbH)Hämophiliebehandlung im praktischen Alltag

13:00 Begrüssung und VorstellungK. Andritschke (Moerfelden-Walldorf, Germany), E. Müller-Kägi (Zurich, Switzerland)

13:10 Klinische Messmethoden in der PraxisM. Stemberger (Munich, Germany)

14:00 Update HämophilietherapieM. Sigl-Kraetzig (Blaubeuren, Germany)

14:30 Kaffeepause

14:45 Hypnose – Wirkungsvolles Skill Set für die HämophiliebehandlungC. Ceppi (Duebendorf, Switzerland)

16:45 Schlusswort & AuswertungK. Andritschke (Moerfelden-Walldorf, Germany), E. Müller-Kägi (Zurich, Switzerland)

13:00 – 13:45

Shanghai 1+2

AG Women’s HealthAktuelles aus der AG Women’s HealthChairs: R. Bauersachs (Darmstadt, Germany), U. Scholz (Leipzig, Germany)

13:00 NOACs und SchwangerschaftB. Linnemann (Frankfurt am Main, Germany)

13:15 NOACs und MenstruationS. Halimeh (Duisburg, Germany)

13:30 Besonderheiten des Von-Willebrand-Syndroms bei FrauenF. Bergmann (Hanover, Germany)

13:00 – 13:45

Boston 1+2

AG Thrombotische MikroangiopathieChair: J. A. Kremer Hovinga (Bern, Switzerland)

13:30 – 14:00

Delhi

German Pediatric Hemophilia Research Database (GEPHARD)Chairs: C. Bidlingmaier (Munich, Germany), C. Königs (Frankfurt am Main, Germany)

Sitzung der Studienkommission

14:00 – 15:15

Boston 1+2

State of the ArtLaboratory DiagnosticsChairs: L. Asmis (Zurich, Switzerland), F. Bergmann (Hanover, Germany)

14:00 Pathophysiological insights into the antiphospholipid syndromeK. Lackner (Mainz, Germany)

14:25 Challenges in diagnosing heparin-induced thrombocytopeniaM. Nagler (Bern, Switzerland)

14:50 Complement and thrombotic microangiopathyS. Meri (Helsinki, Finland)

14:00 – 15:15

Shanghai 1+2

State of the ArtAtherothrombosis and PlateletsChairs: M. Elvers (Duesseldorf, Germany), K. Jurk (Mainz, Germany)

14:00 Effects of omega-3 alpha-linolenic acid on platelets and endothelial cellsJ. H. Beer (Baden, Switzerland)

14:25 MicroRNA-mediated mechanisms of the cellular stress response in atherosclerosisA. Schober (Munich, Germany)

14:50 Serotonin and thrombosisD. Dürschmied (Freiburg, Germany)

14:00 – 15:15

Sydney

State of the ArtHemostasis in the ElderlyChairs: C. Ay (Vienna, Austria), A. ten Cate-Hoek (Maastricht, The Netherlands)

14:00 Use of DOACs in elderly patients – opportunities and risksJ. Beyer-Westendorf (Dresden, Germany)

14:25 VTE in the elderly – insights gained from SWITCOD. Aujesky (Bern, Switzerland)

14:50 Hemostasis and CancerI. Pabinger-Fasching (Vienna, Austria)

13:30 – 15:15

Shanghai 3+4

State of the ArtPerioperative HemostasisChair: W. Korte (St. Gallen, Switzerland)

13:30 Quality assurance in thrombelastographic methods – difficulties and resultsM. Spannagl (Munich, Germany)

13:55 Peripartal fibrinogen determination – what is the best way?L. Kaufner (Berlin, Germany)

14:20 Anesthesiological management in postpartal hemorrhage in the light of the new 2016 AWMF guidelineH. Lier (Cologne, Germany)

14:45 Managing platelet inhibitors in the perioperative settingM. Cattaneo (Milan, Italy)

2120W

EDNE

SDAY

THUR

SDAY

FRID

AYSA

TURD

AY

WED

NESD

AYTH

URSD

AYFR

IDAY

SATU

RDAY

SC

IEN

TIFI

C P

RO

GR

AM

SC

IEN

TIFI

C P

RO

GR

AM



15:30 – 17:00

Boston 1+2

Satellite Symposium Pfizer AGSIPPET and the Future Management of HemophiliaChair: T. Lehmann (St. Gallen, Switzerland)

15:30 WelcomeT. Lehmann (St. Gallen, Switzerland)

15:35 Factor concentrates: History & ChallengesB. T. Colvin (Chislehurst, United Kingdom)

15:55 Why SIPPET matters: Plasma the resurrected star?N. von der Weid (Basel, Switzerland)

16:15 SIPPET in context: a critical reflectionT. Lehmann (St. Gallen, Switzerland)

16:35 Q & AT. Lehmann (St. Gallen, Switzerland)

16:55 Conclusion and closureT. Lehmann (St. Gallen, Switzerland)

15:30 – 17:00

Delhi

Satellite Symposium Daiichi Sankyo Deutschland GmbHSafety first: Antikoagulation auch bei Risikopatienten?Chairs: E. Minar (Vienna, Austria), D. Tsakiris (Basel, Switzerland)

15:30 BegrüssungE. Minar (Vienna, Austria), D. Tsakiris (Basel, Switzerland)

15:35 Einfach und sicher antikoagulieren bei Risiko-PatientenC. Espinola-Klein (Mainz, Germany)

16:00 Thromboseprophylaxe und -therapie bei Tumorpatienten – welche Rolle spielen NOAKs?C. Ay (Vienna, Austria)

16:25 2037 – Zukunft der Gesundheit: Thesen des ZukunftsforschersG. T. Roos (Lucerne, Switzerland)

16:50 Zusammenfassung und VerabschiedungE. Minar (Vienna, Austria), D. Tsakiris (Basel, Switzerland)

15:30 – 17:00

Kairo 1+2

Satellite Symposium CSL Behring GmbHBeginn einer neuen Zeitrechnung – neue Optionen zur Individualisierung der Therapie der Hämophilie A und BChairs: R. Klamroth (Berlin, Germany), I. Pabinger-Fasching (Vienna, Austria)

15:30 rVIII-SingleChain: Ergebnisse aus den StudienprogrammenA. Veldman (Marburg, Germany)

15:48 rVIII-SingleChain: Ein neues Faktorkonzentrat im Übergang von klinischer Studie zur klinischen PraxisG. Goldmann (Bonn, Germany)

16:06 IDELVION®: Ergebnisse aus den StudienprogrammenA. Tiede (Hanover, Germany)

16:24 IDELVION®: Klinische PraxisW.-A. Hassenpflug (Hamburg, Germany)

16:42 Herausforderung in der Diagnostik von FVIII/FIX: Was ist zu beachten?U. Scholz (Leipzig, Germany)

15:30 – 17:00

Shanghai 1+2

Satellite Symposium Grifols Deutschland GmbHCurrent Views on Immunology in Hemophilia and von Willebrand DiseaseChair: J. Oldenburg (Bonn, Germany)

15:30 Welcome and IntroductionJ. Oldenburg (Bonn, Germany)

15:35 Strategies to minimize incidence of FVIII inhibitorsE. Santagostino (Milan, Italy)

15:55 Cost impact of inhibitor developmentJ. Oldenburg (Bonn, Germany)

16:15 The protective role of VWF against FVIII inhibitorsS. Lacroix-Desmazes (Paris, France)

16:30 Acquired von Willebrand Syndrome in patients with ventricular assist device (VAD) or extracorporeal life support (ECLS)B. Zieger (Freiburg, Germany)

16:45 Summary and DiscussionJ. Oldenburg (Bonn, Germany)

2322W

EDNE

SDAY

THUR

SDAY

FRID

AYSA

TURD

AY

WED

NESD

AYTH

URSD

AYFR

IDAY

SATU

RDAY

SC

IEN

TIFI

C P

RO

GR

AM

SC

IEN

TIFI

C P

RO

GR

AM



15:30 – 17:00

Shanghai 3+4

Satellite Symposium Biotest AG“Wer die Wahl hat …”Chair: J. A. Kremer Hovinga (Bern, Switzerland)

15:30 Die Qual der WahlM. Wehr (Tuebingen, Germany)

15:53 rFVIII-Konzentrate: Welches wählen?C. Escuriola-Ettingshausen (Moerfelden-Walldorf, Germany)

16:16 SIPPET-Studie und PUPs: Hat man eine Wahl?M. Albisetti Pedroni (Zurich, Switzerland)

16:39 Unsere Wahl: “Wie human”J. Schüttrumpf (Dreieich, Germany)

16:15 – 17:15

Sydney

BDDH SymposiumThrombophilie und Wirtschaftlichkeitsprinzip: Pro und ContraChairs: J. Koscielny (Berlin, Germany), U. Scholz (Leipzig, Germany)

ContraC.-E. Dempfl e (Mannheim-Lindenhof, Germany)

ProR. B. Zotz (Duesseldorf, Germany)

17:30 –*19:15

San Francisco

Opening Ceremony

Welcome AddressB. Kemkes-Matthes (Giessen, Germany)

Welcome AddressAcknowledgmentsJ. A. Kremer Hovinga (Bern, Switzerland)

Welcome AddressLukas Engelberger, Member of the Government of the Canton Basel-StadtHead of the Public Health Department

Alexander-Schmidt-LecturePrognostic factors for remission and survival in acquired hemophiliaA. Tiede (Hanover, Germany)

Keynote LectureMassimo Rocchi (Basel, Switzerland)

Recipient of the Salzburger Stier 1996, the Swiss Award 2005, the Schweizer Kleinkunstpreis 2008 and many other awards as well as of a honory doctorate of the University of Fribourg, Switzerland in 2011.

*approximately Award Ceremony GTH 2017

Followed by Welcome Reception and Get Together in the Industrial Exhibition on the fi rst fl oor (until 21:00).

Ansprechpartner Deutschland: LFB GmbH, An der Alten Ziegelei 5, 48157 Münster, Deutschland, Tel.: 0251/3270-217, Fax: 0251/3270-212

www.lfb-pharma.de

You can rely on LFB

Powder and solvent for solution for injection/infusion

ILLFACT®

2524W

EDNE

SDAY

THUR

SDAY

FRID

AYSA

TURD

AY

WED

NESD

AYTH

URSD

AYFR

IDAY

SATU

RDAY

SC

IEN

TIFI

C P

RO

GR

AM

SC

IEN

TIFI

C P

RO

GR

AM



SCIENTIFIC PROGRAM


Foyer 2. OG 2nd Floor

Montreal 2nd Floor

Singapore 2nd Floor

Sydney 2nd Floor

San Francisco 3rd Floor

08:00

Poster Exhibition

Special SymposiumFactor XIII Structure

and Functions

State of the ArtVTE Management

State of the ArtPediatric – Hemostasis

08:3008:4509:0009:1509:30

Plenary Session I09:4510:0010:1510:30 Bayer Thrombosis Award10:45

Special SymposiumClinical aspects of

factor XIII

11:00

Highlight Session IIHemostasis

Highlight Session IIIThrombosis

11:1511:3011:4512:0012:15

Satellite SymposiumPfizer Pharma GmbH

Hämophilie-Therapie in der Zukunft – von guten Prognosen und neuen Behandlungsansätzen

12:3012:4513:0013:1513:3013:4514:00

State of the ArtWomen issues

State of the ArtHemophilia &

inhibitors

State of the ArtVTE intervention

14:1514:3014:4515:0015:1515:30

Plenary Session II15:4516:0016:1516:3016:4517:0017:1517:3017:4518:0018:1518:3018:4519:00


Delhi Ground Floor




08:00

State of the ArtVon-Willebrand-Factor

State of the ArtPlatelets

Oral Communications

Laboratory

08:3008:4509:0009:1509:3009:4510:0010:1510:3010:4511:00

Highlight Session IMiscellaneous

Best Poster Basic Science

11:1511:3011:4512:0012:15

Satellite SymposiumCSL Behring GmbH

Vielfältigkeit von angebore-nen Gerinnungs störungen

und Angio pathien – Theorie und Praxis

Satellite SymposiumBayer

Moderne Anti - ko agulation –

Von Pionier- zu Alltagsfragen

Satellite SymposiumOctapharma GmbH

Challenges and opportunities in

hemophilia A and VWD

Satellite SymposiumSwedish Orphan Biovitrum GmbH

Half-life extension in hemophilia – A practical

guide for Fc fusion proteins

12:3012:4513:0013:1513:3013:4514:00

Oral Communications

Innovation and Novelty

Oral Communications

Vascular wall, platelets and acquired

problems

14:1514:3014:4515:0015:1515:3015:4516:0016:1516:3016:45

Satellite SymposiumLFB GmbH

Die aktuelle Herausfor-derung: atypische Von-Willebrand-

Patienten

Satellite SymposiumLEO PHARMA GmbH

Antikoagulation in Therapie und Pro-

phylaxe – wohin geht die Reise?

Satellite SymposiumNovo Nordisk Pharma

GmbH Chancen einer

individualisierten Hämophilietherapie

Satellite SymposiumStago

Laborkontrolle der Antikoagulation

Satellite SymposiumShire – Baxalta

Deutschland GmbH ADYNOVI – Von Stu-dienergebnissen zur klinischen Erfahrung

17:0017:1517:3017:4518:0018:1518:3018:4519:00

WED

NESD

AYTH

URSD

AYFR

IDAY

SATU

RDAY

THURSDAY, 16 FEBRUARY 2017 THURSDAY, 16 FEBRUARY 2017

SCIENTIFIC PROGRAM

2726

WED

NESD

AYTH

URSD

AYFR

IDAY

SATU

RDAY

SC

IEN

TIFI

C P

RO

GR

AM

SC

IEN

TIFI

C P

RO

GR

AM

08:00 – 09:15

Boston 1+2

State of the ArtVon Willebrand FactorChairs: F. Langer (Hamburg, Germany), B. Zieger (Freiburg, Germany)

08:00 Von Willebrand factor processingM. A. Brehm (Hamburg, Germany)

08:25 Acquired Von Willebrand syndrome in patients with aortic valve diseaseS. Susen (Lille Cedex, France)

08:50 Effect of DDAVP on hemostasis – more than just VWF releaseL. Alberio (Lausanne, Switzerland)

08:00 – 09:15

Delhi

State of the ArtPlateletsChairs: K. Jurk (Mainz, Germany), J. Koscielny (Berlin, Germany)

08:00 Indications and triggers for platelet transfusionsB. Mansouri Taleghani (Bern, Switzerland)

08:25 In vitro platelet productionD. Baruch (Paris, France)

08:50 Platelet proteomicsR. Zahedi (Dortmund, Germany)

08:00 – 09:15

Shanghai 1+2

Oral CommunicationsLaboratoryChairs: L. Graf (St. Gallen, Switzerland), M. Spannagl (Munich, Germany)

08:00 The implementation of a high-throughput sequencing test for diagnosing inherited bleeding, thrombotic, and platelet disorders: lessons learned from an international studyT. Bakchoul, H. Schulze, E. Simeoni, W. Ouwehand, E. Turro (Tuebingen, Germany)

08:12 Diagnosing heparin-induced thrombocytopenia (HIT) in 30 minutes: A prospective evaluation of a rapid diagnostic work-upM. Marchetti, S. Barelli, F. Monnin, N. Nicolas, E. Matthey, C. Gerschheimer, L. Alberio (Lausanne, Switzerland)

08:24 Multianalyte determination of NOAC using LC-MS/MS and comparison with functional coagulation assaysL. Slavik, J. Lukes, M. Zhanelova, M. Nemcova, J. Ulehlova, J. Prochazkova, A. Hlusi, M. Palova, J. Vaclavik (Olomouc, Czech Republic)

08:36 Fibrin clot formation properties in patients on treatment with oral anticoagulants correlate with drug concentration and intensity of anticoagulationO. Königsbrügge1, G. Weigel 2, I. Pabinger1, C. Ay1 (1Vienna, Austria, 2Innsbruck, Austria)

08:48 Spatial fibrin clot formation is less affected by clotting factor deficiency than thrombin generationE. Zöhrer, A. Schlagenhauf, S. Pohl, B. Leschnik, H. Haidl, S. Gallistl (Graz, Austria)

09:00 Catching microparticles – a methodical comparisonC. Plattfaut, F. Gieseler, A. Freund, G. Riemekasten, A. Müller (Luebeck, Germany)

08:00 – 09:15

Montreal

Special SymposiumFactor XIII Structure and FunctionsChairs: H.-P. Kohler (Bern, Switzerland), L. Muszbek (Debrecen, Hungary)

08:00 Novel biochemical and structural aspects of FXIIIL. Muszbek (Debrecen, Hungary)

08:25 FXIII and fibrin structureR. Ariëns (Leeds, United Kingdom)

08:50 FXIII-A in energy metabolismM. Kaartinen (Montreal, Canada)

08:00 – 09:15

Singapore

State of the ArtVTE ManagementChairs: R. Bauersachs (Darmstadt, Germany), S. Konstantinides (Mainz, Germany)

08:00 Predictive variables of recurrence – how to choose long-term anticoagulation in VTEP. A. Kyrle (Vienna, Austria)

08:25 Advantages and limitations of patient self-management of oral anticoagulation in VKAW. A. Wuillemin (Lucerne, Switzerland)

08:50 Post-thrombotic syndrome – implications and managementA. ten Cate-Hoek (Maastricht, The Netherlands)

WED

NESD

AYTH

URSD

AYFR

IDAY

SATU

RDAY



2928

WED

NESD

AYTH

URSD

AYFR

IDAY

SATU

RDAY

SC

IEN

TIFI

C P

RO

GR

AM

SC

IEN

TIFI

C P

RO

GR

AM

08:00 – 09:15

Sydney

State of the ArtPediatric – HemostasisChairs: K. Kurnik (Munich, Germany), N. von der Weid (Basel, Switzerland)

08:00 Plasma-derived versus recombinant factor concentrates in PUPs: a never ending debateE. Berntorp (Malmö, Sweden)

08:25 Gynecological aspects of adolescents with rare bleeding disordersR. Kulkarni (East Lansing, United States)

08:50 Care, needs and perceptions of adolescents and young adults growing up with hemophilia A or B in GermanyD. Richter, C. Heller, M. Heuer, S. Schultze-Strasser, D. Schwabe, C. Königs (Frankfurt am Main, Germany)

09:02 An alternative immune tolerance induction therapy for patients with inhibitors in hemophilia AW.-A. Hassenpflug, J. Schrum, R. Dittmer, R. Schneppenheim (Hamburg, Germany)

09:30 – 10:30

San Francisco

Plenary Session IChairs: M. A. Brehm (Hamburg, Germany), E. R. Weibel (Bern, Switzerland)

09:30 Life cycle of Weibel Palade bodiesH.C.J. Eikenboom (Leiden, The Netherlands)

10:00 Regulation of angiogenesis by Von Willebrand factorA. Randi (London, United Kingdom)

10:30 – 10:45

San Francisco

Bayer Thrombosis AwardAnnouncement and Presentation of AwardeeBayer Science and Education Foundation B. Kemkes-Matthes (Giessen, Germany)

10:45 – 12:15

Montreal

Special SymposiumClinical Aspects of Factor XIIIChairs: A. Ichinose (Yamagata, Japan), V. Schröder (Bern, Switzerland)

10:45 Functional and clinical aspects of FXIIIH.-P. Kohler (Bern, Switzerland)

11:10 The first case of congenital FXIII deficiency – A Swiss storyV. Schröder (Bern, Switzerland)

11:35 Acquired FXIII deficiencyA. Ichinose (Yamagata, Japan)

12:00 Coagulation factor XIII: its possible role in corneal wound healingZ. Z. Orosz1,2, A. Szöor1, Z. Veréb2, Z. Hassan1, E. Katona1, G. Vereb1, A. Facskó2, L. Muszbek1 (1Debrecen, Hungary, 2Szeged, Hungary)

11:00 – 12:00

Boston 1+2

Highlight Session IMiscellaneousChairs: B. Kehrel (Muenster, Germany), M. Skowronska (Bern, Switzerland)

11:00 New treatment options for thrombotic thrombocytopenic purpura (TTP)P. Knöbl (Vienna, Austria)

11:20 Clinical PearlB. Kemkes-Matthes (Giessen, Germany)

11:35 Warfarin inhibits VKORC1 by competitive slow tight bindingK. J. Czogalla1, A. Biswas1, K. Höning1, V. Hornung1,2, K. Liphardt1, M. Watzka1, J. Oldenburg1 (1Bonn, Germany, 2Munich, Germany)

11:47 Cardiac Protease-Activated Receptor 2 expression is involved in cardiac fibrosis, diastolic dysfunction and immunological response in the aged heartJ. Friebel1, M. Witkowski1, A. Weithäuser1, K. Savvatis2, D. Steffens1, M. Kasner1, T. Tabaraie1, M. Wegner1, U. Landmesser1, U. Rauch-Kröhnert1 (1Berlin, Germany, 2London, United Kingdom)

WED

NESD

AYTH

URSD

AYFR

IDAY

SATU

RDAY



3130

WED

NESD

AYTH

URSD

AYFR

IDAY

SATU

RDAY

SC

IEN

TIFI

C P

RO

GR

AM

SC

IEN

TIFI

C P

RO

GR

AM

11:00 – 12:00

Shanghai 3+4

Best PosterBasic Science – see also poster list page 60ffChairs: M. Schaller Tschan (Bern, Switzerland), W. A. Wuillemin (Lucerne, Switzerland)

11:00 Differential effects of novel anticoagulants: FXa versus FIIa inhibition on coagulation and inflammationS. Nazir1, K. Shahzad1, I. Gadi1, M. Al-Dabet1, S. Kohli1, S. Ranjan1, F. Bock1,2, B. Isermann1 (1Magdeburg, Germany, 2Nashville, United States)

11:06 Annexin A7 (ANX7) regulates collagen-dependent platelet activation and Ca2+ signalingS. Geue, B. Walker-Allgaier, D. Eißler, P. Münzer, F. Lang, M. Gawaz, O. Borst (Tuebingen, Germany)

11:12 P2Y6 depletion enhances metabolic activity and ameliorates outcome of high fat diet induced obesity in miceJ. Merz, P. Stachon, P. Albrecht, F. Ünal, S. von Garlen, A. Heidenreich, N. Hoppe, B. Duffner, C. Bode, A. Zirlik (Freiburg, Germany)

11:18 Introduction of a guideline for the treatment of synovitis in patients with hemophiliaB. Habermann1, A. Seuser2, T. Hilberg3 (1Mainz, Germany, 2Bonn, Germany, 3Wuppertal, Germany)

11:24 The coagulation Factor XIII (FXIII) A subunit activation peptide directs the evolution of FXIIIA as a proteolytically activated dimeric moleculeA. Biswas, S. Singh, V. Ivaskevicius, J. Oldenburg (Bonn, Germany)

11:30 CLIC1 supports mechanisms related to thrombosis and vascular repairL. M. Knowles, P. Niewald, E. Ampofo, A. Drawz, I. Müller, H. Eichler, J. Pilch (Homburg, Germany)

11:36 Collagen V alpha 2 as a direct target of miR-143 in arteriogenesisT. Hammerschick1, K. Troidl2, K. T. Preissner1, S. Fischer1 (1Giessen, Germany, 2Bad Nauheim, Germany)

11:42 Phosphorylation of the protein phosphatase 2A inhibitor alpha- endosulfine (ENSA) at two distinct sites, serine 67 and serine 109, in human plateletsE. Walter1, O. Pagel2, R. Zahedi2, A. Smolenski3, S. Gambaryan1,4, U. Walter1, K. Jurk1 (1Mainz, Germany, 2Dortmund, Germany, 3Dublin, Ireland, 4St. Petersburg, Russian Federation)

11:48 Fucoidans inhibit cellular responses to the chemokine IL-8 and the anaphylatoxin C5a better than heparinS. Alban, K. Ehrig, I. Liewert (Kiel, Germany)

11:54 FSAP and altered fibrin clot structure: Is there a link to FXIII?M. Etscheid, N. Beer, R. Seitz, J. Dodt (Langen, Germany)

11:00 – 12:00

Singapore

Highlight Session IIHemostasisChairs: W. Miesbach (Frankfurt am Main, Germany), D. Tsakiris (Basel, Switzerland)

11:00 A new era of treatment for patients with hemophilia A with and without inhibitors?R. Klamroth (Berlin, Germany)

11:15 Clinical PearlJ.-D. Studt (Zurich, Switzerland)

11:30 IPS derived endothelial cells from hemophilia A patients with nonsense mutations contain endogenous FVIII and the high risk inhibitor mutation R1941X shows abnormal intracellular trafficking of the FVIII heavy chainH. Singer, N. Nuesgen, J. Oldenburg, O. El-Maarri (Bonn, Germany)

11:47 Targeting anticoagulant protein S to achieve hemostasis in hemophiliaS. Calzavarini1, L. Bologna1, R. Prince1, M. Manetti2, D. Melchiorre2, I. Rosa2, N. Dewarrat1, P. Amini1, J.A. Fernandez3, C. Quarroz1, Y. Matsumura4, J. A. Kremer Hovinga1, J.H. Griffin3, H.-U. Simon1, L. Ibba Maneschi2, F. Saller5, A. Angelillo-Scherrer1 (1Bern, Switzerland, 2Florence, Italy, 3La Jolla, United States,4Chiba, Japan, 5Paris, France)

11:00 – 12:00

Sydney

Highlight Session IIIThrombosisChairs: L. Asmis (Zurich, Switzerland), I. Pabinger-Fasching (Vienna, Austria)

11:00 Highlight ThrombosisR. E. Scharf (Duesseldorf, Germany)

11:20 Clinical PearlC. Ay (Vienna, Austria)

11:35 Clinical course of isolated distal deep vein thrombosis in patients with active cancer: a large multicenter cohort studyF. Dentali1, S. Pegoraro1, S. Barco2, M. di Minno2, D. Mastroiacovo3, F. Pomero4, C. Lodigiani5, F. Bagna6, W. Ageno1, M. di Nisio1,7 (1Varese, Italy, 2Mainz, Germany, 3Naples, Italy, 4Avezzano, Italy, 5Cuneo, Italy, 6Rozzano-Milano, Italy, 7Chieti, Italy)

11:47 Platelet transcriptome analysis of mice with altered thrombin signalingS. Schubert, F. Marini, C. Santos, H. Binder, W. Ruf (Mainz, Germany)

WED

NESD

AYTH

URSD

AYFR

IDAY

SATU

RDAY



3332

WED

NESD

AYTH

URSD

AYFR

IDAY

SATU

RDAY

SC

IEN

TIFI

C P

RO

GR

AM

SC

IEN

TIFI

C P

RO

GR

AM

12:15 – 13:45

Boston 1+2

Satellite Symposium CSL Behring GmbHVielfältigkeit von angeborenen Gerinnungsstörungen und Angio pathien – Theorie und PraxisChairs: A. Huth-Kühne (Heidelberg, Germany), J. A. Kremer Hovinga (Bern,

Switzerland)

12:15 Voncento®: Studiendaten und klinische AnwendungC. Bidlingmaier (Munich, Germany)

12:38 Angeborene Thrombozytopathien und DifferentialdiagnoseB. Zieger (Freiburg, Germany)

13:00 Facetten des VWS: AngiodysplasienW. Eberl (Braunschweig, Germany)

13:22 Faktor IX – ein faszinierendes MolekülJ. A. Kremer Hovinga (Bern, Switzerland)

12:15 – 13:45

Kairo 1+2

Satellite Symposium BayerModerne Antikoagulation – Von Pionier- zu AlltagsfragenChairs: B. Kemkes-Matthes (Giessen, Germany), W. Korte (St. Gallen, Switzerland)

12:15 BegrüssungW. Korte (St. Gallen, Switzerland)

12:20 Venöse Thromboembolien – Studienlage und Realität zu Behandlungskonzepten und TherapieansätzenS. Haas (Munich, Germany)

12:40 NOAKs im Alltag – Gibt es noch Überraschungen?J. Beyer-Westendorf (Dresden, Germany)

12:55 Diskussion

13:00 Triple-Therapie mit NOAK – Praxis und StudienlageC. Bode (Freiburg, Germany)

13:20 Praktisches Management in besonderen Situationen – Do’s and Dont’sW. A. Wuillemin (Lucerne, Switzerland)

13:40 Diskussion

ZusammenfassungB. Kemkes-Matthes (Giessen, Germany)

12:15 – 13:45

Shanghai 1+2

Satellite Symposium Octapharma GmbHChallenges and opportunities in hemophilia A and VWDChairs: I. Hegemann (Zurich, Switzerland), K. Schmitt (Linz, Austria)

12:15 Inhibitor development in hemophilia A – A lifelong challengeC. Escuriola-Ettingshausen (Moerfelden-Walldorf, Germany)

12:35 How to start treatment in hemophilia A PUPs in the light of the SIPPET study – single center experienceS. Halimeh (Duisburg, Germany)

13:00 Management of surgeries in VWD – maintaining the balanceL. Graf (St. Gallen, Switzerland)

13:20 Current aspects of prophylaxis in VWDU. Nowak-Göttl (Kiel, Germany)

12:15 – 13:45

Shanghai 3+4

Satellite Symposium Swedish Orphan Biovitrum GmbHHalf-life Extension in Hemophilia – A Practical Guide for Fc Fusion ProteinsChairs: D. Tsakiris (Basel, Switzerland), N. von der Weid (Basel, Switzerland)

12:15 IntroductionD. Tsakiris (Basel, Switzerland), N. von der Weid (Basel, Switzerland)

12:20 Features of recombinant Factor Fc – Immunological potentialF. Nimmerjahn (Erlangen, Germany)

12:40 Elocta & Alprolix – Long term data in adults and adolescentsR. Klamroth (Berlin, Germany)

13:00 Elocta & Alprolix – Long term data in childrenC. Wermes (Hanover, Germany)

13:20 How to use Elocta – Real world experience from BonnG. Goldmann (Bonn, Germany)

13:40 Conclusion & DiscussionG. Goldmann (Bonn, Germany) D. Tsakiris (Basel, Switzerland) R. Klamroth (Berlin, Germany) N. von der Weid (Basel, Switzerland) F. Nimmerjahn (Erlangen, Germany) C. Wermes (Hanover, Germany)

WED

NESD

AYTH

URSD

AYFR

IDAY

SATU

RDAY



3534

WED

NESD

AYTH

URSD

AYFR

IDAY

SATU

RDAY

SC

IEN

TIFI

C P

RO

GR

AM

SC

IEN

TIFI

C P

RO

GR

AM

12:15 – 13:45

Sydney

Satellite Symposium Pfizer Pharma GmbHHämophilie-Therapie in der Zukunft – von guten Prognosen und neuen BehandlungsansätzenChairs: C. Königs (Frankfurt am Main, Germany), J. Oldenburg (Bonn, Germany),

J. Rischewski (Lucerne, Switzerland)

12:15 Neue Konzepte in der Hämophiliebehandlung – Grundlagen der GentherapieR. M. Linden (London, United Kingdom)

12:45 Fallstricke der Faktorenmessung im Hämostase-LaborU. Scholz (Leipzig, Germany)

13:15 Haemoassist 2 – eine gute PrognoseA. Tiede (Hanover, Germany)

14:00 – 15:15

Boston 1+2

Oral CommunicationsInnovation and NoveltyChairs: Z. Cermakova (Ostrava, Czech Republic), R. Rieben (Bern, Switzerland)

14:00 Microvascular flow model to study clot formation in real-timeL. Jenny1, J. Dobó2, P. Gál2, W. Lam3, V. Schröder1 (1Bern, Switzerland, 2Budapest, Hungary, 3Atlanta, United States)

14:12 rhADAMTS13 treatment improves ventricular remodelling and functionality after cardiac injury in miceT. Witsch1,2, K. Martinod2, D. D. Wagner2 (1Freiburg, Germany, 2Boston, United States)

14:24 Activated protein C is a sensitive biomarker to monitor the activity level of the hemostatic system after activation by recombinant activated factor VIIH. Rühl, C. Berens, F. I. Winterhagen, J. Müller, J. Oldenburg, B. Pötzsch (Bonn, Germany)

14:36 In vitro evaluation of aptamer-based reversible inhibition of anti-coagulant activated protein C as a novel supportive hemostatic approachN. Shahidi Hamedani1, H. Rühl1, S. Gasper1, J. J. Zimmermann1, T. Heiseler2, J. Oldenburg1, G. Mayer1, B. Pötzsch1, J. Müller1 (1Bonn, Germany, 2Dreieich, Germany)

14:48 Regulation of complement and contact system activation via C1 inhibitor potentiation and factor XIIa activity modulation by heparins, glycosa-minoglycans and other sulfated glycansS. Alban, E. Lahrsen, A.-K. Schoenfeld (Kiel, Germany)

15:00 Interim results from a dose escalating study of AMT-060 (AAV5-hFIX) gene transfer in adult patients with severe hemophilia BW. Miesbach1, M. Tangelder1, K. Meijer2, G. Castaman3, F. Cattaneo4, M. Cop-pens1, P. Kampmann5, R. Klamroth6, R. Schutgens7, E. Seifried8, J. Schwaeble8 (1Amsterdam, The Netherlands, 2Groningen, The Netherlands, 3Florence, Italy, 4Parma, Italy, 5Copenhagen, Denmark, 6Berlin, Germany, 7Utrecht, The Nether-lands, 8Frankfurt am Main, Germany)

14:00 – 15:15

Shanghai 1+2

Oral CommunicationsVascular Wall, Platelets, and Acquired ProblemsChairs: T. Bakchoul (Tuebingen, Germany), C.-E. Dempfle (Mannheim-Lindenhof,

Germany)

14:00 Role of platelet factor 4 (PF4) and anti-PF4/polyanion IgG in human platelet FcRIIA mediated anti-bacterial activityR. Palankar, T. Kohler, N. Medvedev, J. Wesche, K. Krauel, S. Hammerschmidt, A. Greinacher (Greifswald, Germany)

14:12 Platelet activation and aggregation provoked by Staphylococcus aureus secreted proteinsU. Binsker1, J. Wesche1, R. Palankar1, T. P. Kohler1, J. Prucha1, B. Bröker1, U. Mamat2, J. Pané-Farré1, F. Schmidt1, A. Greinacher1, S. Hammerschmidt1 (1Greifswald, Germany, 2Borstel, Germany)

14:24 Altered platelet lipidomic profile influences thrombotic disposition: modulation by the CXCL12-CXCR4-CXCR7 axisM. Chatterjee, D. Rath, J. Schlotterbeck, J. Rheinlaender, B. Walker-Allgaier, T. E. Schäffer, M. Lämmerhofer, M. Gawaz (Tuebingen, Germany)

14:36 Metformin alters the epigenetic regulation of tissue factor in diabetesM. Witkowski1, A. Weithauser1, T. Tabaraie1, D. Steffens1, J. Friebel1, A. Doerner1, M. Kasner1, B. Stratmann2, D. Tschoepe2, U. Landmesser1, U. Rauch1(1Berlin, Germany, 2Bad Oeynhausen, Germany)

14:48 D-dimer, but not the Khorana score predicts venous thromboembolism in lung cancer patientsE. Grilz, O. Königsbrügge, J. Riedl, J. Thaler, R. Pirker, C. Ay, I. Pabinger (Vienna, Austria)

15:00 Randomized, double-blind, placebo-controlled trial of recombinant human C1 inhibitor for prophylaxis of hereditary angioedema attacksB. Giannetti1, V. Grivcheva Panovska2, D. Moldovan3, A. Reshef4, S. Andrejevic5, R. Hakl6, S. Kivity7, L. Bellizzi1, A. Relan1, B. Giannetti1, M. Cicardi8 (1Leiden, The Netherlands, 2Skopje, Republic of Macedonia, 3Tirgu Mures, Romania, 4Tel-Hashomer, Israel, 5Belgrade, Serbia, 6Brno, Czech Republic, 7Tel Aviv, Israel, 8Milan, Italy)

14:00 – 15:15

Montreal

State of the ArtWomen IssuesChairs: Y. Fujimura (Nara, Japan), B. Lämmle (Mainz, Germany)

14:00 Management of pregnancy in carriers of hemophilia and rare bleeding disordersU. Scholz (Leipzig, Germany)

14:25 Insights into preeclampsia and HELLPM. Mohaupt (Bern, Switzerland)

14:50 Pregnancy in patients with acquired and hereditary TTPA. S. von Krogh (Trondheim, Norway)

WED

NESD

AYTH

URSD

AYFR

IDAY

SATU

RDAY



3736

WED

NESD

AYTH

URSD

AYFR

IDAY

SATU

RDAY

SC

IEN

TIFI

C P

RO

GR

AM

SC

IEN

TIFI

C P

RO

GR

AM

14:00 – 15:15

Singapore

State of the ArtHemophilia & InhibitorsChairs: G. Auerswald (Bremen, Germany), C. Königs (Frankfurt am Main, Germany)

14:00 Role and mode of action of T cells in inhibitor formation in hemophilia AK. Pratt (Bethesda, United States)

14:25 Immune tolerance treatment in children and in adults with hemophilia and inhibitorsR. d’Oiron (Le Kremlin-Bicêtre, France)

14:50 Insights into the autoimmune response in acquired hemophilia AA. Tiede (Hanover, Germany)

14:00 – 15:15

Sydney

State of the ArtVTE InterventionChairs: V. Hach-Wunderle (Frankfurt am Main, Germany), M. Schindewolf (Bern,

Switzerland)

14:00 How to prevent chronic thromboembolic pulmonary hypertension after PE/VTES. Konstantinides (Mainz, Germany)

14:25 Minimal-invasive endovascular treatment of acute deep vein thrombosisN. Kucher (Bern, Switzerland)

14:50 Surgical and interventional therapy for chronic thromboembolic pulmo-nary hypertension (CTEPH)C. B. Wiedenroth (Bad Nauheim, Germany)

15:30 – 16:30

San Francisco

Plenary Session IIChairs: P. A. Kyrle (Vienna, Austria), E. Lindhoff-Last (Frankfurt am Main, Germany)

15:30 Fibrinogen, factor XIII, and red blood cells in thrombosisA. S. Wolberg (Chapel Hill, United States)

16:00 Thrombophilia and pregnancy complicationsS. Middeldorp (Amsterdam, The Netherlands)

16:45 – 18:15

Boston 1+2

Satellite Symposium LFB GmbHDie aktuelle Herausforderung: atypische Von-Willebrand-PatientenChairs: J. Koscielny (Berlin, Germany), W. Miesbach (Frankfurt am Main, Germany)

16:45 Begrüssung und EinführungJ. Koscielny (Berlin, Germany), W. Miesbach (Frankfurt am Main, Germany)

16:50 Individuelle Behandlung atypischer VWD-PatientenC.-E. Dempfle (Mannheim-Lindenhof, Germany)

17:10 Diskussion

17:15 Von-Willebrand-Faktor bei Patienten in der HerzchirurgieU. Scholz (Leipzig, Germany)

17:35 Diskussion

17:40 Prevention of hemorrhage after implantation of mechanical circulatory supportS. Susen (Lille Cedex, France)

18:00 Diskussion

18:05 ZusammenfassungJ. Koscielny (Berlin, Germany), W. Miesbach (Frankfurt am Main, Germany)

16:45 – 18:15

Delhi

Satellite Symposium LEO PHARMA GmbHAntikoagulation in Therapie und Prophylaxe – wohin geht die Reise?Chair: H. Riess (Berlin, Germany)

16:45 VTE-Prophylaxe im klinischen Alltag – Hochrisikopatienten und perioperatives Management im FokusC. von Heymann (Berlin, Germany)

17:15 Update 2017: Was gibt es Neues in der Behandlung tumorassoziierter Thromboembolien?H. Riess (Berlin, Germany)

17:45 German Evaluation of Cancer Associated Thrombosis (GECAT) – Eine pro-spektive Registerstudie zur Versorgung onkologischer Patienten mit VTER. Klamroth (Berlin, Germany)

16:45 – 18:15

Kairo 1+2

Satellite Symposium Novo Nordisk Pharma GmbHChancen einer individualisierten Hämophilietherapie – spezialisierte Physiotherapie – gewichtsadaptierte Dosierung – individuelle Pharmako-kinetikChairs: G. Auerswald (Bremen, Germany), J. A. Kremer Hovinga (Bern, Switzerland)

16:45 Bedeutung der individualisierten Physiotherapie aus der Sicht des Hämostaseologen, Orthopäden und Physiotherapeuten – ein Experten-dialogS. Halimeh (Duisburg, Germany), M. Rosenthal (Duisburg, Germany), A. Seuser (Bonn, Germany)

17:25 GuardianTM9: Untersuchung der Pharmakokinetik von Turoctocog alfa im Verhältnis zum BMIG. Goldmann (Bonn, Germany)

17:45 Individual pharmacokinetic assessment – the WAPPS-Hemo ProjectA. McEneny-King (Waterloo, Canada)

WED

NESD

AYTH

URSD

AYFR

IDAY

SATU

RDAY



3938

WED

NESD

AYTH

URSD

AYFR

IDAY

SATU

RDAY

SC

IEN

TIFI

C P

RO

GR

AM

SC

IEN

TIFI

C P

RO

GR

AM

16:45 – 18:15

Shanghai 1+2

Satellite Symposium StagoLaborkontrolle der AntikoagulationChair: D. Tsakiris (Basel, Switzerland)

16:45 Monitoring der Heparine: APTT, Thrombinzeit oder Anti-FXa?W. A. Wuillemin (Lucerne, Switzerland)

17:05 Diskussion

17:15 Monitoring der DOAC: Wann, wie, bei wem?D. Peetz (Berlin, Germany)

17:35 Diskussion

17:45 Thrombophilie-Screening und Interferenzen durch die DOACS. Eichinger-Hasenauer (Vienna, Austria)

18:05 Diskussion, Zusammenfassung und Schlussbemerkungen

16:45 – 18:15

Shanghai 3+4

Satellite Symposium Shire – Baxalta Deutschland GmbHOne size does not fi t all – Individualisierte Behandlungsziele unter ADYNOVI-ProphylaxeChair: A. Huth-Kühne (Heidelberg, Germany)

16:45 Begrüssung und EinleitungA. Huth-Kühne (Heidelberg, Germany)

16:55 Die Evolution der Hämophilie A BehandlungF. Langer (Hamburg, Germany)

17:25 Der pädiatrische EHL-Patient – alles gleich oder doch ganz anders?C. Bidlingmaier (Munich, Germany)

17:50 Wer EHL sagt, muss auch PK sagenI. Hegemann (Zurich, Switzerland)

Das erste und einzige rekombinante porcine-Sequenz FVIII Produkt zur Behandlung der erworbenen Hemmkörperhämophilie A.

HEM

150

02-

2017

Referenzen: 1 OBIZUR Fachinformation, Stand der Information Juni 2016. 2 Kruse-Jarres R et al. Efficacy and safety of OBI-1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A. Haemophilia. 2015 Mar;21(2):162-70 & Supplement.

OBIZUR® ZUSAMMENSETZUNG Susoctocogum alfa; Applikation 500E. INDIKATION Behandlung von Blutungsepisoden bei erwachsenen Patienten mit erworbener Hämophilie, die durch Antikörper gegen den Faktor VIII verursacht wird. OBIZUR ist für die Behandlung angeborener Hämophilie A nicht indiziert. DOSIERUNG/ANWEN-DUNG Die Dosis, Häufigkeit und Dauer der Therapie mit OBIZUR richten sich nach dem Ort, Ausmass und Schweregrad der Blutungsepisode, nach den angestrebten Faktor VIII Spiegeln und dem klinischen Zustand des Patienten; intravenöse Verabreichung. KONTRAINDIKATION Bekannte anaphylaktische Reaktionen gegen den Wirkstoff, gegen Hamsterproteine, sowie gegen einen der Hilfsstoffe. VORSICHTSMASSNAHMEN Bei Auftreten von Überempfindlichkeitsreaktionen wie Ausschlag, generali-sierte Urtikaria, Engegefühl in der Brust, Keuchatmung, Hypotonie und Anaphylaxie sollte die Verabreichung gestoppt werden. Neutralisierende Antikörper gegen porcinen Faktor VIII wurden vor und nach der OBIZUR-Exposition festgestellt. Es wird empfohlen die Behandlung auf der klinischen Beurteilung zu basieren und nicht auf der Bestimmung von inhibierenden Antikörpern. SCHWANGERSCHAFT Anwendung nur bei eindeutiger Indikationsstellung. UNERWÜNSCHTE WIRKUNGEN

Häufigstes Ereignis in der klinischen Studiewar ein positiver Test für Antikörper gegen porcinen Faktor VIII. Überempfindlichkeit und allergische Reaktionen sind möglich. INTERAKTIONEN Es wurde über keine Interaktionen von OBIZUR mit anderen Arzneimitteln berich-tet. PACKUNGEN Lyophilisat mit 500E. OBIZUR/1ml Wasser für Injektionszwecke. Abgabekategorie B. ZULASSUNGSINHABERIN Baxalta Schweiz AG, CH-8604 Volketswil. Stand derInformation: Juni 2016. Ausführliche Informationen finden Sie unter www.swissmedicinfo.ch.

Messung der FVIII Aktivität mittels eines Standard-Assays, um das Ansprechen zu objektivieren1.2

Schnelle Evaluierung (nach 30 Min.), ob die verabreichte Dosis den gewünschten FVIII Anstieg bewirkt1

Individuelle Dosiseinstellung reduziert das Risiko einer Unter- oder Überdosierung1

100 %Ansprech-

rate

100 % Ansprechrate1,2 24 Stunden nach initialer Dosierungvon OBIZUR (n=28/28)

THURSDAY, 16 FEBRUARY 2017

SCIENTIFIC PROGRAM

41W

EDNE

SDAY

THUR

SDAY

FRID

AYSA

TURD

AYS

CIE

NTI

FIC

PR

OG

RA

M

SCIENTIFIC PROGRAM



Delhi Ground Floor




08:00 Oral Communications

Bleeding disorders – Basic science

Oral Communications

Vascular Wall

08:3008:4509:0009:1509:3009:4510:0010:1510:3010:45

Special Symposium (Bayer)

Workshop Schmerz und Hämophilie – Interdisziplinäre Falldiskussionen mit Experten

11:00Highlight Session IVPediatric and Women

Issues

Best PosterClinical Science

11:1511:3011:4512:0012:15 Satellite Symposium

Bristol-Myers Squibb GmbH & Co. KGaA und Pfizer Pharma GmbH

Moderne Gerinnungshem-mung – Was gehört dazu,

was ist zu beachten?

Satellite SymposiumAspen Germany GmbH

HIT oder nicht HIT – das ist hier die Frage!

Satellite SymposiumShire – Baxalta

Deutschland GmbH Neue Behandlungswe-ge bei Hemmkörpern

Satellite SymposiumBayer

Ein Jahr im Zeichen von Kovaltry®

Satellite SymposiumAlexion Pharma Germany

GmbH Thrombosen unklarer

Ätiologie – Herausforde-rungen im klinischen Alltag

12:3012:4513:0013:1513:3013:4514:0014:1514:3014:4515:0015:1515:3015:4516:0016:1516:3016:4517:0017:1517:3017:4518:0018:1518:3018:4519:00

Foyer 2. OG 2nd Floor

Montreal 2nd Floor

Singapore 2nd Floor

Sydney 2nd Floor

08:00

Poster Exhibition

State of the ArtPediatric Thrombosis

State of the ArtAging with Hemophilia

Oral CommunicationsVenous Thrombosis

08:3008:4509:0009:1509:30

Plenary Session III09:4510:0010:1510:3010:4511:00

NEW, HOT or DISCUSSED I

Hemophilia

NEW, HOT or DISCUSSED II

VTE: Diagnosis and Treatment Issues

Highlight Session VPlatelets

11:1511:3011:4512:0012:1512:3012:4513:0013:1513:3013:4514:00

GTH General Assembly

14:1514:3014:4515:0015:1515:3015:4516:00

Plenary Session IV16:1516:3016:4517:0017:15

Poster viewing session

17:3017:4518:0018:1518:3018:4519:00

WED

NESD

AYTH

URSD

AYFR

IDAY

SATU

RDAY

FRIDAY, 17 FEBRUARY 2017 FRIDAY, 17 FEBRUARY 2017

SCIENTIFIC PROGRAM

4342

WED

NESD

AYTH

URSD

AYFR

IDAY

SATU

RDAY

SC

IEN

TIFI

C P

RO

GR

AM

SC

IEN

TIFI

C P

RO

GR

AM

08:00 – 09:15

Boston 1+2

Oral CommunicationsBleeding disorders – Basic scienceChairs: C. von Auer (Mainz, Germany), W.-A. Hassenpflug (Hamburg, Germany)

08:00 Investigating the pathomolecular mechanisms an in-frame heterozygous von Willebrand factor large deletion in a von Willebrand disease patient with significant bleeding historyH. Yadegari1, N. Marquardt1, V. Ivaskevicius1, O. Rawley2, L. Swystun2, D. Lillicrap2, J. Oldenburg1 (1Bonn, Germany, 2Kingston, Canada)

08:12 Possible role of protein disulfide isomerase PDIA1 in mechanisms of von Willebrand disease type 3M. A. Brehm, S. Vollmers, T. Obser, R. Schneppenheim (Hamburg, Germany)

08:24 Synergistic effects of a procoagulant bispecific antibody and rescue therapy on thrombin generation – a potential safety risk?R. Hartmann1, S. Knappe1, B. Goldstein2, B. Ewenstein2, L. Valentino3, F. Scheiflinger1 (1Vienna, Austria, 2Cambridge, United States, 3Bannockbum, United States)

08:36 Calcium binding sites of coagulation factor XIII (FXIII) A subunit and their functional relevance to the activation of FXIII A subunitS. Singh1, C. Krettler 2, C. Reinhart 2, J. Dodt 3, V. Ivaskevicius1, J. Olden burg1, A. Biswas1 (1Bonn, Germany, 2Frankfurt am Main, Germany, 3Langen, Germany)

08:48 Hemophilia macrophages exhibit specific defects relating to wound healingJ. Pilch, D. Lessig, M. Bernard, E. C. Schwarz, H. Eichler, L. M. Knowles (Homburg, Germany)

09:00 Plasma derived FVIII concentrates induce neutrophil activation and neutrophil extracellular trap formationB. E. Kehrel, A. Bertling, M. F. Brodde (Muenster, Germany)

08:00 – 09:15

Shanghai 1+2

Oral CommunicationsVascular WallChairs: M. Gawaz (Tuebingen, Germany), A. Zirlik (Freiburg, Germany)

08:00 Early atheroprotection through fostamatinib fails in established disease when local macrophage proliferation dominates lesion progressionC. Härdtner1, A. Lindau1, B. Dufner1, N. Hoppe1, F. K. Swirski2, P. Libby2, C. S. Robbins3, C. Bode1, A. Zirlik1, I. Hilgendorf1 (1Freiburg, Germany, 2Boston, United States, 3Toronto, Canada)

08:12 The role of the purinergic receptor P2X7 in the pathogenesis of athero-sclerosisS. von Garlen, A. Heidenreich, P. Stachon, J. Merz, S. Geis, B. Dufner, N. Hoppe, N. Anto Michel, C. Bode, M. Idzko, A. Zirlik (Freiburg, Germany)

08:24 Targeting coagulation factor Xa with rivaroxaban reduces the onset and progression of atherosclerosis and enhances plaque stability in ApoE null miceJ. Posthuma1, J. Posma1, R. van Gorp1, A. Jaminon1, P. Leenders1, R. van Oerle1, S. Heitmeier2, L. Schurgers1, H. ten Cate1, H. Spronk1 (1Maastricht, The Netherlands, 2Wuppertal, Germany)

08:36 MicroRNA-23a regulates the tissue factor alternative splicing and throm-bogenicityT. Tabaraie, M. Witkowski, J. Friebel, A. Doerner, U. Landmesser, U. Rauch (Berlin, Germany)

08:48 ADAMTS13 activity, neutrophil extracellular traps (NETs) and platelet functional capacity in patients with strokes from different etiologiesH. S. Bölting, M. Rumpf, R. Dittrich, J. Minnerup, L. Schuengel, M. F. Brodde, M. Ritter, B. E. Kehrel (Muenster, Germany)

09:00 The cross talk between coagulation cascade and endothelial cells in a porcine limb ischemia reperfusion injury model and the protective role of C1-INHM. Abdelhafez, J. Shaw, D. Sutter, J. Schnider, H. Jenni, E. Voegelin, M. Constantinescu, R. Rieben (Bern, Switzerland)

08:00 – 09:15

Montreal

State of the ArtPediatric ThrombosisChairs: M. Albisetti Pedroni (Zurich, Switzerland), R. Knöfler (Dresden, Germany)

08:00 Thrombophilia in pediatric cancerA. K. C. Chan (Hamilton, Canada)

08:25 Thrombophilia screening in adolescentsU. Nowak-Göttl (Kiel, Germany)

08:50 Cerebral venous thrombosis in neonates, children and adolescents; results from the German pediatric surveillance unit for rare pediatric diseases (ESPED)S. Holzhauer1, K. Kentouche2, A. Kruempel3, C. Heller4, R. Knoefler5, R. Straeter3, U. Nowak-Göttl6 (1Berlin, Germany, 2Jena, Germany, 3Muenster, Germany, 4Frankfurt am Main, Germany, 5Dresden, Germany, 6Kiel, Germany)

09:02 Faster spatial fibrin clot formation in neonates than in adultsA. Schlagenhauf1, S. Pohl, E. Zöhrer, B. Leschnik, H. Haidl, S. Gallistl, W. Muntean (Graz, Austria)

WED

NESD

AYTH

URSD

AYFR

IDAY

SATU

RDAY



4544

WED

NESD

AYTH

URSD

AYFR

IDAY

SATU

RDAY

SC

IEN

TIFI

C P

RO

GR

AM

SC

IEN

TIFI

C P

RO

GR

AM

08:00 – 09:15

Singapore

State of the ArtAging with HemophiliaChairs: A. Huth-Kühne (Heidelberg, Germany), W. Schramm (Munich, Germany)

08:00 Management of cardiovascular disease in aging patients with hemophiliaR. Schutgens (Utrecht, The Netherlands)

08:25 Treatment of hepatitis C – what the hemostasiologist should knowJ.-F. Dufour (Bern, Switzerland)

08:50 Value of factor prophylaxis in elderly patients with hemophiliaJ. Oldenburg (Bonn, Germany)

08:00 – 09:15

Sydney

Oral CommunicationsVenous ThrombosisChairs: J. Beyer-Westendorf (Dresden, Germany), S. Schellong (Dresden, Germany)

08:00 DOACs dose adherence during initial and long term VTE management. Practical implications, findings from the RIETE registry.E. Papadakis1, J. Trujillo-Santos2, P. Di Micco3, F. Dentali4, J.-A. Diaz- Peromingo5, M.-J. Nunez6, I. Canas7, D. Mastroiacovo8, M.-S. De Sousa9, A. Banti1, M. Monreal10 (1Thessaloniki, Greece, 2Murcia, Spain, 3Naples, Italy, 4Varese, Italy, 5Santiago de Compostela, Spain, 6Pontevedra, Spain, 7Barcelona, Spain, 8Avezzano, Italy, 9Vila Nova de Gaia, Portugal, 10Badalona, Spain)

08:12 Patterns of VTE treatment with rivaroxaban in cancer patients – Results of the prospective Dresden NOAC registry (NCT01588119)S. Endig, S. Marten, A. Reitter, K. Daschkow, L. Tittl, J. Beyer-Westendorf (Dresden, Germany)

08:24 Survival and recurrent venous thromboembolism in 834 subjects after a first episode of isolated distal or proximal deep vein thrombosis without pulmonary embolismS. Barco1, M. Corti2, A. Trinchero1, C. Picchi2, S.V. Konstantinides1, C. Ambaglio2, F. Dentali3, M. Barone2 (1Mainz, Germany, 2Pavia, Italy, 3Varese, Italy)

08:36 Clinical outcomes of a management strategy consisting of tailored anti-coagulant treatment based on residual vein thrombosis: contemporary dataM. Nagler1, H. ten Cate2, M. Prins2, A. ten Cate-Hoek2 (1Bern, Switzerland, 2Maastricht, The Netherlands)

08:48 Innate effector-memory T cell activation regulates post-thrombotic vein wall inflammation and thrombus resolutionF. Shahneh, N. Luther, M. Brähler, F. Krebs, S. Jäckel, P. Wenzel, K. Schäfer, C. Becker (Mainz, Germany)

09:00 Genotype phenotype association in a large cohort of subjects with pro-tein C or protein S deficiencyL. Böff1, F. Bergmann2, A. Czwalinna2, C. Heller1, M. Krause3, W. Miesbach1, S. Körber1, E. Seifried1, C. Geisen1 (1Frankfurt am Main, Germany, 2Hanover, Germany, 3Wiesbaden, Germany)

09:30 – 10:30

Montreal

Plenary Session IIIChairs: A. Angelillo-Scherrer (Bern, Switzerland), B. Zieger (Freiburg, Germany)

09:30 Diagnosis and management of immune thrombocytopenia in childhoodT. Kühne (Basel, Switzerland)

10:00 How a protein becomes an autoantigen, lessons learned from HITA. Greinacher (Greifswald, Germany)

10:45 – 12:00

Delhi

Special Symposium (Bayer)Workshop Schmerz und Hämophilie – Interdisziplinäre Falldiskus sionen mit ExpertenChair: K. Holstein (Hamburg, Germany)

Unter der Mitwirkung von- M. Bernateck (Hanover, Germany)- C. Gura (Berlin, Germany)- P. H. Pennekamp (Cologne, Germany)- A. Tiede (Hanover, Germany)werden Fälle aus der Praxis und die verschiedenen Behandlungsoptionen diskutiert.

11:00 – 12:00

Boston 1+2

Highlight Session IVPediatric and Women IssuesChairs: W. Eberl (Braunschweig, Germany), U. Scholz (Leipzig, Germany)

11:00 Highlight: Myocardial infarction in a neonate: Lessons for neonatal and internal medicineW. Streif (Innsbruck, Austria)

11:20 Clinical PearlM. Albisetti Pedroni (Zurich, Switzerland)

11:35 The staphylococcal toxin Panton-Valentine Leukocidin induces neutro-phil extracellular trap (NET) formation that leads to platelet activationM. F. Brodde1, A. Bertling1, S. Niemann1, A. C. Fender2, H. Van de Vyver1, B. Schlott3, C. Heilmann1, G. Peters1, B. Löffler3, B. E. Kehrel1 (1Muenster, Germany, 2Duesseldorf, Germany, 3Jena, Germany)

11:47 Prothrombin fragment F1+2 in pregnancy is associated with thrombo-philic risk factors and a history of venous thromboembolism (VTE)R. B. Zotz1, R. E. Scharf1, A. Gerhardt2,1 (1Duesseldorf, Germany, 2Ulm, Germany)

WED

NESD

AYTH

URSD

AYFR

IDAY

SATU

RDAY



4746

WED

NESD

AYTH

URSD

AYFR

IDAY

SATU

RDAY

SC

IEN

TIFI

C P

RO

GR

AM

SC

IEN

TIFI

C P

RO

GR

AM

11:00 – 12:00

Shanghai 1+2

Best PosterClinical Science – see also poster list page 60ffChairs: F. Langer (Hamburg, Germany), M. Nagler (Bern, Switzerland)

11:00 Development and evaluation of a novel FVIII domain-specific immunoassay for characterization of anti-FVIII antibodiesB. Pezeshkpoor, A.-C. Berkemeier, J. Müller, T. Albert, J. Oldenburg (Bonn, Germany)

11:06 Blood clotting supports glioma invasion and colonizationJ. Pilch, A. Burkardt, C. Wolter, S. Urbschat, R. Ketter, D. Lessig, I. Müller, H. Eichler, L. M. Knowles (Homburg, Germany)

11:12 rVIII-SingleChain: Results of a Phase III PK, efficacy and safety study in children less than 12 years of age with severe hemophilia AI. Pabinger1, O. Stasyshyn2, G. Iosava3, C. Djambas Khayat4, J. Ong5, K. Fischer6, F. Abdul Karim7, A. Veldman8, K. St. Ledger9 (1Vienna, Austria, 2Lviv, Ukraine, 3Tbilisi, Georgia, 4Beirut, Lebanon, 5Davao, Philippines, 6Ultrecht, The Nether-lands, 7Kuala Lumpur, Malaysia, 8Marburg, Germany)

11:18 Comparison of biomarkers and immunological parameters between haemophilia patients, rheumatoid arthritis patients, and control subjectsR. Toenges1, A. Wittenbrinck1, S. Gundermann1, M. Wahle2, R. Schäfer1, W. Miesbach1 (1Frankfurt am Main, Germany, 2Augsburg, Germany)

11:24 Activation and Inactivation of rVIII-SingleChainC. Horn, H.J. Metzner (Marburg, Germany)

11:30 Molecular genetic investigations and demonstration of founder effect in Osler-Rendu-Weber diseaseR. Gindele1, T. Major2, Z. Szabo1, K. B. Kovács1, G. Pfliegler1, Z. Bereczky1 (1Debrecen, Hungary, 2Eger, Hungary)

11:36 The special role of anti-ADAMTS13-IgA in acquired TTP: Production induced by infectious microorganisms?I. Scharrer, J. Falk (Mainz, Germany)

11:42 Variable linkage with platelet functions of genetic mutations in ORAI1, STIM1 or FERMT3 in patients with severe immune deficienciesM. Nagy1, T. G. Mastenbroek1, N. J. A. Mattheij1, S. de Witt1, K. J. Clemetson2, J. Kirschner3,A. S. Schulz4, J. M. E. M. Cosemans1, B. Zieger3, J. W. M. Heemskerk1 (1Maastricht, The Netherlands, 2Bern, Switzerland, 3Freiburg, Germany, 4Ulm, Germany)

11:48 Development and application of methods for the selective measurement of the human single amino acid exchange variant factor IX PaduaA. Weber1, A. Engelmaier1, D. Voelkel2, R. Pachlinger2, F. Scheiflinger1, H. Rottensteiner1 (1Vienna, Austria, 2Orth, Austria)

11:54 Development, validation and application of a polysialylation-dependent FVIII activity assay to measure SHP656 (BAX 0826), a next generation extended half-life recombinant factor VIII productA. Weber, S. Haindl, G. Mohr, A. Engelmaier (Vienna, Austria)

10:45 – 12:00

Montreal

NEW, HOT or DISCUSSED IHemophiliaChairs: C. Escuriola-Ettingshausen (Moerfelden-Walldorf, Germany),

K. Kentouche (Jena, Germany)

10:45 Many new factor concentrates – what to know and consider before switchingC. Male (Vienna, Austria)

11:10 New FVIII and FIX products – laboratory requirementsB. Pötzsch (Bonn, Germany)

11:35 Possibilities to rebalance hemostasis in hemophiliaA. Angelillo-Scherrer (Bern, Switzerland)

10:45 – 12:00

Singapore

NEW, HOT or DISCUSSED IIVenous Thrombosis: Diagnosis and Treatment IssuesChairs: B. Kemkes-Matthes (Giessen, Germany), H. ten Cate (Maastricht, The

Netherlands)

10:45 Rivaroxaban or fondaparinux for superficial-vein thrombosis – a randomized controlled non-inferiority trialJ. Beyer-Westendorf1,2, S. Schellong1, H. Gerlach3, E. Rabe4, J. Weitz5, K. Jersemann1, K. Sahin6, R. Bauersachs7,8 (1Dresden, Germany, 2London, United Kingdom, 3Mannheim, Germany, 4Bonn, Germany, 5Hamilton, Canada, 6Cologne, Germany, 7Darmstadt, Germany, 8Mainz, Germany)

11:00 Thrombophilia screening – Which patients, when, and what is appropriateE. Lindhoff-Last (Frankfurt am Main, Germany)

11:30 How to reverse anticoagulation – options for vitamin K antagonists and DOACsS. Eichinger-Hasenauer (Vienna, Austria)

11:00 – 12:00

Sydney

Highlight Session VPlateletsChairs: L. Alberio (Lausanne, Switzerland), C. Mannhalter (Vienna, Austria)

11:00 Highlight: Platelet granules – secretory and secretiveK. Jurk (Mainz, Germany)

11:20 Clinical Pearl: Inherited thrombocytopenia due to ANKRD26 mutationJ. Rufener (Bern, Switzerland)

11:35 Phospholipase D1 is a regulator of inflammatory platelet-endothelial interactions under high shear conditionsM. Klier1, N. Gowert1, S. Jäckel2, C. Reinhardt2, M. Elvers1 (1Duesseldorf, Germany, 2Mainz, Germany)

11:47 Heterogeneous regulation of platelet adhesive-receptor shedding in thrombus formationC. C. F. M. J. Baaten1, F. Swieringa1, T. Misztal2, T. G. Mastenbroek1, M. A. H. Feijge1, M. M. P. C. Donners1, P. W. Collins3, P. E. J. van der Meijden1, J. W. M. Heemskerk1 (1Maastricht, The Netherlands, 2Bialystok, Poland, 3Cardiff, United Kingdom)

WED

NESD

AYTH

URSD

AYFR

IDAY

SATU

RDAY



4948

WED

NESD

AYTH

URSD

AYFR

IDAY

SATU

RDAY

SC

IEN

TIFI

C P

RO

GR

AM

SC

IEN

TIFI

C P

RO

GR

AM

12:15 – 13:45

Boston 1+2

Satellite Symposium Bristol Myers Squibb GmbH & Co KGaA und Pfizer Pharma GmbHModerne Gerinnungshemmung – Was gehört dazu, was ist zu beachten?Chairs: R. Bauersachs (Darmstadt, Germany), V. Hach-Wunderle (Frankfurt am

Main, Germany)

12:15 Wie setzt man die oralen Antikoagulanzien am besten ein?C.-E. Dempfle (Mannheim-Lindenhof, Germany)

12:45 Antikoagulation und SchlaganfallprophylaxeM. Moser (Freiburg, Germany)

13:15 Behandlung und Rezidivprophylaxe von VTER. Bauersachs (Darmstadt, Germany)

12:15 – 13:45

Delhi

Satellite Symposium Aspen Germany GmbHHIT oder nicht HIT – das ist hier die Frage!Chair: A. Greinacher (Greifswald, Germany)

12:15 Einführung und BegrüssungA. Greinacher (Greifswald, Germany)

12:25 HIT – im Alltag relevant?E. Lindhoff-Last (Frankfurt am Main, Germany)

12:45 HIT? HIT! Vom Verdacht zur DiagnoseT. Bakchoul (Tuebingen, Germany)

13:05 Therapieansätze beim HIT-PatientenA. Greinacher (Greifswald, Germany)

13:25 Der HIT-Patient in der PraxisJ. H. Beer (Baden, Switzerland)

12:15 – 13:45

Kairo 1+2

Satellite Symposium Shire – Baxalta Deutschland GmbHNeue Behandlungswege bei HemmkörpernChair: A. Tiede (Hanover, Germany)

12:15 Begrüssung und EinleitungA. Tiede (Hanover, Germany)

12:25 Die individualisierte Therapie bei erworbener Hemmkörper HämophilieP. Knöbl (Vienna, Austria)

12:55 40 Jahre FEIBA: Erfahrungen während der ITIJ. Oldenburg (Bonn, Germany)

13:20 Bypassing Agenzien während der ITI: Interim Analyse der ObsITI StudieC. Escuriola-Ettingshausen (Moerfelden-Walldorf, Germany)

12:15 – 13:45

Shanghai 1+2

Satellite Symposium BayerEin Jahr im Zeichen von Kovaltry®

Chairs: A. Huth-Kühne (Heidelberg, Germany), R. Knöfler (Dresden, Germany)

12:15 Einführung

12:20 Pharmakokinetik in der Hämophilie-TherapieD. Garmann (Wuppertal, Germany)

12:40 Faktor VIII im Labor – eine Frage des AssaysJ. Müller (Bonn, Germany)

13:00 Ein Jahr Kovaltry – Erfahrungen aus der klinischen Praxis mit pädiatrischen PatientenC. Bidlingmaier (Munich, Germany)

13:15 Ein Jahr Kovaltry – Erfahrungen aus der klinischen Praxis mit erwachsenen PatientenG. Goldmann (Bonn, Germany)

12:15 – 13:45

Shanghai 3+4

Satellite Symposium Alexion Pharma Germany GmbHThrombosen unklarer Ätiologie – Herausforderungen im klinischen AlltagChair: M. Spannagl (Munich, Germany)

12:15 Umfelddiagnostik bei spontanen ThrombosenF. Langer (Hamburg, Germany)

12:45 Thrombosen bei hämatologischen ErkrankungenH. K. Al-Ali (Halle, Germany)

13:15 Fallbeispiel atypische Thrombosen bei PNHJ. Chromik (Frankfurt am Main, Germany)

14:00 – 15:30

Montreal

GTH General Assembly

16:00 – 17:00

Montreal

Plenary Session IVChairs: K. J. Clemetson (Bern, Switzerland), J. Oldenburg (Bonn, Germany)

16:00 Therapeutic genome editing with engineered nucleasesT. Cathomen (Freiburg, Germany)

16:30 Phenotypic disorder profiling and next generation sequencing in bleeding disordersW. H. Ouwehand (Cambridge, United Kingdom)

WED

NESD

AYTH

URSD

AYFR

IDAY

SATU

RDAY



5150

WED

NESD

AYTH

URSD

AYFR

IDAY

SATU

RDAY

SC

IEN

TIFI

C P

RO

GR

AM

SC

IEN

TIFI

C P

RO

GR

AM

17:15 – 18:15

Foyer2nd Floor

Poster viewing session

Approx. 18:00 Presentation of Best Poster Awards

From 18:30 Door opening Networking Evening at the Offene Kirche ElisabethenElisabethenstrasse 10 –14, 4051 Basel

6210

0-02

08-0

2/16

Eine Operation, Chemo therapie und intensive Betreuung.

Ein Thromboembolie-Rezidiv könnte alles zunichte machen.*

NEUEinziges NMH mit Zulassung zur Behandlung und anschliessenden Rezidivprophylaxe symptomatischer VTE bei Krebspatienten in der Schweiz.1

*fiktives Patientenbeispiel Behandlung und anschliessende Rezidivprophylaxe symptomatischer VTE bei Krebspatienten1

1. Fragmin® (Dalteparin): aktuelle Fachinformation unter www.swissmedicinfo.ch.

Fragmin® (Natriumdalteparin). Indikationen: Thromboembolieprophylaxe, u.a. Prophylaxe bei immobilisierten Patienten; Gerinnungshemmung während Hämodialyse/Hämofiltration; Therapie akuter tiefer Venenthrombosen und Lungenembolien, wenn keine thrombolytische Behandlung oder Embolektomie indiziert ist; Behandlung und anschliessende Rezidivprophylaxe symptomatischer venöser Thromboembolien bei Krebspatienten; instabile koronare Herzkrankheit. Dosierung: Thromboembolieprophylaxe: 2500-5000 IE s.c. 1x täglich; Patienten mit eingeschränkter Mobilität: 5000 IE s.c. 1x täglich während 12-14 Tagen oder länger; Gerinnungshemmung während Hämodialyse/Hämofiltration: Bolusinjektion von 5000 IE i.v. oder 30-40 IE/kg KG und anschliessend i.v. Infusion von 10-15 IE/kg KG/h; akute tiefe Venenthrombosen und Lungenembolien: 200 IE/kg KG s.c. 1x täglich; Behandlung und anschliessende Rezidivprophylaxe symptomatischer venöser Thromboembolien bei Krebspatienten: Dosierungsschemata siehe Arzneimittel-Fachinformation; instabile koronare Herzkrankheit: 120 IE/kg KG s.c. 2x täglich kombiniert mit ASS. Kontraindikationen: Überempfindlichkeit auf Dalteparin/Heparine (z.B. immunol. bedingte heparininduzierte Thrombozytopenie); schwere Gerinnungsstörungen; akute, klinisch bedeutsame Blutungen; bakterielle Endokarditis; drohende Fehlgeburt; operative Eingriffe am ZNS/Auge/Ohr; rückenmarksnahe Regionalanästhesie bei Dosen >5000 IE/24 h; Mehrfach-Stechampulle: Schwangerschaft, Neu-/Frühgeborene (wegen Gehalt an Benzylalkohol). Vorsichtsmassnahmen: Spinal-/Epiduralanästhesie; mit einem Blutungsrisiko verbundene Erkrankungen; Lungenembolie mit hämodynamischer Instabilität; Beckenvenenthrombosen; Thrombozytopenie; Auswirkungen auf Laborparameter (Transaminasen); Patienten mit Hyperkaliämie-Risiko; Osteoporose; Herzklappenprothesen; Untergewicht;. Kinder; peripartale Anwendung. Interaktionen: Vorsicht bei gleichzeitiger Anwendung mit Thrombolytika, oralen Antikoagulantien, Thrombozytenaggregationshemmern, NSAR, Dextran, systemischen Glucocorticoiden, Clopidogrel, Glykoproteinantagonisten. Unerwünschte Wirkungen: Thrombozytopenie (Typ I), Hämorrhagien, vorübergehender Anstieg der Transaminasen (AST, ALT), Schmerzen und Hämatome an der Injektionsstelle. Packungen: s. Arzneimittel-Fachinformation. Verkaufskategorie B. Zulassungsinhaberin: Pfizer PFE Switzerland GmbH, Zürich. Ausführliche Informationen siehe Arzneimittel-Fachinformation unter www.swissmedicinfo.ch. (V017)

Pfizer PFE Switzerland GmbH, Schärenmoosstrasse 99, Postfach, 8052 Zürich

62100-0208-0216_Fragmin_CLOT_Anzeige_D_A5_20161208.indd 1 08.12.16 09:27

FRIDAY, 17 FEBRUARY 2017

SCIENTIFIC PROGRAM

53W

EDNE

SDAY

THUR

SDAY

FRID

AYSA

TURD

AYS

CIE

NTI

FIC

PR

OG

RA

M

Plenary Highlight Poster State of the Art Working Group Miscellaneous

NEW, HOT or DISCUSSED Oral Communication Sat./Lunch Symposium Symposium Workshop

Delhi Ground Floor

Montreal 2nd Floor

Singapore 2nd Floor

Sydney 2nd Floor

08:0008:30 Special Symposium

Neue Möglichkeiten (und Grenzen?) durch eine standardisierte

Ultraschall-Untersuchung früher Gelenkveränderungen

(HEAD-US) bei Patienten mit schwerer Blutungs-neigung – Theorie und

praktische Demonstrationen für Behandler und Patienten

Special SymposiumTTP & ADAMTS13

Oral CommunicationsBleeding Disorders –

Clinical Studies

State of the ArtInflammation

08:4509:0009:1509:3009:4510:00

Special SymposiumTTP & ADAMTS13

Special SymposiumHIV-Langzeitüberlebende

nach Infektion durch Blutprodukte

Oral CommunicationsPlatelets

10:1510:3010:4511:0011:1511:30

Plenary Session V11:4512:0012:1512:30 Closing ceremony

SCIENTIFIC PROGRAM

Faktor IX (rekombinant), Albumin-Fusionsprotein

®

FAKFAKFAKTOR!TOR!TOR!FAKFAKFAKTOR!FAKFAKFAKTOR!FAKFAKFAKTOR!FAKFAKFAKNEU: Nur 1 Injektion für bis zu 14 Tage Schutz in der Langzeitprophylaxe* – mit IDELVION®

HÄMOPHIL IE - B - THERAPIE

IDELVION®: Erster und einziger rIX mit Albumin-Fusionstechnologie – für eine neue Zeitrechnung in der Hämophilie-B-Therapie

• Verlängerte Wirksamkeit von bis zu 14 Tagen mit nur 1 Injektion 1 - bis zu 75 % weniger Injektionen!#

• FIX-Aktivität: Talspiegel von > 5 % – auch nach 14 Tagen‡,1, 4

• Mediane AsBR von 0,00†, 1

FREISTOSS INS LEBEN

IDELVION® 250 I.E./500 I.E./1000 I.E./2000 I.E. Pulver und Lösungsmittel zur Herstellung einer Injektionslösung. Wirkstoff: Rekombinantes Fusionsprotein aus Blutgerinnungsfaktor IX und Albumin. Zusammensetzung: IDELVION® 250 I.E./500 I.E./1000 I.E./2000 I.E. enth. nominal 250 I.E. (100 I.E./ ml), 500 I.E. (200 I.E./ ml), 1000 I.E. (400 I.E./ml) bzw. 2000 I.E. (400 I.E./ml) rekombinantes Fusionsprotein aus Blutgerinnungsfaktor IX und Albumin (Albutrepenonacog alfa). Sonst. Bestandteile: Tri-Natriumcitrat Dihydrat, Polysorbat 80, Mannitol, Saccharose, HCl. Lösungsmittel: Wasser f. Injektionszwecke. Anwendungsgebiete: Therapie u. Prophylaxe von Blutungen bei Pat. mit Hämophilie B (kongenitaler Faktor-IX-Mangel). Gegenanzeigen: Überempfindlichkeit gg. den Wirkstoff od. sonst. Bestandteile des Präparates, bekannte allergische Reaktion auf Hamsterprotein. Nebenwirkungen: Häufig: Reaktionen a. d. Injektionsstelle, Kopfschmerzen. Gelegentlich: Schwindel, Überempfindlichkeit, Nesselsucht, Ekzem. Selten: Überempfindlichkeitsreaktionen od. allerg. Reaktionen (z. B. Angio ödem, Brennen u. Stechen a. d. Injektions- / Infusionsstelle, Schüttelfrost, Hautrötung mit Hitzegefühl, generalisierte Nesselsucht, Kopfschmerzen, quaddelartigen Hautausschlag, Hypotonie, Lethargie, Übelkeit, Unruhe, Tachykardie, Engegefühl i. d. Brust, Zittern, Erbrechen od. Stridor ) können sich in manchen Fällen zu schweren Anaphylaxie (inkl. Schock) ent wickeln. In Fällen schwerer Anaphylaxie traten diese in engem zeitlichen Zusammen hang mit der Entwicklung von Faktor-IX-Hemmkörpern auf. Nephrotisches Syndrom (nach versuchter Immuntoleranz-Induktion bei Hämophilie-B-Patienten mit Faktor IX-Hemmkörpern u. bekannter allerg. Reaktion). Sehr selten: Entwicklung von Antikörpern gg. Hamsterproteine nach d. Anwendung von Faktor IX Produkten aus CHO Zellen., Bildung neutralisierender Antikörper (Hemmkörper) gegen Faktor IX. Häufigkeit nicht bekannt: Thrombo embol. Ereignisse (Risiko bei weniger gut gereinigten Präparaten höher). Verschreibungspflichtig. Pharmazeutischer Unternehmer: CSL Behring GmbH, Emil-von-Behring-Str. 76, 35041 Marburg. Stand: April 2016

* Patienten ≥ 12 Jahre: Manche Patienten, die auf ein einmal wöchentliches Therapie-schema gut eingestellt sind, können mit bis zu 75 I.E./ kg in einem Intervall von 10 oder 14 Tagen behandelt werden.

# im Vergleich zur bisherigen prophylaktischen Therapie laut Fachinformationen 2, 3

‡ bei Anwendung von 50 I.E./ kg IDELVION®

† im Beobachtungszeitraum in den klinischen Phase-III- Studien bei vorbehandelten Erwachsenen und Kindern1

1 Santagostino et al., Blood 2016;127(1):1761– 9.2 Fachinformation IDELVION®, Stand: April 2016.3 Fachinformation BeneFIX®

250/500/1000/2000/3000 I.E., Stand: Okt. 2015.4 Santagostino et al., Blood 2012;120(12):2405 –11.

N6043_Sonderformat_DINA5_161219.indd 1 19.12.16 14:09

SATURDAY, 18 FEBRUARY 2017

55W

EDNE

SDAY

THUR

SDAY

FRID

AYSA

TURD

AYS

CIE

NTI

FIC

PR

OG

RA

M

08:00 – 11:00

Delhi

Special SymposiumNeue Möglichkeiten (und Grenzen?) durch eine standardisierte Ultra-schall-Untersuchung früher Gelenkveränderungen (HEAD-US) bei Patienten mit schwerer Blutungsneigung – Theorie und praktische Demonstrationen für Behandler und PatientenChairs: B. Habermann (Mainz, Germany), M. Sigl-Kraetzig (Blaubeuren, Germany)

08:30 Einleitung – wieso Ultraschall zur Bildgebung bei hämophiler Arthropathie?M. Sigl-Kraetzig (Blaubeuren, Germany)

08:35 Synovitis bei Patienten mit schwerer Blutungsneigung – frühe pathologi-sche Veränderungen bei Hämophiler Arthropathie und neue Erkenntnisse im Rahmen der Erstellung einer neuen Leitlinie zu Diagnostik und Therapie.B. Habermann (Mainz, Germany)

08:50 Ultraschall - wie funktioniert das? Technische Grundlagen, Artefakte, Chancen und Grenzen der Methode zur Bildgebung an GelenkenL. Steffgen (Mainleus, Germany)

09:10 Ultraschall als Tool des Behandlers zur Darstellung von Gelenkver-änderungen bei Patienten mit BlutungsneigungM. Sigl-Kraetzig (Blaubeuren, Germany)

09:30 Der HEAD-US-Score: untersucherunabhängige Einteilung der durch standardisierten Ultraschall darstellbaren GelenkveränderungenI. Hegemann (Zurich, Switzerland)

09:45 Kernspintomographie oder standardisierter Ultraschall zur Darstellung von Gelenkveränderungen bei Blutungsneigung – was ist besser?M. Püsken (Cologne, Germany), M. Sigl-Kraetzig (Blaubeuren, Germany)

10:05 Falldemonstrationen von Patienten mit sonographisch darstellbaren Gelenkveränderungen (Probanden für die praktische Demonstration)R. Kobelt (Wabern, Switzerland)

10:15 Praktische Demonstration des Untersuchungsganges der standardisierten Gelenksonographie nach der Methode von C. Martinoli (HEAD-US) an ProbandenI. Hegemann (Zurich, Switzerland), M. Sigl-Kraetzig (Blaubeuren, Germany)

08:30 – 09:45

Montreal

Special SymposiumTTP & ADAMTS13(with simultaneous oral translation English-Deutsch / Deutsch-English)Chairs: P. Knöbl (Vienna, Austria), J. A. Kremer Hovinga (Bern, Switzerland)

08:30 Historical perspective of TTP and ADAMTS13B. Lämmle (Mainz, Germany)

08:55 ADAMTS13 interaction with VWFK. Vanhoorelbeke (Kortrijk, Belgium)

09:20 Insights into the immune response to ADAMTS13 in acquired TTPM. Schaller Tschan (Bern, Switzerland)

08:30 – 09:45

Singapore

Oral CommunicationsBleeding Disorders – Clinical StudiesChairs: C. Bidlingmaier (Munich, Germany), R. Klamroth (Berlin, Germany)

08:30 Immunogenicity of BAX 855 in previously treated patients with congenital severe hemophilia AF. M. Horling1, P. Allacher2, H. Koppensteiner1, W. Engl1, F. Scheiflinger1, B. Abbühl1, B. M. Reipert1 (1Vienna, Austria, 2Krems, Austria)

08:42 Danger signal-dependent activation of human immune cells by factor VIII productsL. Miller, K. M. Kistner, E. Ringler, Z. Waibler, on behalf of the ABIRISK consortium (Langen, Germany)

08:54 Immune tolerance induction (ITI) with factor IX and combined immunosuppressive therapy in two patients with severe hemophilia B, longstanding inhibitors and previous allergic reactionsK. Holstein, M. Voigtländer, C. Dicke, F. Langer (Hamburg, Germany)

09:06 Very low-dose recombinant activated factor VII for treatment of major surgical bleedingT. Hoffmann, S. Sixt, A. Albert, A. Dierksen, E. Roussel, A. Lichtenberg, A. Assmann (Duesseldorf, Germany)

09:18 Identification of eight novel mutations and one recurrent mutation in F13B gene leading to inherited, heterozygous FXIII deficiencyV. Ivaskevicius1, A. Biswas1, S. Singh1, G. Kappert2, S. Halimeh2, H. Rott2, S. Flommersfeld3, H. Trobisch2, U. Kreibich4, M. Olivieri5, J. Oldenburg1(1Bonn, Germany, 2Duisburg, Germany, 3Marburg, Germany, 4Zwickau, Germany, 5Munich, Germany)

09:30 Characterization of GGCX mutations identified in VKCFD1 patientsS. Ghosh1, K. J. Czogalla1, K. Liphardt 1, J. Müller 1, K. Höning 1, V. Hornung1,2, M. Watzka1, J. Oldenburg1 (1Bonn, Germany, 2Munich, Germany)

08:30 – 09:45

Sydney

State of the ArtInflammationChairs: W. Korte (St. Gallen, Switzerland), V. Schröder (Bern, Switzerland)

08:30 DAMPs in systemic inflammation: where they come from and how to get rid of them?S. Zeerleder (Amsterdam, The Netherlands)

08:55 Complement activation in sepsis and traumaM. Huber-Lang (Ulm, Germany)

09:20 Tissue factor and inflammatory mediators of thrombosisW. Ruf (Mainz, Germany)

WED

NESD

AYTH

URSD

AYFR

IDAY

SATU

RDAY

SATURDAY, 18 FEBRUARY 2017 SATURDAY, 18 FEBRUARY 2017


5756

WED

NESD

AYTH

URSD

AYFR

IDAY

SATU

RDAY

SC

IEN

TIFI

C P

RO

GR

AM

SC

IEN

TIFI

C P

RO

GR

AM

10:00 – 11:15

Montreal

Special SymposiumTTP & ADAMTS13(with simultaneous oral translation English-Deutsch / Deutsch-English)Chairs: Z. Cermakova (Ostrava, Czech Republic) A. S. von Krogh (Trondheim,

Norway)

10:00 Leben mit TTP – Sicht der BetroffenenS. Könen (Niestetal, Germany)

10:25 Treatment of acquired TTPP. Coppo (Paris, France)

10:50 Hereditary TTP (Upshaw-Schulman syndrome)Y. Fujimura (Nara, Japan)

10:00 – 11:30

Singapore

Special SymposiumHIV-Langzeitüberlebende nach Infektion durch BlutprodukteChairs: S. Flommersfeld (Marburg, Germany), R. Zimmermann (Heidelberg,

Germany)

10:00 Bericht aus Sicht der DHG (Deutsche Hämophilie Gesellschaft)W. Kalnins (Nettersheim, Germany)

10:20 Bericht aus Sicht der BetroffenenM. Diederich (Ulm, Germany)

10:40 Bericht aus Sicht der PolitikH. Schmidbauer (Nürnberg, Germany)

11:00 Schweizer PerspektiveR. Schwabe (Bern, Switzerland)

11:20 Diskussionsrunde mit allen Vortragenden

10:00 – 11:15

Sydney

Oral CommunicationsPlateletsChairs: L. Alberio (Lausanne, Switzerland), D. Dürschmied (Freiburg, Germany)

10:00 A novel splice-specific GFI1B mutation in a family with recessive macrothrombocytopeniaH. Schulze1, A. Schlagenhauf2, G. Manukjan1, O. Andres1, E. Klopocki1, S. Panzer3, C. Beham-Schmid2, K. Althaus4, A. Greinacher4, T. Bakchoul4, M. G. Seidel2 (1Wuerzburg, Germany, 2Graz, Austria, 3Vienna, Austria, 4Greifswald, Germany)

10:12 Antibody-mediated platelet-desialylation: a potential role in platelet destruction in autoimmune thrombocytopeniaR. Jouni1, J. Alex2, I. Marini2, L. Janzen2, A. Greinacher2, T. Bakchoul1 (1Tuebingen, Germany, 2Greifswald, Germany)

10:24 Reelin is important for PLCgamma2 phosphorylation upon platelet activation and integrin outside-in signalingI. Krueger, M. Klier, N. S. Gowert, M. Elvers (Duesseldorf, Germany)

10:36 Platelets are a previously unrecognized source of immune-modulatory CXCL14A. Witte, J. Lu, M. Gawaz (Tuebingen, Germany)

10:48 Specific inhibition of extracellular CyPA affects platelet and monocyte functions in vitro and in vivoS. von Ungern-Sternberg1, B. Walker-Allgaier1, S. Vogel1, E. Kremmer2, O. Borst1, T. Billar3, A. May1, M. Gawaz1, P. Seizer1 (1Tuebingen, Germany, 2Munich, Germany, 3Pittsburgh, United States)

11:00 High shear induced platelet rolling velocity and adhesion onto von Wille-brand factor are mediated by GpIb alpha clustering as demonstrated by FRET/FLIM and can be inhibited by alpha linolenic acidS. Stivala1,2, D. van den Heuvel3, S. De Meyer4, S. Gobbato1, N. Bonetti1, H. Deckmyn4, G. G. Camici1, T. F. Lüscher1, R. Urbanus3, H. Gerritsen3, J. H. Beer1,2 (1Zurich, Switzerland, 2Baden, Switzerland, 3Utrecht, The Nether-lands, 4Kortrijk, Belgium)

11:30 – 12:30

Montreal

Plenary Session VChairs: S. Eichinger-Hasenauer (Vienna, Austria), M. Nagler (Bern, Switzerland)

11:30 Choosing wisely with the help of risk scores – balancing the risk of stroke and bleeding in atrial fibrillationG. Y. Lip (Birmingham, United Kingdom)

12:00 How the hemostatic system modulates atherosclerosisH. ten Cate (Maastricht, The Netherlands)

12:30 – 12:45

Montreal

Closing Ceremony

Farewell and HandoverJ. A. Kremer Hovinga (Bern, Switzerland)

Sabine Eichinger-Hasenauer and Paul Alexander Kyrle (Vienna, Austria)

WED

NESD

AYTH

URSD

AYFR

IDAY

SATU

RDAY

SATURDAY, 18 FEBRUARY 2017 SATURDAY, 18 FEBRUARY 2017


5958

WED

NESD

AYTH

URSD

AYFR

IDAY

SATU

RDAY

SC

IEN

TIFI

C P

RO

GR

AM

SC

IEN

TIFI

C P

RO

GR

AM

No. Title Authors No. Title Authors

Acquired problems and alterations of coagulation

1

Blood clotting supports glioma invasion and colonization

J. Pilch, A. Burkardt, C. Wolter, S. Urbschat, R. Ketter, D. Lessig, I. Müller, H. Eichler, L. M. Knowles (Homburg, Germany)

2 Improved values regarding acquired von Willebrand syndrome in patients with HeartMate III compared to HeartMate II

U. Geisen1, K. Brehm1, G. Trummer1, F. Beyersdorf1, M. Berchtold-Herz1, C. Heilmann1, J. Schelling1, A. Schlagen-hauf2, B. Zieger1 (1Freiburg, Germany, 2Graz, Austria)

3 Reconstituted whole blood using fresh frozen plasma versus coagulation factor concentrates: an in vitro study

G. E. Iapichino1,2, M. Ponschab1,3, C. J. Schlimp1,4, S. Süssner3, J. Cadamuro5, H. Redl1, H. Schöchl1,5 (1Vienna, Austria, 2Milan, Italy, 3Linz, Austria, 4Edinburgh, United Kingdom, 5Salzburg, Austria)

4 Hemostatic potential of reconstituted whole blood using fresh frozen plasma versus increasing concentration of lyoplasma

G. E. Iapichino1,2, M. Ponschab1,3, C. J. Schlimp1,4, C. Gabriel3, J. Cadamuro5, H. Redl1, H. Schöchl1,5 (1Vienna, Austria, 2Milan, Italy, 3Linz, Austria, 4Edinburgh, United Kingdom, 5Salzburg, Austria)

5 Trend in hospital cases of acquired hemophilia A (AHA) 2010 – 2014 in Germany

S. Wahler1, A. Tiede2 (1Hamburg, Germany, 2Hanover, Germany)

6 Procoagulant microparticles and nanoparticles from whole blood reconstituted with age-different blood components

M. Ponschab1,2, C. J. Schlimp1,3, L. Wisgrill1, A. Spittler1, C. Gabriel2, J. Zipperle1, G. E. Iapichino1,4, H. Redl1, H. Schöchl1,5 (1Vienna, Austria, 2Linz, Austria, 3Edinburgh, United Kingdom, 4Milan, Italy, 5Salzburg, Austria)

7 Longitudinal analyses of microparticle-associated tissue factor activity and venous thromboembolism (VTE) in cancer patients

E.-M. Reitter, A. Kaider, C. Ay, J. Thaler, C. Marosi, I. Pabinger (Vienna, Austria)

8 Thrombin formation capacity in patients with two different left-ventricular assist devices and after heart transplantation

A. Schlagenhauf1, U. Geisen2, K. Brehm2, G. Trummer2, F. Beyersdorf2, M. Berchtold-Herz2, B. Zieger2 (1Graz, Austria, 2Freiburg, Germany)

9 Chronic disseminated intravascular coagulation in a patient with antiphospholipid antibodies and acquired protein S deficiency

C. Dicke, K. Holstein, M. Voigtländer, F. Stahl, U. Schnoor, C. Bokemeyer, F. Langer (Hamburg, Germany)

10 Successful inhibitor eradication with ofatumumab in a patient with acquired hemophilia A

R. Fischer, M. Alrifai, K. Heidinger, B. Kemkes-Matthes (Giessen, Germany)

11 Is a too low plasminogen level in the plasma of kidney trans-plant recipients the reason of irreversible rejection reactions?

H. E. Karges (Marburg, Germany)

12 Venous thromboembolism and vascular access thrombosis in patients with end-stage renal disease on chronic hemodialy-sis: results of the VIVALDI study

O. Königsbrügge, E. Grilz, I. Pabinger, M. Säemann, C. Ay (Vienna, Austria)

13 Dual mechanical assistance with veno-arterial extracorporeal membrane oxygenation and percutaneous continuous-flow device: double trouble for von Willebrand factor

A. Rauch, F. Vincent, E. Jeanpierre, C. Caron, A. Dupont, N. Rousse, A. Vincentelli, E. Robin, E. Van Belle, J. Goudemand, S. Susen (Lille, France)

14 Direct oral thrombin inhibitor dabigatran etexilate is able to control chronic disseminated intravasal coagulation: a case report

W. Korte, L. Graf (St. Gallen, Switzerland)

15 Management of epidural bleeding in a patient with acquired hemophilia A masked by phenprocoumon therapy

M. Alrifai, R. Fischer, K. Heidinger, B. Kemkes-Matthes (Giessen, Germany)

Antithrombotic treatment

16 Differential effects of novel anticoagulants: fXa versus fIIa

inhibition on coagulation and inflammation S. Nazir1, K. Shahzad1, I. Gadi1, M. Al-Dabet1, S. Kohli1, S. Ran-jan1, F. Bock1,2, B. Isermann1 (1Magdeburg, Germany, 2Nashville, United States)

17 How to assess in vivo anticoagulant effect of Rivaroxaban D. Bertaggia Calderara1, D. Kröll2, C. Gerschheimer1, N. Nicolas1, G. Stirnimann2, L. Alberio1 (1Lausanne, Switzerland, 2Bern, Switzerland)

18 Single-center experience with thrombolysis in high- and intermediate-risk pulmonary embolism

N. Herr, C. Bode, T. Wengenmayer, D. Duerschmied (Freiburg, Germany)

19 Real life efficacy and safety of edoxaban for stroke prevention in atrial fibrillation – Results of the prospective NOAC registry (NCT01588119)

L. Tittl, J. Hecker, L. Wunder, T. Schreier, A. Reitter, J. Beyer-Wes-tendorf (Dresden, Germany)

20 Prevention and treatment of venous thromboembolism in patients with solid brain neoplasms: results of a survey among Italian physicians

N. Mumoli1, S. Barco2, M. Cei3, M. Giorgi-Pierfranceschi3, M. Campanini4, A. Fontanella5, W. Ageno6, F. Dentali6 (1Livorno, Italy, 2Mainz, Germany, 3Piacenza, Italy, 4Novara, Italy, 5Napoli, Italy, 6Varese, Italy)

21 CONKO-011: Rivaroxaban in the treatment of venous thrombembolism (VTE) in cancer patients – a randomized phase III study

M. Sinn1, A. Jühling1, J. Heinz2, M. Hellmann3, R. U. Trappe4, T. Südhoff5, B. Günther6, L. Wislocka1, J. Striefler1, U. Pelzer1, H. Riess1 (1Berlin, Germany, 2Freiburg, Germany, 3Cologne, Germany, 4Bremen, Germany, 5Passau, Germany, 6Duesseldorf, Germany)

22 Long-term clinical outcomes of patients with CYP2C9 and VKORC1 variants treated with vitamin K antagonists: A prospective, multicenter cohort study of elderly patients with venous thromboembolism

M. Nagler1, A. Angelillo-Scherrer1, M. Mean1, A. Limacher1, C. Abbal2, M. Righini3, H.-J. Beer4, J. Osterwalder5, B. Frauchiger6, M. Aschwanden7, C. Matter8, N. Kucher1, J. Cornuz2, M. Banyai9, M. Husmann8, D. Staub7, L. Mazzolai2, O. Hugli2, N. Rodondi1, D. Aujesky1 (1Bern, Switzerland, 2Lausanne, Switzerland, 3Geneva, Switzerland, 4Baden, Switzerland, 5St. Gallen, Switzerland, 6Frauenfeld, Switzerland, 7Basel, Switzerland, 8Zurich, Switzer-land, 9Lucerne, Switzerland)

23 Clinical observations on potential interactions of phenprocou-mon, colchicine and rivaroxaban in a patient with compound homozygosity for FV Leiden and familial Mediterranean fever (FMF, M680I)

L. Graf, K. Jung, W. Korte (St. Gallen, Switzerland)

Arterial thrombosis

24 Activation of neutrophils – but not endothelial cells – is regu-lated by serotonin during myocardial reperfusion injury

M. Mauler, F. Glatzki, N. Herr, C. Schoenichen, T. Witsch, D. Stallmann, C. Bode, I. Ahrens, I. Hilgendorf, D. Duerschmied (Freiburg, Germany)

25 Protein C and factor X activities from patients with ischemic stroke and type II diabetes mellitus

O. Kravchenko, O. Savchuk, T. Tsarenko, L. Ostapchenko (Kiev, Ukraine)

26 Inhibition of coagulation factor Xa attenuates myocardial ischemia reperfusion injury in mice

J. J. Posma, J. J. Posthuma, R. Van Oerle, H. ten Cate, H. H. Spronk (Maastricht, The Netherlands)

27 Idiopathic catastrophic thrombosis with happy end – a case report

J. Heid, H. A. Katus, O. Müller (Heidelberg, Germany)

28 The molecular etiology and pathophysiology of platelet-me-diated aspirin responsive erythromelalgia and microascular thrombosis in JAK2, CALR and MPL mutated thrombocythemia

J. J. Michiels1,2 (1Antwerp, Belgium, 2Rotterdam, The Nether-lands)

29 Effect of alpha-2 plasmin inhibitor p.Arg6Trp polymorphism and antigen level on the risk of myocardial infarction in young patients

E. Katona, A. Orosz, Z. Mezei, L. Balogh, Z. Bereczky, I. Edes, L. Muszbek (Debrecen, Hungary)

Bleeding disorders, coagulation and fibrinolytic factors

30 rVIII-SingleChain: results of a phase III PK, efficacy and

safety study in children less than 12 years of age with severe hemophilia A

I. Pabinger1, O. Stasyshyn2, G. Iosava3, C. Djambas Khayat4, J. Ong5, K. Fischer6, F. Abdul Karim7, A. Veldman8, K. St. Ledger9 (1Vienna, Austria, 2Lviv, Ukraine, 3Tbilisi, Georgia, 4Beirut, Lebanon, 5Davao, Philippines, 6Ultrecht, The Netherlands, 7Kuala Lumpur, Malaysia, 8Marburg, Germany, 9King of Prussia, United States)

31 Comparison of biomarkers and immunological parameters

between hemophilia patients, rheumatoid arthritis patients and control subjects

R. Toenges1, A. Wittenbrinck1, S. Gundermann1, M. Wahle2, R. Schäfer1, W. Miesbach1 (1Frankfurt am Main, Germany, 2Augsburg, Germany)

POSTER LIST

6160P

OS

TER

LIS

T

PO

STE

R L

IST

POSTER LIST


32 Introduction of a guideline for the treatment of synovitis

in patients with hemophiliaB. Habermann1, A. Seuser2, T. Hilberg3 (1Mainz, Germany, 2Bonn, Germany, 3Wuppertal, Germany)

33 The coagulation factor XIII (FXIII) A subunit activation

peptide directs the evolution of FXIIIA as a proteolytically activated dimeric molecule

A. Biswas, S. Singh, V. Ivaskevicius, J. Oldenburg (Bonn, Germany)

34 FSAP and altered fibrin clot structure: Is there a link to

FXIII?M. Etscheid, N. Beer, R. Seitz, J. Dodt (Langen, Germany)

35 Amidolytic thrombin activity under the ischemic stroke peptide pool influence

T. Katrii, O. Savchuk (Kiev, Ukraine)

36 What hemophilia patients expect from the new extended half-life (EHL) products and their willingness to switch – Results from the DACH region

S. von Mackensen1, W. Kalnins1, L. Hostettler2, J. Krucker2, M. Albisetti3, J. Weiss4, I. Pabinger4, J. Oldenburg5 (1Hamburg, Germany, 2Altstaetten, Switzerland, 3Zurich, Switzerland, 4Vienna, Austria, 5Bonn, Germany)

37 Monitoring of perioperative factor VIII treatment in a remote hospital by electronic diary smart medicationTM

W. Mondorf, D. Schmoldt (Frankfurt am Main, Germany)

38 An Asp94Gly missense mutation in GP1BB causes severe Bernard-Soulier syndrome in an Iraqi family

D. Boeckelmann, E. Lerner, J. Schelling, K. Neubauer, K. Sandrock-Lang, B. Zieger (Freiburg, Germany)

39 Impact of maintaining higher FVIII trough levels with BAX 855: Rationale and design of the PROPEL study

H.-Y. Lee1, B. E. Abbuehl2, A. Hafeman3, W. Engl2, L. Patrone3, L. A. Valentino4, B. M. Ewenstein5 (1Zurich, Switzerland, 2Vienna, Austria, 3Westlake Village, United States, 4Chicago, United States, 5Cambridge, United States)

40 Nonacog beta pegol in adult and paediatric patients: pooled data from the paradigmTM clinical program

J. Oldenburg1, M. Carcao2, S. R. Lentz3, J. Mahlangu4, M. Mancuso5, T. Matshushita6, C. Négrier7, W. H. Ong Clausen8, S. Ehrenforth8, G. Young9 (1Bonn, Germany, 2Toronto, Canada, 3Iowa, United States, 4Johannesburg, South Africa, 5Milan, Italy, 6Nagoya, Japan, 7Lyon, France, 8Søborg, Denmark, 9Los Angeles, United States)

41 Challenges in immune tolerance induction in an adult patient with non-severe hemophilia A

P. Kuta1, S. Achenbach1, T. Zöller2, R. Zimmermann1 (1Erlangen, Germany, 2Coburg, Germany)

42 Prevalence of overweight and obesity in children, adolescents and young adults with severe hemophilia A – results of 3 German pediatric hemophilia treatment centers

M. Olivieri1, C. Königs2, S. Horneff3, C. Bidlingmaier1 (1Munich, Germany, 2Frankfurt am Main, Germany, 3Bonn, Germany)

43 Pharmacokinetic results of two studies with a novel fibrinogen concentrate in subjects with afibrinogenaemia

W. Stevens1, A. Bellon1, F. Bridey1, Ph. de Moerloose2 (1Les Ulis, France, 2Geneva, Switzerland)

44 Pitfalls in carrier testing of hemophilia A B. Preisler1, I. Radermacher1, I. Schwarze1, R. Kuhlemann1, R. Maurer1, J. Beckedahl1, L. Rothbrust1, J. Junen1, U. Scholz2, B. Pezeshkpoor1, B. A. Pavlova1, J. Oldenburg1 (1Bonn, Germany, 2Leipzig, Germany)

45 Long-term use of recombinant fusion protein linking coa-gulation factor IX with albumin (rIX-FP) in previously treated patients with hemophilia B

S. Halimeh1, A. Lubetsky2, U. Martinowitz2, T. Lissitchkov3, A. Veldman4, E. Santagostino5 (1Duisberg, Germany, 2Tel Hasho-mer, Israel, 3Sofia, Bulgaria, 4Marburg, Germany, 5Milan, Italy)

46 Resolution of target joints during once-weekly prophylaxis with rIX-FP in patients with hemophilia B

H. J. Laws1, H. Hanabusa2, C. Négrier3, T. Lissitchkov4, G. Casta-man5,6, A. Tagliaferri7, K. Fukutake2, M. F. López Fernández8, A. Veldman9, E. Santagostino10 (1Duesseldorf, Germany, 2Tokyo, Japan, 3Lyon, France, 4Sofia, Bulgaria, 5Vicenza, Italy, 6Florence, Italy, 7Parma, Italy, 8La Coruña, Spain, 9Marburg, Germany, 10Milan, Italy)

47 Epidemiological insights about hemophilia B by analysis of German hospital quality reports

S. Wahler1, A. Müller2 (1Hamburg, Germany, 2Munich, Germany)

48 Efficacy and safety of a VWF/FVIII concentrate in surgical procedures – results from the ongoing study Wilate-STATE

S. Halimeh1, M. Daoud1, M. Rieke2, T. Lang2, J. Kadar3, S. Alesci4, J. Koscielny5, J. Feddern6, S. Seeger6 (1Duisburg, Germany, 2Hohne, Germany, 3Cologne, Germany, 4Bad Homburg, Germany, 5Berlin, Germany, 6Langenfeld, Germany)

49 Combined congenital deficiency of coagulation factors VII and X in two siblings with heterozygous factor V Leiden mutation (R506Q)

K. Heidinger1, R. Fischer1, M. Alrifai1, A. Pavlova2, B. Kem-kes-Matthes1 (1Gießen, Germany, 2Bonn, Germany)

50 Efficacy and safety of rVIII-SingleChain in 21 major surgeries J. Oldenburg1, C. Djambas Khayat2, J. Mahlangu3, R. Baker4, C. Leissinger5, E. Santagostino6, M. F. Lopez-Fernandez7, F. Abdul Karim8, A. Veldman9, K. St. Ledger10, I. Pabinger11 (1Bonn, Germany, 2Beirut, Lebanon, 3Johannesburg, South Africa, 4Nedlands, Australia, 5New Orleans, United States, 6Milan, Italy, 7La Coruña, Spain, 8Kuala Lumpur, Malaysia, 9Marburg, Germany, 10King of Prussia, United States, 11Vienna, Austria)

51 A preliminary study to find novel interaction partners for the coagulation factor XIII (FXIII) B subunit free form

S. Singh1, J. Dodt2, A. Reuter2, V. Ivaskevicius1, J. Oldenburg1, A. Biswas1 (1Bonn, Germany, 2Langen, Germany)

52 Determining the causality of heterozygous missense muta-tions detected in F13A1 and F13B genes and reported from patients with mild coagulation factor XIII (FXIII) deficiency

A. Biswas1, A. Thomas1, J. Dodt2, H. Philippou3, E. Heathershaw3, H. E. Jürgen1, V. Ivaskevicius1, J. Oldenburg1 (1Bonn, Germany, 2Langen, Germany, 3Leeds, United Kingdom)

53 Annual bleeding vs. factor VIII/IX consumption – comparison of result in 2014 and 2015 according to electronic diary smart-medicationTM

R. Fischer1, H. Eichler2, K. Holstein3, R. Klamroth4, A. Nimtz-Talaska5, H. Richter6, K. Severin7, C. Wermes8, W. Mondorf9 (1Giessen, Germany, 2Homburg/Saar, Germany, 3Hamburg, Germany, 4Berlin, Germany, 5Frankfurt an der Oder, Germany, 6Muenster, Germany, 7Cologne, Germany, 8Hanover, Germany, 9Frankfurt am Main, Germany)

54 The regulatory profile of the 5´ untranslated region of F13A1 gene of coagulation factor XIII (FXIII) A subunit

M. A. Jamil, S. Singh, V. Ivaskevicius, O. El-Maarri, J. Oldenburg, A. Biswas (Bonn, Germany)

55 Long-term immunogenicity, safety and efficacy of human-cl rhFVIII in previously treated children with severe hemophilia A

J. Bichler1, A. Klukowska2, V. Vdovin3, T. Szczepanski4, I. Dzhunova1, R. Liesner5 (1Lachen, Switzerland, 2Warsaw, Poland, 3Moscow, Russian Federation, 4Katowice, Poland, 5London, United Kingdom)

56 Individualized prophylaxis with Nuwiq® (human-cl rhFVIII) in adult PTPs with severe hemophilia A

J. Bichler1, C. Kessler2, K. Meijer3, A. Armstrong4, S. Knaub1, G. Pezeshki5, M. Wang6 (1Lachen, Switzerland, 2Washington DC, United States, 3Groningen, The Netherlands, 4Helsinki, Finland, 5Hoboken, United States, 6Aurora, United States)

57 Efficacy and safety of Nuwiq® in clinical trials with previously treated patients with severe hemophilia A

R. Klamroth1, J. Bichler2, M. Jansen3, L. Belyanskaya2, S. Knaub2, R. Liesner4, J. Oldenburg5, A. Tiede6, C. Kessler7 (1Berlin, Germany, 2Lachen, Switzerland, 3Vienna, Austria, 4London, United Kingdom, 5Bonn, Germany, 6Hanover, Germany, 7Washington DC, United States)

58 Interim bleeding data of 522 hemophilia A patients from the international AHEAD Study after 3 years of observation

K. Steinitz-Trost1, J. Oldenburg2, D. A. Tsakiris3, C. Hermans4, K. Khair5, R. Liesner5, M. G. Mazzucconi6, G. Spotts7, A. J. Rei-ninger1, A. Gringeri1 (1Vienna, Austria, 2Bonn, Germany, 3Basel, Switzerland, 4Brussels, Belgium, 5London, United Kingdom, 6Rome, Italy, 7Westlake Village, United States)

59 Feiba global outcome study (FEIBA-GO): first demographic data from a real world study on FEIBA in patients with inhibitors

K. Steinitz-Trost1, C. Escuriola Ettingshausen2, C. Hermans3, P. A. Holme4, C. Negrier5, S. Rangarajan6, A. Rocino7, J. Windyga8, A. Gringeri1, R. Crea1, A. R. Cid9 (1Vienna, Austria, 2Frankfurt- Moerfelden, Germany, 3Brussels, Belgium, 4Oslo, Norway, 5Bron, France, 6Basingstoke, United Kingdom, 7Naples, Italy, 8Warsaw, Poland, 9Valencia, Spain)

6362P

OS

TER

LIS

T

PO

STE

R L

IST

POSTER LIST POSTER LIST


60 Inhibitor development in previously untreated patients with severe hemophilia A treated with human-cl rhFVIII, a new generation recombinant FVIII of human origin

A. Russo1, C. Altisent2, A. Borel-Derlon3, H. Chambost4, M. Gattens5, Y. Gruel6, A. Klukowska7, C. Koenigs8, T. Lambert9, R. J. Liesner10, M. Sigaud11, M. Abashidze12, O. Aleinkova13, M. J. Belletrutti14, M. Carcao15, A. K. C. Chan16, L. Dubey17, J. Ducore18, N. A. Fouzia19, N. Kavardakova20, M. El Khorassani21, S. Lohade22, V. Turea23, J. K. M. Wu24, V. Vdovin25 (1Mainz, Germany, 2Barcelona, Spain, 3Caen, France, 4Marseille, France, 5Cambridge, United Kingdom, 6Tours, France, 7Warsaw, Poland, 8Frankfurt am Main, Germany, 9Le Kremlin Bicetre, France, 10London, United Kingdom, 11Nantes, France, 12Tbilisi, Georgia, 13Minsk, Belarus, 14Edmonton, Canada, 15Toronto, Canada, 16Hamilton, Canada, 17Lviv, Ukraine, 18Sacramento, United States, 19Vellore, India, 20Kiev, Ukraine)

61 Autologous serum infusion induces no thrombin formation but generation of activated protein C

C. Berens, H. Rühl, J. Rossa, A. Winterhagen, J. Oldenburg, J. Müller, B. Pötzsch (Bonn, Germany)

62 Treatment of acquired hemophilia A with recombinant porcine FVIII in Germany

C. Hart1, A. Huth-Kühne2, R. Klamroth3, M. Angstwurm4, M. Stemberger4, M. Spannagl4 (1Regensburg, Germany, 2Heidelberg, Germany, 3Berlin, Germany, 4Munich, Germany)

63 Pulmonary embolism in a patient with severe factor VII defi-ciency after femoral neck fracture despite thromboprophylaxis with low-molecular-weight heparin

K. Holstein, M. Voigtländer, C. Dicke, F. Langer (Hamburg, Germany)

64 Genetic therapy for hemophilia: What’s new? M.-K. Holz1, K. Waack-Buchholz1, D. Reinhardt1, H. Hanenberg2 (1Essen, Germany, 2Duesseldorf, Germany)

65 In-vitro analysis of siRNA based inhibition of function of activated protein C (APC): Towards an alternative therapeutic option for hemophilia

D. Mirgal1, V. Pujari1, K. Ghosh2, S. Shetty1 (1Mumbai, India, 2Surat, India)

66 Novel insights in the molecular etiology of recessive von Willebrand disease 2N due to D’D3 Factor VIII-binding site mutations of von Willebrand factor

J. J. Michiels1,2, F. Hansen3, R. Dingle3, A. Batorova4, T. Prigan-cova4, P. Smejkal5, M. Penka5, I. Vangenechten1, A. Gadisseur1 (1Edegem, Belgium, 2Rotterdam, The Netherlands, 3London, United Kingdom, 4Bratislava, Slovakia, 5Brno, Czech Republic)

67 Protein S and purpura fulminans: What’s new? R. Prince1, S. Calzavarini1, M. Yasuhiro2, J. H. Griffin3, J. A. Fernández3, F. Saller4, A. Angelillo-Scherrer1 (1Bern, Switzerland, 2Chiba, Japan, 3La Jolla, United States, 4Le Kremlin-Bicetre, France)

68 Successful factor VIII re-exposure after long-term aPCC prophylaxis in two hemophilia A patients with inhibitors

C. Königs1, A. Siegemund2, D. Stichel1, A. Orlowski1, C. Heller1, J. Kahle1, D. Schwabe1, U. Scholz2 (1Frankfurt am Main, Germany, 2Leipzig, Germany)

69 rVIII-SingleChain in hemophilia A patients: A population pharmacokinetic model

Y. Zhang2, J. Roberts2, D. Bensen-Kennedy2, A. Veldman1, K. S. Ledger2, J. Sidhu3 (1Marburg, Germany, 2King of Prussia, United States, 3Parkville, Australia)

70 Comparison of data security of the electronic patient diary smart medicationTM with manual documentation in a paper diary

A. Roesch1, R. Fischer2, W. Mondorf3, D. Schmoldt1 (1Dreieich, Germany, 2Giessen, Germany, 3Frankfurt am Main, Germany)

Laboratory tests

71 Development and evaluation of a novel FVIII domain-

specific immunoassay for characterization of anti-FVIII antibodies

B. Pezeshkpoor, A.-C. Berkemeier, J. Müller, T. Albert, J. Olden-burg (Bonn, Germany)

72

Activation and inactivation of rVIII-SingleChain

C. Horn, H. J. Metzner (Marburg, Germany)

73 Protein Z – Does its analyzation make any clinical sense? G. Kappert, M. Daoud, M. Siebert, H. Rott, S. Halimeh (Duisburg, Germany)

74 Platelet aggregation testing on a routine coagulation analyzer W. Miesbach, B. Zwinge, R. Toenges, L. Karmal, V. Makki, S. Müller, S. Gundermann (Frankfurt am Main, Germany)

75 Unambiguous and sensitive measurement of active coagula-tion proteases

A. Weber, A. Engelmaier, G. Prodinger (Vienna, Austria)

76 Quantification of TAFI in human plasma by LC-MS/MS M. Rauh, S. Weiß, K. Heußner, M. Chada, J. Zierk, W. Rascher, H.-G. Topf (Erlangen, Germany)

77 Diagnostic challenges of von Willebrand disease S. Schneppenheim, R. Dittmer, H. El-Abd Müller, U. Budde (Hamburg, Germany)

78 A rapid and simple assay for the determination of ADAMTS-13 activity

M. Griffiths, H. Vetr, N. B. Binder (Vienna, Austria)

79 Evaluation and clinical validation of a chromogenic FIX assay for reliable post infusion measurements of recombinant and next generation factor IX products

J. Müller, J. Oldenburg, B. Pötzsch (Bonn, Germany)

80 TechnoZym® ADAMTS-13 activity assay for determination of inhibitory antibodies against ADAMTS-13

L. Wagner, F. Nasufi, M. Kafka, N. B. Binder (Vienna, Austria)

81 Measuring direct oral anticoagulants in standardized fully automated thrombin generation on Ceveron® alpha

L. Wagner1, E. Wimmer2, J. Seier2, N. B. Binder1, A. C. Haushofer2 (1Vienna, Austria, 2Wels, Austria)

82 Evaluation of DOAC Interferences on Technoclot® PT Owren L. Rosenmayr, L. Wagner, N. B. Binder (Vienna, Austria)

83 Difficulties in diagnosing antiphospholipid syndrome in patients undergoing DOAC therapy

T. Flieder1, M. Weiser1, T. Eller2, M. Dittrich3, K. von Bargen1, F. Knüttgen1, A. Hohbein1, J. Kuhn1, C. Knabbe1, I. Birschmann1 (1Bad Oeynhausen, Germany, 2Bad Salzuflen, Germany, 3Wuerzburg, Germany)

84 Performance of a recombinant fusion protein linking coa-gulation factor IX with recombinant albumin (rIX-FP) in the one-stage assay

A. Veldman1, A. Feussner1, U. Kalina1, K. St. Ledger2 (1Marburg, Germany, 2King of Prussia, United States)

85 Development, validation and application of a polysialyla-

tion-dependent FVIII activity assay to measure SHP656 (BAX 0826), a next generation extended half-life recombinant factor VIII product

A. Weber, S. Haindl, G. Mohr, A. Engelmaier (Vienna, Austria)

86 rVIII-SingleChain plasma activity can be measured using both the one-stage and the chromogenic substrate assay: Results from an international field study

A. Veldman1, A. Feussner1, U. Kalina1, H. Metzner1, C. Horn1, A. Stowers1, K. St. Ledger2 (1Marburg, Germany, 2King of Prussia, United States)

87 Platelet-dependent von Willebrand factor activity – an important constituent of the diagnostic repository to classify von Willebrand syndrome

O. Tiebel, K. Trautmann, U. Platzbecker, R. Knöfler, G. Siegert (Dresden, Germany)

88 Rapid immunoassays for diagnosis of heparin-induced throm-bocytopenia: comparison of diagnostic accuracy, reproduci- b ility, and costs in clinical practice

A. Bankova1, Y. Andres2, M. Horn3, L. Alberio4, M. Nagler3 (1Lucerne, Switzerland, 2Muri, Switzerland, 3Bern, Switzerland, 4Lausanne, Switzerland)

89 Is platelet aggregation testing dependent on fibrinogen level? L. Graf, J. Worden, W. Korte (St. Gallen, Switzerland)

90 Replacing the aPTT for monitoring of unfractionated heparin with the Prothrombinase induced Clotting Time (PiCT) – signi-ficant influence on dosing

W. Korte, L. Graf, C. Knöpfel (St. Gallen, Switzerland)

91 Clauss fibrinogen assay obviously underestimates fibrinogen level not confirmed in thromboelastometry – A case report

T. Lang1, M. Rieke1, M. Bachler2, B. Schenk2, M. Hermann2, M. Tollnick1, D. Fries2 (1Hohne, Germany, 2Innsbruck, Austria)

92 A Flow cytometer-based platelet aggregation assay permits platelet function testing in small blood volumes

S. Liedtke, J. Wesche, K. Althaus, T. Thiele, A. Greinacher (Greifswald, Germany)

93 Genetic heterogeneity in patients with von Willebrand disease type I: a regional study from Northeast Germany

M. Steiner, D. Jenzen, R. Toenges, D. Friday, B. Krammer-Steiner (Rostock, Germany)

6564P

OS

TER

LIS

T

PO

STE

R L

IST



94 Comparison of factor VIII assays using physiological triggers G. J. Praefcke, M. Kusch, C. Grundmann, S. Keitel, A. Hunfeld, R. Seitz (Langen, Germany)

Pediatric and neonatal thrombosis and hemostasis

95 The „German Pediatric Hemophilia Research Database“ (GEPHARD) – a project of the `Standing Committee Pediatrics of the Society for Thrombosis and Hemostasis Research´ to improve the quality of hemophilia care for children

C. Bidlingmaier1, C. Escuriola Ettingshausen2, K. Kentouche3, M. Olivieri1, W. Eberl4, B. Zieger5, K. Kurnik1, C. Königs6, for the GEPHARD Study Group (1Munich, Germany, 2Moerfelden, Germany, 3Jena, Germany, 4Braunschweig, Germany, 5Freiburg, Germany, 6Frankfurt am Main, Germany)

96 Acquired von Willebrand disease in infants with aortopulmo-nary shunt

G. Wiegand1, V. Icheva1, U. Budde2, M. Hofbeck1 (1Tuebingen, Germany, 2Hamburg, Germany)

97 Late onset of thrombosis in siblings with homozygous protein C deficiency

C. Wermes, M. Suslovych, C. Detering, M. von Depka (Hanover, Germany)

98 Adolescent male suffering from thrombosis is not uncommon I. Wieland1, A. Biering2, K. W. Sykora1 (1Hanover, Germany, 2Wolfsburg, Germany)

99 Thrombotic events in the neonatal period – a case series of common manifestations

M. Rohde, V. Vaillant, H. Ehrhardt, K.-P. Zimmer, B. Kemkes- Matthes, C. Mauz-Körholz, H. Hauch (Giessen, Germany)

100 Anterior spinal artery syndrome in pediatric patients: diagno-stic and therapy

A. M. Cseh, J. Kirschner, H. Meinicke, H. Fuchs, B. Zieger (Freiburg, Germany)

101 Systemic mast cell activation disease during adolescence and heparin levels in blood plasma

M. Vysniauskaite, A. Selbitz, S. Unkrig, F.-J. Dumoulin, J. Homann, J. Oldenburg, G. J. Molderings, H.-J. Hertfelder (Bonn, Germany)

Platelets – Physiology and Disorders of platelet number and function

102 Annexin A7 (ANX7) regulates collagen-dependent platelet

activation and Ca2+ signalingS. Geue, B. Walker-Allgaier, D. Eißler, P. Münzer, F. Lang, M. Gawaz, O. Borst (Tuebingen, Germany)

103 The special role of anti-ADAMTS13-IgA in acquired TTP:

Production induced by infectious microorganisms?J. Falk, T. Vigh, I. Scharrer (Mainz, Germany)

104 Variable linkage with platelet functions of genetic

mutations in ORAI1, STIM1 or FERMT3 in patients with severe immune deficiencies

M. Nagy1, T. G. Mastenbroek1, N. J. A. Mattheij1, S. de Witt1, K. J. Clemetson2, J. Kirschner3, A. S. Schulz4, J. M. E. M. Cosemans1, B. Zieger3, J. W. M. Heemskerk1 (1Maastricht, The Netherlands, 2Bern, Switzerland, 3Freiburg, Germany, 4Ulm, Germany)

105 Phosphorylation of the protein phosphatase 2A inhibitor

alpha-endosulfine (ENSA) at two distinct sites, serine 67 and serine 109, in human platelets

E. Walter1, O. Pagel2, R. Zahedi2, A. Smolenski3, S. Gambaryan1,4, U. Walter1, K. Jurk1 (1Mainz, Germany, 2Dortmund, Germany, 3Dublin, Ireland, 4St. Petersburg, Russian Federation)

106 Immunoglobulin G subclass distribution of anti-ADAMTS13 antibodies in a cohort of 47 patients with acquired thrombotic thrombocytopenic purpura

G. Sinkovits, M. Réti, Z. Prohászka (Budapest, Hungary)

107 Intra- and intercellular fate of iron oxide nanoparticles in platelets

K. Aurich, J. Wesche, R. Koch, J. Fuhrmann, A. Greinacher (Greifswald, Germany)

108 Frequency and analysis of hospital cases of heparin induced thrombocytopenia type 2 (HIT 2) in Germany

S. Wahler1, A. Müller2 (1Hamburg, Germany, 2Munich, Germany)

109 Phenotyping platelets from patients with inherited platelet disorders by immunofluorescence microscopy

K. Althaus1, C. Blumentritt1, U. Strobel1, T. Bakchoul2, A. Greinacher1 (1Greifswald, Germany, 2Tuebingen, Germany)

110 Initiation of a prospective observational cohort study of patients with acquired thrombotic thrombocytopenic purpura (TTP)

T. Falter1, A. Trinchero1, K. Jurk1, H. Roßmann1, K. Lackner1, B. Lämmle1,2, C. von Auer1 (1Mainz, Germany, 2Bern, Switzer-land)

111 Evaluation of platelet parameters in pediatric throm-bocytopenic patients

R. Knöfler, S. Hackel, B. Arneth, J. Lohse, J. Stächele, O. Tiebel (Dresden, Germany)

112 This abstract has been withdrawn

113 The power of large platelets: Comprehensive functional characterization of large and small platelets from healthy volunteers

S. Handtke, R. Palankar, M. Ferrara, S. Cauhan, A. Greinacher, T. Thiele (Greifswald, Germany)

114 Evaluation of platelet activation after electric cardioversion J. Gaugler, A. Schlagenhauf, B. Egner, W. Schwinger, E. Bisping, S. Gallistl, H. Haidl (Graz, Austria)

115 Platelet dense granule production and dense granule release defects in pediatric patients with storage pool disorder

J. Eilenberger1, G. Manukjan1, O. Andres1, C. Schambeck2, S. Eber2, H. Schulze1 (1Wuerzburg, Germany, 2Munich, Germany)

116 Practical limitations of diagnostic algorithms in heparin induced thrombocytopenia: A case report

S. Nowak-Harnau, S. Enkel, B. Zimmermann, C. Reiss, T. Bakchoul (Tuebingen, Germany)

117 Supra-normal closure time caused by recombinant von Willebrand factor in PFA

T. Kragh, M. Spannagl (Munich, Germany)

118 Prophylactic plasma treatment in patients with hereditary thrombotic thrombocytopenic purpura

Z. Cermakova1, P. Kovarova1, J. A. Kremer Hovinga2 (1Ostrava, Czech Republic, 2Bern, Switzerland)

Vascular wall biology and disorders

119 Molecular genetic investigations and demonstration of

founder effect in Osler-Rendu-Weber diseaseR. Gindele1, T. Major2, Z. Szabo1, K. B. Kovács1, G. Pfliegler1, Z. Bereczky1 (1Debrecen, Hungary, 2Eger, Hungary)

120 CLIC1 supports mechanisms related to thrombosis and

vascular repairL. M. Knowles, P. Niewald, E. Ampofo, A. Drawz, I. Müller, H. Eichler, J. Pilch (Homburg, Germany)

121 Collagen V alpha 2 as a direct target of miR-143 in

arteriogenesisT. Hammerschick1, K. Troidl2, K. T. Preissner1, S. Fischer1 (1Giessen, Germany, 2Bad Nauheim, Germany)

122 Activated protein C protects against accelerated athero-sclerosis in diabetes by restricting p66shc expression in macrophages

K. Shahzad1, I. Gadi1, S. Nazir1, M. Al-Dabet1, S. Kohli1, S. Ran-jan1, F. Bock1,2, B. Isermann1 (1Magdeburg, Germany, 2Nashville, United States)

123 Autophagy status in factor VIII secreting endothelial cells M. A. Jamil, H. Singer, N. Nüsgen, J. Oldenburg, O. El-Maarri (Bonn, Germany)

124 Analysis of proteolytic von Willebrand factor (VWF) fragments in patients with VWF-related diseases

J. Irle1, K. Schwierczek1, H. Rossmann1, T. Falter1, C. von Auer1, A. Trinchero1, K. Lackner1, Z. Ruggeri2, B. Lämmle1, K. Jurk1 (1Mainz, Germany, 2La Jolla, United States)

125 In patients with uncontrolled arterial hypertension platelets and coagulation factor XI are responsible of modifications of thrombin generation

J. Lagrange, Y. Weihert, S. Kossmann, T. Münzel, S. Karbach, P. Wenzel (Mainz, Germany)

126 Investigating the interconnection between complement and coagulation in xenotransplantation

R. Sfriso1, N. Klymiuk2, E. Wolf2, J. Seebach3, R. Rieben1 (1Bern, Switzerland, 2Munich, Germany, 3Geneva, Switzerland)

127 Platelet-localized FXI promotes a vascular coagulation-inflam-matory circuit in arterial hypertension

S. Kossmann1, J. Lagrange1, S. Jackel1, K. Jurk1, M. Ehlken1, A. Daiber1, U. Walter1, T. Renné2,3, W. Ruf1,4, T. Münzel1, P. Wenzel1 (1Mainz, Germany, 2Hamburg, Germany, 3Stockholm, Sweden, 4La Jolla, United States)

Venous thrombosis

128 Clinical relevance of marginal low Protein S P. Lodemann1, D. Peetz1, T. Held1, W. Ludwig1, J. Oldenburg2 (1Berlin, Germany, 2Bonn, Germany)

129 Characterisation of previously unknown protein C gene variants

S. Körber1, L. Böff1, F. Bergmann2, A. Czwalinna2, B. Bomke3, C. Heller1, M. Krause4, B. Luxembourg1, K. Kurnik5, W. Miesbach1, C. Geisen1 (1Frankfurt am Main, Germany, 2Hanover, Germany, 3Duesseldorf, Germany, 4Wiesbaden, Germany, 5Munich, Germany)

130 GE-CAT – German Evaluation of Cancer associated Thrombo-sis A prospective register trial for patients with hematological and oncological diseases and venous thromboembolism in Berlin

A. Jühling, M. Sinn, E. T. Wolter, S. Bischoff, U. Pelzer, L. Wislocka, J. K. Striefler, F. Brandes, H. Riess, R. Klamroth (Berlin, Germany)

131 Study of fibrinolytic parameters in Indian patients with venous thrombosis

A. Prabhudesai1, S. Shetty1, K. Ghosh2, B. Kulkarni1 (1Mumbai, India, 2Surat, India)

132 Characterization of antithrombin variants in thrombotic patients with normal and reduced activity

R. Deshpande1, B. Kulkarni1, K. Ghosh2, S. Shetty1 (1Mumbai, India, 2Surat, India)

6766P

OS

TER

LIS

T

PO

STE

R L

IST



133 Application of massive parallel sequencing searching for rare genetic variants associated with thrombophilia – implementa-tion to clinical practice

P. Vrtel, L. Slavik, R. Vodicka, R. Vrtel, L. Slavik, J. Ulehlova, J. Prochazkova, A. Hlusi, M. Palova, M. Prochazka (Olomouc, Czech Republic)

134 Advances in diagnosis, classification and management of lower extremity deep vein thrombosis (DVT), prevention of DVT recurrence and the post-thrombotic syndrome: personal experiences and appraisal of the literature

J. J. Michiels1,2, W. Moossdorff1, J. M. Michiels1,3, M. U. Lao1, H. Maasland1, H. Smeets1, M. Han1, P. Dulicek4, V. Stvrtinova4,5, Z. Pecsvarady4, P. Poredos4,6, A. Gadisseur7, W. Schroyens7 (1Rijn-mond Rotterdam, The Netherlands, 2Rotterdam, The Netherlands, 3Rotterdam-Zuid, The Netherlands, 4Prague, Czech Republic, 5Bratislava, Slovakia, 6Ljubljana, Slovenia, 7Antwerp, Belgium)

135 The role of an endothelial specific g-protein coupled receptor in thrombosis

L. Gottlob1, P. Dusart1, L. Fagerberg2, D. A. Trégouët3, P. Morange4, M. Germain3, M. Civelek5, T. Renne1,6, J. Odeberg1, L. Butler1 (1Stockholm, Sweden, 2Solna, Sweden, 3Paris, France, 4Marseille, France, 5Charlottesville, United States, 6Hamburg, Germany)

Women issues in thrombosis and hemostasis

136 Angiogenesis in a porcine von Willebrand disease model M. von Depka, H. Allerkamp, C. Pfarrer, M. Ekhlasi-Hundrieser, C. Detering, S. Lehner (Hanover, Germany)

137 Successful pregnancy in patient with homozygous sickle cell disease and prior pulmonary embolism – a case report

J. Notter, G. Amstad, B. Drexler, K. Loukidis (Basel, Switzerland)

138 Highly procoagulant extracellular vesicles in amniotic fluid J. Thaler1, L. Hell1, L. Wisgrill1, C. Ay1, A. Spittler1, M. Schwameis1, B. Jilma1, P. Altevogt2, I. Pabinger1 (1Vienna, Austria, 2Heidelberg, Germany)

139 Dead fetus syndrome (DFS) in 2017 – a no more existing entity? From individual patients to pathophysiological insights

F. Bergmann1, A. Czwalinna2, H. Groening1, R. Schwerdfeger1, R. Schild1, U. Budde2 (1Hanover, Germany, 2Hamburg, Germany)

140 Risk of pregnancy-associated recurrent venous throm-boembolism (VTE) in women with a history of first venous thrombosis

A. Gerhardt1,2, R. E. Scharf2, R. B. Zotz2 (1Ulm, Germany, 2Duesseldorf, Germany)

141 Comparison of two laboratory methods for thrombin generation in pregnancy with high risk for thrombosis

M. Schwethelm, M. Martinez, I. Hoesli, D. Tsakiris (Basel, Switzerland)

142 Bernard Soulier syndrome in pregnancy and delivery – a case report

K. Liebscher, I. Niemann, I. Bogner, A. Siegemund, M. Krause, U. Scholz (Leipzig, Germany)

143 Successful pregnancy outcome in a case of JAK2 positive essential thrombocytemia after treatment with peginterferon alpha-2b

M.-V. Teleanu, S. Jaramillo, S. Schönsteiner, S. Estenfelder, P. Schwarzwälder, C. Langer, M. Kull (Ulm, Germany)

Innovation and Novelty

144 P2Y6 depletion enhances metabolic activity and amelio-

rates outcome of high fat diet induced obesity in miceJ. Merz1, P. Stachon, P. Albrecht, F. Ünal, S. von Garlen, A. Heidenreich, N. Hoppe, B. Duffner, C. Bode, A. Zirlik (Freiburg, Germany)

145 Development and application of methods for the selective

measurement of the human single amino acid exchange variant factor IX Padua

A. Weber1, A. Engelmaier1, D. Voelkel2, R. Pachlinger2, F. Scheif-linger1, H. Rottensteiner1 (1Vienna, Austria, 2Orth, Austria)

146 Fucoidans inhibit cellular responses to the chemokine

IL-8 and the anaphylatoxin C5a better than heparinS. Alban, K. Ehrig, I. Liewert (Kiel, Germany)

Late breaking posters

147 The effect of storage on the platelet hemostatic activity E. V. Roitman, I. M. Kolesnikova (Moscow, Russian Federation)

148 Evaluation of platelet hemostatic capacity using new thrombo-elastography-based assay

E. V. Roitman, I. M. Kolesnikova (Moscow, Russian Federation)

149 Blood rheology factors for thrombus formation in some oncohematological diseases

E. V. Roitman, I. M. Kolesnikova (Moscow, Russian Federation)

150 Identification of novel mutations in FGA fibrinogen gene in Pakistani congenital afibrinogenemia patients

T. Khan1, A. Naz1, A. Biswas2, N. Ahmed3, S. Ahmed1, T. Shamsi1, J. Oldenburg2 (1Karachi, Pakistan, 2Bonn, Germany, 3Lahore, Pakistan)

152 Quantification of the antimetastatic effects of heparins by Single-cell force spectroscopy

H. Schillers, A. Schmidt, S. Bobe, N. Martins-Castanheira (Muenster, Germany)

153 Gene polymorphism of plasminogen activator inhibitor-1 is a risk factor of thrombosis in patients with antiphospholipid syndrome

L. Mukhametova, R. Aisina, T. Reshetnyak, L. Patrushev, K. Gershkovich (Moscow, Russian Federation)

155 Combinations of recombinant staphylokinase (STA) and sing-le-chain urokinase-type plasminogen activator (scuPA) induce synergistic thrombolysis in vitro

R. Aisina, L. Mukhametova, K. Gershkovich, S. Varfolomeyev (Moscow, Russian Federation)

156 Positive and negative role of oxidative stress in the prognosis of patients with gastric cancer.

M. K dzierska, J. Kolodziejczyk-Czepas, J. Jakubik, J. Piekarski, A. Jeziorski, P. Nowak, P. Potemski (Lodz, Poland)

6968P

OS

TER

LIS

T

PO

STE

R L

IST


LIST OF CHAIRS, SPEAKERS AND AUTHORS

Abdelhafez, Mai 45Aisina, Roza 69Al-Ali, Haifa Kathrin 51Alban, Susanne 32, 36, 68Alberio, Lorenzo 28, 49, 58Albisetti Pedroni, Manuela 24, 45, 47Alrifai, Mohammed 60Althaus, Karina 66Andritschke, Karin 20Angelillo-Scherrer, Anne 47, 49Ariëns, Robert 29Asmis, Lars 20, 33Auerswald, Günter 38, 39Aujesky, Drahomir 21Aurich, Konstanze 66Ay, Cihan 21, 22, 33Baaten, Constance C. F. M. J. 49Bakchoul, Tamam 28, 37, 50, 58Bankova, A. 65Barco, Stefano 33, 46, 61Baruch, Dominique 28Bauersachs, Rupert 20, 29, 50Beer, Jürg Hans 21, 50Berens, Christina 64Bergmann, Frauke 20, 68Bernateck, Michael 47Berntorp, Erik 30Bertaggia Calderara, Debora 60Beyer-Westendorf, Jan 21, 34, 46, 49Bichler, J. 63Bidlingmaier, Christoph 20, 34, 41, 51,

57, 66Binsker, Ulrike 37Biswas, Arijit 32, 62, 63Bode, Christoph 34Boeckelmann, Doris 62Böff, L. 46Bölting, H. S. 45Brehm, Maria Alexandra 28, 30, 44Brodde, M. F. 44Calzavarini, Sara 33Cathomen, Toni 51Cattaneo, Marco 21ten Cate, Hugo 49, 59ten Cate-Hoek, Arina 21, 29Ceppi, Camilla 20Cermakova, Zuzana 36, 58, 67Chan, Anthony K. C. 45Chatterjee, Madhumita 37Chromik, Jörg 51Clemetson, Kenneth J. 51Colvin, Brian T. 22Coppo, Paul 58Cseh, Annamaria 66Czogalla, Katrin Jeannette 31Dayo, John 18

Dempfle, Carl-Erik 24, 37, 38, 50Deshpande, Rutuja 67Dicke, Christina 60Diederich, Michael 58D’Oiron, Roseline 38Dufour, Jean-François 46Dürschmied, Daniel 21, 58Eberl, Wolfgang 34, 47Eichinger-Hasenauer, Sabine 41, 49, 59Eikenboom, H. C. J. 30Eilenberger, J. 67Elvers, Margitta 21Engelberger, Lukas 25Endig, S. 46Escuriola-Ettingshausen, 24, 35, 49, 50 CarmenEspinola-Klein, Christine 22Etscheid, Michael 32, 62Falk, Jennifer 66Falter, Tanja 66Fischer, Ronald 60, 63Flieder, Tobias 65Flommersfeld, Sabine 58Friebel, Julian 31Fujimura, Yoshihiro 37, 58Garmann, Dirk 51Gaugler, J. 67Gawaz, Meinrad 44Gerhardt, Andrea 68Geue, Sascha 32, 66Ghosh, Suvoshree 57Giannetti, B. 37Gindele, Réka 48, 67Goldmann, Georg 23, 35, 39, 51Gottlob, Leonardo 68Gottstein, Saskia 18Graf, Lukas 19, 28, 35, 61,

65Greinacher, Andreas 47, 50Griffiths, M. 65Grilz, Ella 37Grosse, Katrin 18Gura, Christoph 47Haas, Sylvia 34Habermann, Björn 32, 56, 62Hach-Wunderle, Viola 38, 50Halimeh, Susan 20, 35, 39, 62Hammerschick, Thomas 32, 67Handtke, Stefan 66Härdtner, Carmen 44Hart, Christina 64Hassenpflug, Wolf-Achim 23, 30, 44Hegemann, Inga 35, 41, 56Heid, Julia 61Heidinger, Kathrin 63Herr, Nadine 61

Hoffmann, Till 57Holstein, Katharina 18, 47, 57, 64Holz, Maj-Kristin 64Holzhauer, Susanne 45Horling, Frank M. 57Horn, Carsten 48, 64Huber-Lang, Markus 57Huth-Kühne, Angela 34, 41, 46, 51Iapichino, Giacomo 60Ichinose, Akitada 31Irle, J. 67Ivaskevicius, Vytautas 57Jamil, Muhammad Ahmer 63, 67Jühling, Anja 67Jurk, Kerstin 21, 28, 49Kaartinen, Mari 29Kalnins, Werner 58Kappert, Günther 64Karges, Hermann E. 60Karst, Andreas 18Katona, Éva 61Katrii, Tetiana 62Kaufner, Lutz 21K dzierska, Magdalena 69Kehrel, Beate 31, 47Kemkes-Matthes, Bettina 25, 30, 31, 34,

49Kentouche, Karim 49Khan, Tehmina 69Klamroth, Robert 19, 22, 33, 35,

39, 57, 63Klier, Meike 49Klose, Gudrun 19Knappe, S. 44Knöbl, Paul 31, 50, 56Knöfler, Ralf 45, 51, 66Knowles, L. M. 32, 67Kobelt, Rainer 56Kohler, Hans-Peter 29, 30Könen, Susanne 58Königs, Christoph 20, 36, 38, 64Königsbrügge, Oliver 28, 60Konstantinides, Stavros 29, 38Körber, S. 67Korte, Wolfgang 19, 21, 34, 57,

60, 65Koscielny, Jürgen 24, 28, 38, 39Kossmann, Sabine 67Kragh, Thorsten 67Kravchenko, Olha 61Kremer Hovinga, Johanna A. 20, 24, 25, 34,

39, 56, 59Krueger, Irena 59Kucher, Nils 38Kühne, Thomas 47Kulkarni, Roshni 30

Kurnik, Karin 19, 30Kuta, Piotr 62Kyrle, Paul A. 29, 38, 59Lackner, Karl 20Lacroix-Desmazes, Sébastien 23Lagrange, Jérémy 67Lämmle, Bernhard 37, 56Lang, Thomas 65Langer, Florian 28, 41, 48, 51Laws, H. J. 62Lee, Hye-Youn 62Lehmann, Thomas 22Liebscher, K. 68Liedtke, S. 65Lier, Heiko 21Linden, R. Michael 36Lindhoff-Last, Edelgard 38, 49, 50Linnemann, Birgit 20Lip, Gregory Y. 57Lodemann, Peter 67Male, Christoph 49Mannhalter, Christine 49Mansouri Taleghani, Behrouz 28Marchetti, Matteo 28Mauler, Maximilian 61McEneny-King, Alanna 39Meri, Seppo 21Merz, Julian 32, 68Michiels, Jan Jacques 61, 64, 68Middeldorp, Saskia 38Miesbach, Wolfgang 33, 36, 38,

39, 65Miller, Lilija 57Minar, Erich 22Mirgal, Darshana 64Mohaupt, Markus 37Mondorf, Wolfgang 62Moser, Martin 50Mukhametova, Lilia 69Müller, Jens 51, 65Müller-Kägi, Elsbeth 20Muszbek, László 29Nagler, Michael 21, 46, 48, 59,

61Nagy, Magdolna 48, 66Nazir, S. 32, 60Nimmerjahn, Falk 35Notter, Julia 68Nowak-Göttl, Ulrike 35, 45Nowak-Harnau, S. 67Oldenburg, Johannes 23, 36, 46, 50,

51, 62, 63Olivieri, Martin 62Orosz, Zsuzsanna Z. 31Ouwehand, Willem H. 51

Pabinger-Fasching, Ingrid 21, 22, 33, 48, 61

Palankar, Raghavendra 37Papadakis, Emmanouil 46Peetz, Dirk 41Pennekamp, Peter H. 47Pezeshkpoor, Behnaz 48, 64Pilch, Jan 44, 48, 60Plattfaut, Corinna 29Posma, Jens J. 61Posthuma, Jelle 45Pötzsch, Bernd 49Prabhudesai, Aniket 67Praefcke, Gerrit J. 66Pratt, Kathleen 38Preisler, Barbara 62Prince, Raja 64Püsken, Michael 56Randi, Anna 30Rauh, Manfred 65Reitter, Eva-Maria 60Richter, D. 30Rieben, Robert 36Riess, Hanno 39Rischewski, Johannes 36Rocchi, Massimo 25Roesch, Andreas 64Rohde, Marius 66Roitman, E. V. 68Roos, Georges T. 22Rosenmayr, L. 65Rosenthal, Marc 39Rothe, Beatrice 18Ruf, Wolfram 57Rufener, Janine 49Rühl, Heiko 36Russo, A. 64Santagostino, Elena 23Schaller Tschan, Monica 32, 56Scharf, Rüdiger E. 33Scharrer, I. 48Schellong, Sebastian 46Schillers, Hermann 69Schindewolf, Marc 38Schlagenhauf, Axel 45, 60Schmidbauer, Horst 58Schmitt, Klaus 35Schneppenheim, Sonja 65Schober, Andreas 21Scholz, Ute 20, 23, 24, 36,

37, 39, 47Schramm, Wolfgang 46Schröder, Verena 31, 36, 57Schubert, Sebastian 33Schulze, Harald 58Schuster, Bernhard 18

Schutgens, Roger 46Schüttrumpf, Jörg 24Schwabe, Rudolf 58Schwethelm, M. 68Seeger, S. 63Seuser, Axel 39Sfriso, Riccardo 67Shahidi Hamedani, Nasim 36Shahneh, Fatemeh 46Shahzad, Khurrum 67Siegert, G. 65Sigl-Kraetzig, Michael 20, 56Singer, Heike 33Singh, Sneha 44, 63Sinkovits, György 66Sinn, Marianne 61Skowronska, Magdalena 31Slavik, Ludek 28Spannagl, Michael 21, 28, 51Steffgen, Ludwig 56Steiner, Michael 65Steinitz-Trost, Katharina 63Stemberger, Michaela 20Stevens, W. 62Stivala, Simona 59Stöver, Gertrud 19Streif, Werner 47Studt, Jan-Dirk 33Susen, Sophie 28, 39, 60Tabaraie, T. 45Teleanu, Maria-Veronica 68Thaler, Johannes 68Tiede, Andreas 23, 25, 36,

38, 47, 50Tittl, Luise 61Toenges, Rosa 48, 61Tsakiris, Dimitrios 22, 33, 35, 41Vanhoorelbeke, Karen 56Veldman, Alex 22, 64, 65von Auer, Charis 44von Depka, M. 68von der Weid, Nicolas 22, 30, 35von Garlen, Sunaina 44von Heymann, Christian 39von Krogh, Anne Sophie 37, 58von Mackensen, Sylvia 62von Ungern-Sternberg, Saskia 59Vrtel, P. 68Vysniauskaite, M. 66Wagner, L. 65Wahler, Steffen 60, 62, 66Walter, E. 32, 66Weber, Alfred 48, 65, 68Wehr, Marco 24Weibel, Ewald R. 30Wermes, Cornelia 35, 66

7170LI

ST

OF

CH

AIR

S, S

PEA

KER

S A

ND

AU

THO

RS

LIS

T O

F C

HA

IRS

, SP

EAK

ERS

AN

D A

UTH

OR

S


Wiedenroth, Christoph B. 38Wiegand, Gesa 66Wieland, Ivonne 66Witkowski, Marco 37Witsch, Thilo 36Witte, Alexander 59Wolberg, Alisa S. 38Wuillemin, Walter A. 29, 32, 34, 41Yadegari, Hamideh 44

Zahedi, René 28Zeerleder, Sacha 57Zieger, Barbara 23, 28, 34,

47, 60Zimmermann, Rainer 58Zirlik, Andreas 44Zöhrer, E. 29Zotz, Rainer B. 24, 47

Das Leben jener Menschen zu verändern, die mit seltenen oder komplexen Erkrankungen leben – das ist unsere Bestimmung.

Unerfüllter Bedarf erfordert unvergleichliches Engagement.

Shire, Baxalta Schweiz AG | CH - 8604 Volketswil

HEM

152

12-2

016

Weitere Informationen auf: www.ShireSwitzerland.ch

73LI

ST

OF

CH

AIR

S, S

PEA

KER

S A

ND

AU

THO

RS


INDUSTRIAL EXHIBITIONFLOOR PLAN

Nairobi

Rio

Saal Sydney

Foyer 2.Stock

Saal Singapore

Auditorium Montreal

SaalGuangzhou

SaalHongkong

SaalMexico

SaalMiami

Saal

SaalReceptionEmpfang

1.52

44

40 41 42

Poster exhibition

BüroBüroBüroBüro

1

2

4

6

5

7

18

91012

14

35

34

33

32

31

17

25

2926

28

36

27a

17a

11

30

27b

16

23 24

19 20 21 22

Info- and voting desk for participantsand Lounge area

Halle 4.1

first floor

second floor

No. Company City Country

1 Swedish Orphan Biovitrum GmbH Martinsried Germany

2 Stago Asnières sur Seine Cedex France

4 CSL Behring GmbH Hattersheim Germany

5 Probe & go Labordiagnostica GmbH Lemgo Germany

6 Mitsubishi Tanabe Pharma GmbH Zurich Switzerland

7 Technoclone GmbH Vienna Austria

9 International Society on Thrombosis and Haemostasis (ISTH) Carrboro United States

10 GTH – Gesellschaft für Thrombose und Hämostaseforschung Hanover Germany

11 Schattauer GmbH Stuttgart Germany

12 Schweizerische Hämophilie-Gesellschaft SHG Altstätten Switzerland

14 DSM Nutritional Products Ltd Aesch Switzerland

16 Chugai Pharma Europe Ltd. Frankfurt am Main Germany

16 Roche Diagnostics Deutschland GmbH Mannheim Germany

16 Roche Pharma AG Grenzach-Wyhlen Germany

17 Sekisui Diagnostics GmbH Pfungstadt Germany

17a Bucher Biotec AG Basel Switzerland

18 Bristol-Myers Squibb GmbH & Co. KGaA und Pfizer Pharma GmbH Munich / Berlin Germany

18 Pfizer Pharma GmbH Berlin Germany

19 ABBOTT AG Baar Switzerland

20 LEO Pharma GmbH Neu-Isenburg Germany

21 Intersero GmbH Walluf Germany

22 Haemochrom Diagnostica GmbH Essen Germany

23 Octapharma GmbH Langenfeld Germany

24 Novo Nordisk Pharma GmbH Mainz Germany

25 Bayer Leverkusen Germany

26 Shire Unterschleissheim Germany

27a BPL Bioproducts Laboratory GmbH Neu-Isenburg Germany

27b Helena Biosciences Europe Gateshead, Tyne and Wear United Kingdom

28 Daiichi Sankyo Deutschland GmbH Munich Germany

29 Alexion Pharma Germany GmbH Munich Germany

30 LFB GmbH Muenster Germany

31 Biotest AG Dreieich Germany

32 Grifols Deutschland GmbH Frankfurt am Main Germany

33 Axon Lab AG Baden Switzerland

33 Werfen GmbH Kirchheim bei München Germany

34 Pfizer PFE Switzerland GmbH Zurich Switzerland

35 CoaChrom Diagnostica GmbH Maria Enzersdorf Austria

35 ENDOTELL AG Allschwil Switzerland

36 Siemens Healthcare Diagnostics GmbH Eschborn Germany

40 ISMAAP (International Self Monitoring Association of oral Anticoagulated Patients) Geneva Switzerland

41 Orphanet Switzerland Geneva Switzerland

42 VFTH e.V. Frankfurt am Main Germany

44 S. Karger Verlag für Medizin und Naturwissenschaften GmbH Freiburg Germany

INDUSTRIAL EXHIBITIONLIST OF EXHIBITORS – NUMERICAL

7574IN

DU

STR

IAL

EXH

IBIT

ION

IND

US

TRIA

L EX

HIB

ITIO

N

Company City Country

Abbott AG Baar Switzerland

Alexion Pharma Germany GmbH Munich Germany

Aspen Germany GmbH Munich Germany

Baxalta Schweiz AG Volketswil Switzerland

Bayer Leverkusen Germany

Biotest AG Dreieich Germany

Bristol-Myers Squibb GmbH & Co. KGaA und Pfizer Pharma GmbH Munich / Berlin Germany

CSL Behring GmbH Hattersheim Germany

Daiichi Sankyo Deutschland GmbH Munich Germany

Grifols Deutschland GmbH Frankfurt am Main Germany

Leinhardt Diagnostics Lenzburg Switzerland

LEO Pharma GmbH Neu-Isenburg Germany

LFB GmbH Muenster Germany

Novo Nordisk Pharma GmbH Mainz Germany

Octapharma GmbH Langenfeld Germany

Pfizer AG Zurich Switzerland

Pfizer PFE Switzerland GmbH Zurich Switzerland

Pfizer Pharma GmbH Berlin Germany

Regierungsrat des Kantons Basel-Stadt Basel Switzerland

Roche Pharma (Schweiz) AG Reinach Switzerland

Shire Unterschleissheim Germany

Stago Asnières sur Seine Cedex France

Swedish Orphan Biovitrum GmbH Martinsried Germany

Technoclone GmbH Vienna Austria

LIST OF SPONSORS

Company City Country No.

ABBOTT AG Baar Switzerland 19

Alexion Pharma Germany GmbH Munich Germany 29

Axon Lab AG Baden Switzerland 33

Bayer Leverkusen Germany 25

Biotest AG Dreieich Germany 31

BPL Bioproducts Laboratory GmbH Neu-Isenburg Germany 27a

Bristol-Myers Squibb GmbH & Co. KGaA und Pfizer Pharma GmbH Munich / Berlin Germany 18

Bucher Biotec AG Basel Switzerland 17a

Chugai Pharma Europe Ltd. Frankfurt am Main Germany 16

CoaChrom Diagnostica GmbH Maria Enzersdorf Austria 35

CSL Behring GmbH Hattersheim Germany 4

Daiichi Sankyo Deutschland GmbH Munich Germany 28

DSM Nutritional Products Ltd Aesch Switzerland 14

ENDOTELL AG Allschwil Switzerland 35

Grifols Deutschland GmbH Frankfurt am Main Germany 32

GTH – Gesellschaft für Thrombose und Hämostaseforschung Hanover Germany 10

Haemochrom Diagnostica GmbH Essen Germany 22

Helena Biosciences Europe Gateshead, Tyne and Wear United Kingdom 27b

International Society on Thrombosis and Haemostasis (ISTH) Carrboro United States 9

Intersero GmbH Walluf Germany 21

ISMAAP (International Self Monitoring Association of oral Anticoagulated Patients) Geneva Switzerland 40

LEO Pharma GmbH Neu-Isenburg Germany 20

LFB GmbH Muenster Germany 30

Mitsubishi Tanabe Pharma GmbH Zurich Switzerland 6

Novo Nordisk Pharma GmbH Mainz Germany 24

Octapharma GmbH Langenfeld Germany 23

Orphanet Switzerland Geneva Switzerland 41

Pfizer PFE Switzerland GmbH Zurich Switzerland 34

Pfizer Pharma GmbH Berlin Germany 18

Probe & go Labordiagnostica GmbH Lemgo Germany 5

Roche Diagnostics Deutschland GmbH Mannheim Germany 16

Roche Pharma AG Grenzach-Wyhlen Germany 16

S. Karger Verlag für Medizin und Naturwissenschaften GmbH Freiburg Germany 44

Schattauer GmbH Stuttgart Germany 11

Schweizerische Hämophilie-Gesellschaft SHG Altstätten Switzerland 12

Sekisui Diagnostics GmbH Pfungstadt Germany 17

Shire Unterschleissheim Germany 26

Siemens Healthcare Diagnostics GmbH Eschborn Germany 36

Stago Asnières sur Seine Cedex France 2

Swedish Orphan Biovitrum GmbH Martinsried Germany 1

Technoclone GmbH Vienna Austria 7

VFTH e.V. Frankfurt am Main Germany 42

Werfen GmbH Kirchheim bei München Germany 33

INDUSTRIAL EXHIBITIONLIST OF EXHIBITORS – ALPHABETICAL

7776IN

DU

STR

IAL

EXH

IBIT

ION

LIS

T O

F S

PO

NS

OR

S

FLOOR PLAN GROUND FLOORFSA DISCLOSURE REQUIREMENT

Company Contribution

Baxalta Deutschland GmbH (now part of Shire)Exhibition spaceHospitality LoungeSymposium

CHF 69,500.00

Bayer

AdvertisingBag insertsExhibition spaceHospitality LoungeSymposium

CHF 117,600.00

Biotest AGExhibition spaceSymposium

CHF 33,250.00

Bristol-Myers Squibb GmbH & Co. KGaA und Pfizer Pharma GmbH

Bag insertsExhibition spaceHospitality loungeSymposium

CHF 27,660.00

Daiichi Sankyo Deutschland GmbHExhibition spaceSymposium

CHF 21,000.00

Mitsubishi Tanabe Pharma GmbH Exhibition space CHF 2,370.00

Novo Nordisk Pharma GmbH

AdvertisingExhibition spaceScientific LoungeSymposiumWorkshop

CHF 86,750.00

Pfizer AG Symposium CHF 12,500.00

Pfizer PFE Switzerland GmbHAdvertisingExhibition space

CHF 8,425.00

Pfizer Pharma GmbH

Bag insertsExhibition spaceHospitality loungeSymposium

CHF 41,490.00

Roche Diagnostics Deutschland GmbH Exhibition space CHF 17,775.00

Swedish Orphan Biovitrum GmbH

AdvertisingExhibition spaceHospitality loungeSymposium

CHF 44,200.00

7978FS

A D

ISC

LOS

UR

E R

EQU

IREM

ENT

FLO

OR

PLA

N G

RO

UN

D F

LOO

R

www.xarelto.de* Prophylaxe v. Schlaganfällen und system. Embolien bei erwachsenen Patienten m. nicht valvulärem Vorhoffl immern und einem od. mehreren Risikofaktoren wie kongestive

Herzinsuffi zienz, Hypertonie, Alter ab 75 J., Diab. mell., vorherigem Schlaganfall od. transitorischer ischämischer Attacke i.d. Anamnese 1 Camm, A. J. et al.,Eur Heart J 2015; DOI:10.1093/eurheartj/ehv466

Dieses Arzneimittel unterliegt einer zusätzlichen Überwachung. Bitte melden Sie jeden Verdachtsfall einer Nebenwirkung über das Bundesinstitut für Arzneimittel und Medizinpro-dukte: www.bfarm.de Xarelto 15 mg/20 mg Filmtabletten. Wirkstoff: Rivaroxaban. Vor Verschreibung Fachinformation beachten. Zusammensetzung: Wirkstoff: 15 mg/20 mg Rivaroxaban. Sonstige Bestandteile: Mikrokristalline Cellulose, Croscarmellose-Natrium, Lactose-Monohydrat, Hypromellose, Natriumdodecylsulfat, Magnesiumstearat, Macrogol (3350), Titanoxid (E171), Eisen(III)oxid (E172). Anwendungsgebiete: Prophylaxe von Schlaganfällen und systemischen Embolien bei erwachsenen Patienten mit nicht-valvulärem Vorhoffl immern und einem oder mehreren Risikofaktoren, wie kongestiver Herzinsuffi zienz, Hypertonie, Alter ab 75 Jahren, Diabetes mellitus, Schlaganfall oder transitorischer ischämischer Attacke in der Anamnese. Behandlung von tiefen Venenthrombosen (TVT) und Lungenembolien (LE) sowie Prophylaxe von rezidivierenden TVT und LE bei Erwachsenen. Besondere Patientengruppen: Patienten, die kardiovertiert werden sollen: Bei Patienten, bei denen eine Kardioversion erforderlich sein kann, kann die Behandlung mit Xarelto begon-nen oder fortgesetzt werden. Gegenanzeigen: Überempfi ndlichkeit gegen Rivaroxaban oder einen d. sonst. Bestandteile; akute, klinisch relevante Blutungen; Läsionen od. Situa-tionen, wenn diese als signifi kantes Risiko für eine schwere Blutung angesehen werden; gleichzeitige Anwendung von anderen Antikoagulanzien außer in der speziellen Situation der Umstellung der Antikoagulationstherapie od. wenn unfrakt. Heparin in Dosen gegeben wird, die notwendig sind, um die Durchgängigkeit eines zentralvenösen oder arteriellen Katheters zu erhalten; Lebererkrankungen, die mit einer Koagulopathie u. einem klinisch relevanten Blutungsrisiko, einschließlich zirrhotischer Patienten mit Child Pugh B und C, verbunden sind; Schwangerschaft u. Stillzeit. Vorsichtsmaßnahmen und Warnhinweise: Klinische Überwachung in Übereinstimmung mit der antikoagulatorischen Praxis während der gesamten Behandlungsdauer empfohlen. Die Gabe von Xarelto sollte bei Auftreten einer schweren Blutung unterbrochen werden. Mit zunehmendem Alter kann sich d. Blutungsrisiko erhöhen. Die Anwendung von Rivaroxaban wird nicht empfohlen bei Patienten: - mit einer schweren Nierenfunktionsstörung (Kreatinin-Clearance < 15 ml/min), - die gleichzeitig eine systemische Behandlung mit Wirkstoffen erhalten, die sowohl CYP3A4 als auch P-gp stark inhibieren, z. B. Azol-Antimykotika oder HIV-Proteaseinhibitoren, - mit erhöhtem Blutungsrisiko, - die gleichzeitig mit starken CYP3A4 Induktoren behandelt werden, es sei denn, d. Patient wird engmaschig auf Zeichen u. Symptome einer Thrombose überwacht; da keine Daten vorliegen, bei Patienten: - unter 18 Jahren, - mit künstlichen Herzklappen, - mit einer LE, die hämodynamisch instabil sind oder eine Thrombolyse oder pulmonale Embolektomie benötigen, - die zeitgleich mit Dronedaron behandelt werden. Die Anwendung sollte mit Vorsicht erfolgen bei Erkrankungen, die mit einem erhöhten Blu-tungsrisiko einhergehen; bei Patienten: - mit einer schweren Nierenfunktionsstörung (Kreatinin-Clearance 15 – 29 ml/min), - mit einer Nierenfunktionsstörung, wenn gleichzeitig an-dere Arzneimittel eingenommen werden, die zu erhöhten Rivaroxaban Plasmaspiegeln führen, - die gleichzeitig auf die Gerinnung wirkende Arzneimittel erhalten; bei Anwendung von neuraxialer Anästhesie oder Spinal/Epiduralpunktion. Für Patienten mit einer mittelschweren oder schweren Nierenfunktionsstörung sowie für Patienten mit einer TVT/LE, deren abgeschätztes Blutungsrisiko überwiegt, gelten spezielle Dosisempfehlungen. Bei Patienten mit dem Risiko einer ulzerativen gastrointestinalen Erkrankung kann eine ulkusprophylak-tische Behandlung erwogen werden. Obwohl d. Behandlung mit Rivaroxaban keine Routineüberwachung d. Exposition erfordert, können d. mit einem kalibrierten quantitativen Anti-Faktor Xa-Test bestimmten Rivaroxaban-Spiegel in Ausnahmesituationen hilfreich sein. Xarelto enthält Lactose. Nebenwirkungen: Häufi g: Anämie, Schwindel, Kopfschmerzen, Augeneinblutungen, Hypotonie, Hämatome, Epistaxis, Hämoptyse, Zahnfl eischbluten, gastrointestinale Blutungen, gastrointestinale u. abdominale Schmerzen, Dyspepsie, Übelkeit, Verstopfung, Durchfall, Erbrechen, Pruritus, Hautrötung, Ekchymose, kutane und subkutane Blutung, Schmerzen in den Extremitäten, Blutungen im Urogenitaltrakt (Menorrhagie sehr häufi g bei Frauen < 55 Jahre b. d. Behandlung d. TVT, LE sowie Prophylaxe von deren Rezidiven), Nierenfunktionseinschränkung, Fieber, periphere Ödeme, verminderte Leistungsfähig-keit, Transaminasenanstieg, postoperative Blutungen, Bluterguss, Wundsekretion. Gelegentlich: Thrombozythämie, allergische Reaktion, allergische Dermatitis, zerebrale und intrakra-nielle Blutungen, Synkope, Tachykardie, trockener Mund, Leberfunktionsstörung, Urtikaria, Hämarthros, Unwohlsein, Anstieg von: Bilirubin, alkalischer Phosphatase im Blut, LDH, Lipase, Amylase, GGT. Selten: Gelbsucht, Blutung in einen Muskel, lokale Ödeme, Anstieg von konjugiertem Bilirubin, vaskuläres Pseudoaneurysma. Häufi gkeit nicht bekannt: Kom-partmentsyndrom oder (akutes) Nierenversagen als Folge einer Blutung. Erfahrungen seit der Marktzulassung (Häufi gkeit nicht abschätzbar): Angioödeme u. allergische Ödeme, Cholestase und Hepatitis (einschließlich hepatozelluläre Schädigung), Thrombozy topenie. Verschreibungspfl ichtig. Stand: FI/15; Juli 2015 Bayer Pharma AG, 13342 Berlin, Deutschland L.

DE.

MKT

.GM

.03.

2016

.277

1

Xarelto®. Test im Praxisalltag bestandenUmfangreiche Daten zur Schlaganfall-Prophylaxe bei nicht valvulärem Vorhoffl immern* aus dem Praxisalltag1.

160429_03_AZ_Karabiner_A5.indd 1 29.04.16 12:16

FLOOR PLAN SECOND AND THIRD FLOOR

second floor

third floor

81FL

OO

R P

LAN

SEC

ON

D A

ND

TH

IRD

FLO

OR














A Congress Center BaselMesseplatz 214058 Basel

B Offene Kirche ElisabethenElisabethenstrasse 104051 Basel

1 Swissôtel Le Plaza, Messeplatz 25, 4005 Basel

2 Hotel The Passage, Steinengraben 51, 4051 Basel

3 Hotel Basel, Münzgasse 12, 4001 Basel

4 Hotel D, Blumenrain 19, 4051 Basel

5 Hotel Novotel Basel City, Grosspeterstrasse 12, 4052 Basel

6 Hotel Krafft, Rheingasse 12, 4058 Basel

7 Hotel Schweizerhof Basel, Centralbahnplatz 1, 4002 Basel

8 Aparthotel Adagio City Basel, Hammerstrasse 46, 4058 Basel

9 Hotel Basilisk, Klingentalstrasse 1, 4057 Basel

CITY MAP OF BASEL

A

B

1

2

3

4

5

6

7

CIT

Y M

AP

OF

BA

SEL

9

8

82

Documents

MAIN PROGRAM - gth2017.org · Rurioctocog alfa pegol (Recombinant Coagulation Factor VIII) SHIRE · BAXALTA SCHWEIZ AG Müllerenstrasse 3, Postfach, CH-8604 Volketswil | Telefon +41